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Abstract 
 Aldehyde oxidase (AO) and xanthine oxidoreductase (XOR) are molybdo-
flavoenzymes (MFEs) involved in the oxidation of hundreds of endogenous and 
exogenous aldehydes and N-heterocyclic compounds many of which are drugs, 
vitamins and environmental pollutants. Mutations in the XOR and molybdenum 
cofactor sulfurase (MCS) genes result in a deficiency of XOR or dual AO/XOR 
deficiency respectively. At present despite AO and XOR being classed as 
detoxification enzymes the definitive experimental proof of this has not been assessed 
in any animals thus far.  
The aim of this project was to evaluate ry and ma-l strains of Drosophila 
melanogaster as experimental models for XOR and dual AO/XOR deficiencies 
respectively and to determine if MFEs have a role in the protection against chemical 
and physical stress. An additional aim was to determine the molecular basis for 
deficiency in ma-l strains by cloning and sequencing the MCS gene. 
Spectrophotometric and HPLC assays demonstrated that Drosophila  AO and XOR 
were able to catalyse the biotransformation of numerous substrates of the well-
scrutinised mammalian orthologs. These included several aromatic aldehydes and N-
heterocyclic pollutants, drugs and endogenous vitamins. Investigation of the enzyme 
activity in ry strain revealed a compromised ability to biotransform several XOR 
substrates that reflected the situation in human hereditary xanthinuria type I. Both ma-
l strains were found to be unable to biotransform all AO substrates tested. These 
results confirmed that Drosophila  were good experimental models for testing the role 
of MFEs as detoxification enzymes. 
In order to test the role of the enzymes in chemoprotection, MFE substrates were 
administered to Drosophila  in media and survivorship monitored. It was demonstrated 
that several methylated xanthines were toxic to XOR-deficient strains.  In addition a 
range of AO substrates including N-heterocycles and aldehydes were significantly 
more toxic to ma-l AO-null strains.  This study therefore provides definitive proof that 
both AO and XOR are involved in detoxification.   
Investigations to determine the effect of MFE deficiencies on lifespan revealed that ry 
and ma-l strains had significantly reduced lifespan when compared with the wild type 
strain with the mean lifespan being reduced approximately 60% and 30% respectively 
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in these strains. The effect the MFE deficiencies have on heat and cold stress indicated 
that ry and ma-l strains had significantly reduced ability to survive, with the 
survivorship of the AO-null ma-l strain being most compromised in these conditions.  
The effect of the toxic chemicals, lifespan and temperature stress were rescued in ry 
mutant animals that had the normal ry (XOR) gene reinserted by transgenesis.  
Cloning and DNA sequencing of the MCS gene in the ma-l strains revealed that the 
mal-1 and mal-f1 strains had a 6 bp insertion and a 23 bp deletion in exon 4 
respectively that are predicted to lead to alterations of the deduced MCS protein 
structure, thus explaining the dual AO/XOR deficiency in these strains. 
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1. Introduction. 
Xenobiotics are compounds that are foreign to the body, which include drugs, 
pollutants and other substances that are not normally present in the body that are 
potentially toxic. Xenobiotic metabolism is the series of metabolic reactions that 
change the chemical structure of xenobiotics; generally acting to detoxify the toxic 
chemical compounds. Sometimes, however, the product of xenobiotic metabolism can 
be the cause of toxic effects (Hodgson & Smart, 2001). Of the biotransformations that 
occur in animals oxidation plays a major role in the metabolism of foreign 
compounds. Although the microsomal cytochrome P-450 mono-oxygenase system is 
of major importance in this respect, enzymes present in the cytosol also contribute to 
this process. This thesis is concerned with two of these enzymes aldehyde oxidase 
(AO; EC 1.2.3.1) and xanthine oxidoreductase (XOR; EC 1.2.3.2) that are molybdo-
flavoenzymes found in nearly every organism from bacteria to human (Beedham, 
2001; Garattini et al., 2008, 2009; Garattini et al., 2003; Garattini & Terao, 2011).  
1.2. Substrate specificity of aldehyde oxidase and xanthine oxidoreductase. 
AO and XOR catalyze the oxidation of many different N-heterocyclic compounds as 
well as aliphatic and aromatic aldehydes to their corresponding lactam and carboxylic 
acids respectively (Beedham, 2001; Garattini et al., 2008; Garattini et al., 2003; 
Garattini & Terao, 2011, 2012). Despite their ability to oxidize the same class of 
substrates and their structural similarities, AO and XOR vary in their substrate 
specificities and their response to inhibitors (Kundu et al., 2007; Mendel & Bittner, 
2006). For this reason, it is experimentally possible to differentiate between the 
enzymes by measuring the activities obtained by reacting them with different 
substrates or by subjecting the oxidation reactions to different inhibitors. For example, 
the well known endogenous substrate xanthine is converted to uric acid by XOR but 
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AO is incapable of catalyzing this reaction (Krenitsky et al., 1986). The physiological 
role of XOR is mainly in purine catabolism in which it catalyzes the oxidation of 
hypoxanthine to xanthine and then to the more polar compound uric acid (Figure 1) 
(Garattini et al., 2008; Kitamura et al., 2006; Krenitsky et al., 1972; Nishino & 
Okamoto, 2000). 
2
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Figure 1: Role of xanthine oxidoreductase in endogenous purine catabolism in mammals.  
AMP: Adenosine monophosphate, IMP: Inosine monophosphate, XMP: Xanthosine 
monophosphate, GMP: Guanosine monophosphate, AMPD: AMP deaminase, NT: 
nucleotidase, AD: adenosine deaminase, PNP: purine nucleoside phosphorylase, GD: guanine 
deaminase, XOR: xanthine oxidoreductase (Boueiz et al., 2008). 
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 Mammalian XOR can exist as a dehydrogenase (XDH) and oxidase (XO) form. XDH 
is the predominant form of the enzyme under non-pathological (normal) conditions 
(Borges et al., 2002). The difference between the two forms is largely based on the 
electron acceptor utilized for catalytic activity. XO transfers reducing equivalents to 
O2, where as XDH transfers them predominantly to NAD+ and to a much lesser extent 
oxygen (Hille & Nishino, 1995; Nishino et al., 2005). XDH can be converted 
irreversibly to XO by limited proteolysis or by reversible oxidation of cysteine 
residues (Nishino & Nishino, 1997; Nishino et al., 2005).  
Due to their structural similarity to the endogenous substrates many exogenous 
methylated xanthines are also substrates for XOR. Methylxanthines are generally 
demethylated by cytochrome P450 1A2 (CYP1A2) and the metabolites generated are 
metabolised by XOR (Arnaud, 2011; Hamelin et al., 1994; Krenitsky et al., 1972; 
Streetman et al., 2000) (shown in figure 2). Bovine milk xanthine oxidase catalyses 
the oxidation of 7-methylxanthine, 1-methylxanthine and theophylline, to varying 
degrees with the 1-methylxanthine being the best substrate (Krenitsky et al., 1972).   
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Figure 2: Role of xanthine oxidoreductase in caffeine metabolism. CYP: Cytochrome P-450. 
XOR: Xanthine oxidoreductase. 
 * indicates not unequivocally proven (Arnaud, 2011; Baselt & Cravey, 1996; Hamelin et al., 
1994; Relling et al., 1992). 
 
Despite its name, AO not only oxidizes aldehydes but also catalyzes the hydroxylation 
of aromatic azaheterocycles possessing a –CH=N- moiety such as phthalazine  (Figure 
3) (Beedham et al., 1990; Panoutsopoulos & Beedham, 2004; Stubley et al., 1979) or 
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aromatic and non-aromatic charged heterocycles with a –CH=N+ group like the 
vitamin B3 metabolite (N1-methylnicotinamide) (Figure 4) (Beedham, 1987, 2001; 
Kundu et al., 2007; Shibata et al., 1988; Sugihara et al., 2006). AO catalyzes the 
oxidation of aldehydes and nitrogeneous heterocyclic xenobiotics like vanillin and 
phenanthridine as well as the oxidative metabolism of a variety of endogenous 
compounds like pyridoxal, retinaldehyde and N1-methylnicotinamide (Beedham, 
1985, 1987; Beedham et al., 1995; Egashira et al., 1999; Huang et al., 1999; Kitamura 
et al., 2006; Rashidi et al., 1997; Shibata et al., 1988; Stanulovic & Chaykin, 1971). 
Although AO catalyses the biotransformation of several endogenous compounds, the 
absolute primary physiological function of AO is yet to be determined. The 
physiological importance of aldehyde oxidase’s role in aldehyde oxidation is in 
question due to the fact that the Michaelis constant (Km) for AO and XO is higher for 
aliphatic aldehydes than is that of another mammalian enzyme, aldehyde 
dehydrogenase (ALDH) [EC; 1.2.1.3] (Jakoby & Ziegler, 1990; Panoutsopoulos et al., 
2004).  
H
Aldehyde oxidase
Phthalazine 1-Phthalazinone
 
 Figure 3: Metabolism of phthalazine in mammals by aldehyde oxidase to 1-phthalazinone 
(Beedham et al., 1987). 
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Figure 4: Metabolism of vitamin B3 in mammals. 
Methylation of nicotinamide by nicotinamide methyltransferase followed by oxidation of N1-
methylnicotinamide by AO to N1-methyl-2-pyridone-5-carboxamide (2-PY) and N1-methyl-4-
pyridone-5-carboxamide (4-PY). Based on Beedham, 2001; Egashira et al., 1999; Shibata et 
al., 1989 and 2006. 
 
As well as N1-methylnicotinamide there are other examples of endogenous 
compounds that are AO substrates (Figure 4). Two notable endogenous substrates for 
AO include retinaldehyde and pyridoxal (Beedham, 2001; Garattini et al., 2008; 
Garattini et al., 2003; Garattini & Terao, 2011, 2012; Huang et al., 1999; Kitamura et 
al., 2006). Retinaldehyde is the principle component of visual pigments and for this 
reason it has been suggested that aldehyde oxidase may play an important part of the 
overall visual process since it catalyzes the biotransformation of this aldehyde to its 
corresponding carboxylic acid, retinoic acid, which is the active form of vitamin A 
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(Calzei et al., 1995; Garattini et al., 2008; Garattini & Terao, 2011, 2012; Huang et 
al., 1999; Stanulovic & Chaykin, 1971). The involvement of AO in all-trans 
retinaldehyde (RA) oxidation to all-trans retinoic acid (ATR) was first seen in rabbit 
liver cytosol, where it was observed that a fraction of the oxidizing activity did not 
require addition of NAD+ and was due to a molybdo-flavoenzymes (MFE) (Garattini 
et al., 2008; Tomita et al., 1993; Tsujita et al., 1994). As well as its ability to catalyses 
the biotransformation of vitamin A and B3 metabolites. AO also converts vitamin B6 
(pyridoxal) to 4-pyridoxic acid (Figure 5) (Tomita et al., 1993). Pyridoxal is a good 
substrate of insect AO in vitro (Browder & Williamson, 1976; Cypher et al., 1982). In 
mice Garattini et al. (2008) reported that pyridoxal can be oxidized by purified mouse 
aldehyde oxidase AOX1 and AOH1, although it is not an efficient substrate in the 
case of AOH2.  
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Figure 5: Conversion of retinal (vitamin A) to its corresponding carboxylic acid (retinoic 
acid) and oxidation of vitamin B6 (pyridoxal) to its corresponding carboxylic acid (4-
pyridoxic acid) catalyzed by aldehyde oxidase. Based on Macrae et al., 1984; Tomita et al., 
1993. 
Examples of xenobiotics that are substrates for AO are shown in figure 6. 
Phenanthridine is a good example of an exogenous toxic pollutant, which is a 
prototypical uncharged xenobiotic substrate of AO. The oxidative product, 6(5H)-
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6(5H)-phenanthridone is a cyclic lactam substituted adjacent to a heterocyclic nitrogen 
atom (Figure 6) (Beedham, 2001; Kitamura et al., 2006; LaVoie et al., 1985). The 
anti-leukemia drug methotrexate (4-amino-N10-methylpteroyl-L-glutamic acid) 
formally known as amethopterin, is a pteridine compound that is metabolised to its 
major metabolite 7-hydroxymethotrexate by mammalian liver aldehyde oxidase 
(Figure 6) (Garattini et al., 2008; Garattini & Terao, 2011, 2012; Kitamura et al., 
1999; Kitamura et al., 2006; Moriyasu et al., 2006).  
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                AO
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H
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H2 H2
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Figure 6: Oxidation of phenanthridine to 6(5H)-phenanthridone and oxidation of 
methotrexate to 7-hydroxymethotrexate by AO. Based on Beedham, 2001; Kitamura et al., 
2006; Lavoie et al., 1985; Sugihara et al., 1999. 
10 
 
Certain compounds are substrates for both AO and XOR two such compounds are 
vanillin and 6-mercaptopurine (Figures 7 and 8). Vanillin, found in food stuffs is an 
aromatic aldehyde compound that was rapidly converted to its metabolite vanillic acid 
by AO with negligible contribution from XO or aldehyde dehydrogenase (ALDH) 
(Figure 7) (Beedham, 2001; Panoutsopoulos & Beedham, 2004; Rashidi, 1996; Sahi et 
al., 2008).  
 
AO
O OH OH
OH OH
OCH3 OCH3
Vanillin Vanillic acid
 
 
Figure 7: Conversion of vanillin to its corresponding carboxylic acid catalyzed by aldehyde 
oxidase. Based on Panoutsopoulos et al., 2004; Rashidi, 1996. 
 
AO like XO can also catalyze the oxidation of certain purines and in some cases with 
higher activity than XO (Beedham, 2001). An example is that 6-mercaptopurine is 
oxidized to 6-methylmercaptopurin-8-one by AO via methyltransferase enzyme and to 
6-mercaptopurin-2-one (6-thioxanthine) by XOR and to 6-thiouric acid (end product) 
by both XOR and AO (Figure 8). This is according administration of 6-
mercaptopurine drug (Beedham, 2001; Kitamura et al., 2006; Rashidi et al., 2007). 
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Figure 8: The oxidation of 6-mercaptopurine, a common substrate for aldehyde oxidase and 
xanthine oxidoreductase to different oxidative products. Based on (Beedham, 2001; Kitamura 
et al., 2006; Rashidi, 1996; Rashidi et al., 2007; Zimm et al., 1984). 
 
In addition to the reactions outlined above AO and XOR can catalyse the oxidation of 
hundreds of other compounds (for reviews see Beedham, 2001, Kitamura et al., 2006 
and Garattini & Terao, 2012).  As it is out with the scope of this thesis to list all these 
only compounds of that were chosen as targets for examination in this research study 
are listed in table 1. 
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Table 1: Examples of mammalian molybdo-flavo enzymes substrates.  
Substrates AO XOR References 
1-methylxanthine  
(caffeine metabolite) - +++ (Krenitsky et al., 1972; Reinke et al., 1987) 
3- methylxanthine  
(caffeine metabolite) - + (Krenitsky et al., 1972) 
6-Mercaptopurine  
(anti-cancer drug) + ++ 
(Beedham, 2001; Garattini & Terao, 2011, 2012; 
Kitamura et al., 2006; Krenitsky et al., 1972; Rashidi, 
1996; Rashidi et al., 2007; Zimm et al., 1984) 
7- methylxanthine  
(caffeine metabolite) - + (Krenitsky et al., 1972) 
Allopurinol  
(hyperuricemia drug) + +++ 
(Beedham, 2001; Garattini & Terao, 2011, 2012; 
Kitamura et al., 2006; Krenitsky et al., 1972; 
Krenitsky et al., 1986; Moriwaki et al., 1993; Reiter 
et al., 1990; Yamamoto et al., 1991) 
Cinchonine 
 (anti-malarial drug) +++ - 
(Beedham et al., 1992; Fukiya et al., 2010; Itoh et al., 
2006; Kitamura et al., 2006) 
Hypoxanthine 
(purine endogenous) - +++ 
(Cao et al., 2010; Kitamura et al., 2006; Krenitsky et 
al., 1972) 
N1-Methylnicotinamide 
(endogenous compound) +++ - 
(Beedham, 2001; Kitamura et al., 2008; Kitamura et 
al., 2006; Krenitsky et al., 1972; Shibata et al., 1988; 
Sugihara et al., 2006) 
Methotrexate (anti-cancer 
drug) +++ - 
(Beedham, 1985, 2001; Chladek et al., 1997; 
Johnson, 1967; Jordan et al., 1999; Kitamura et al., 
1999; Kitamura et al., 2006; Moriyasu et al., 2006) 
Paraxanthine  
(metabolite of caffeine) - - (Lelo et al., 1989) 
Phenanthridine  
(environmental pollutant) +++ - 
(Beedham, 2001; Garattini & Terao, 2011, 2012; 
Rashidi, 1996; Rashidi et al., 2011; Rashidi et al., 
1997; Stubley & Stell, 1980; Taylor et al., 1984) 
Phthalazine  
(representative of a class of N-
heterocycles used and widely 
used in pharmacology 
industry) 
+++ + 
(Beedham et al., 1990; Beedham et al., 1995; 
Garattini & Terao, 2011, 2012; Kitamura et al., 2006; 
Obach, 2004; Panoutsopoulos & Beedham, 2004; 
Stubley et al., 1979) 
Pyrazinamide  
(tuberculosis drug) + +++ 
(Kitamura et al., 2006; Lacroix et al., 1989; 
Moriwaki et al., 1993; Shibutani et al., 1999; 
Yamamoto et al., 1991; Yamamoto et al., 1987) 
Pyridoxal  
 (vitamin B6) +++ - 
(Garattini et al., 2008; Garattini & Terao, 2011, 
2012; Kitamura et al., 2006; Krenitsky et al., 1972; 
Schwartz & Kjeldgaard, 1951; Stanulovic & 
Chaykin, 1971) 
Quinidine  
(anti-malarial drug) +++ - 
(Beedham, 1987; Beedham et al., 1992; Itoh et al., 
2006; Kitamura et al., 2006) 
Retinaldehyde  
 (vitamin A aldehyde) +++ - 
(Garattini et al., 2008; Garattini & Terao, 2011, 
2012; Huang et al., 1999; Huang & Ichikawa, 1994; 
Kitamura et al., 2006; Terao et al., 2009) 
Theobromine   
(primary methylxanthine in 
chocolate) 
- - (Krenitsky et al., 1972) 
Theophylline  
(asthma drug) - + (Krenitsky et al., 1972) 
Vanillin 
 (present in food stuffs) +++ - 
(Beedham, 2001; Garattini & Terao, 2011, 2012; 
Obach, 2004; Panoutsopoulos, 2005; Panoutsopoulos 
& Beedham, 2004; Rashidi, 1996; Sahi et al., 2008) 
Xanthine   
(endogenous purine) - +++ 
(Krenitsky et al., 1972; Krenitsky et al., 1986; 
Yamaguchi et al., 2007) 
(+++ = high activity ++   = intermediate activity + = low activity - = no activity). 
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In addition to the oxidation of substrates both enzymes have reductase activity. In the 
presence of an adequate electron donor or strictly anaerobic conditions, the reduction 
rates are dependent on the concentration of electron donor (Beedham, 2001; Kitamura 
et al., 2006; Obach, 2004). Beedham, (2001) reported that the reduction rates of XOR 
is much lower than AO in many of reactions. Examples of reduction reactions 
catalyzed by AO and XOR are summarised in tables 2 and 3. 
 
Table 2: Reduction of various compounds by aldehyde oxidase. 
 AO substrates AO generated metabolites References 
Fenthion sulfoxide Fenthion (Kitamura et al., 1999) 
Nitrated polycyclic hydrocarbons Hydroxylamines (Tatsumi et al., 1986) 
Nicotinamide-N-oxide, 
imipramine-N-oxide, 
cyclobenzaprine-N-oxide and 
s-(-)-nicotine-1-N-oxide 
Their parent amines 
(nicotinamide and 
imipramine) 
(Kitamura et al., 2001; 
Kitamura & Tatsumi, 
1984; Sugihara et al., 
1996) 
Acetophenone oxime, 
salicylaldoxime and 
benzamidoxime 
Corresponding oxo 
compounds and a ketimine (Tatsumi & Ishigai, 1987) 
Methyl red and orange Cleavage of the azo linkage 
(Kitamura & Tatsumi, 
1983; Stoddart & Levine, 
1992) 
Aromatic and heterocyclic 
hydroxamic acids (e.g 
salicylhydroxamic acid) 
Amides (salicylamide) (Sugihara & Tatsumi, 1986) 
Nitrosoamines (N-
nitrosodiphenylamine) 
Hydrazines (1,1-
diphenylhydrazine) (Tatsumi et al., 1983) 
Sulindac sulfoxide Sulindac sulfide 
(Duggan, 1981; Kitamura 
et al., 2001; Pay et al., 
1980) 
Zonisamide 2-sulfamoylacetylphenol (Kitamura et al., 2001) 
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Table 3: Xanthine oxidoreductase catalyzed reduction of various compounds. 
XOR substrates 
XOR generated 
metabolites References 
Nitrated 
polycyclichydrocarbons Hydroxylamines (Tatsumi et al., 1986) 
S-(-)-nicotine-1-N-
oxide Nicotine (Sugihara et al., 1996) 
6-bromomethyl-(9H)-
purine 6-methylpurine (Porter, 1990) 
Mitomycin C 2,7-diaminomitosene (Gustafson & Pritsos, 1992; Pan et 
al., 1984) 
Doxorubicin its semiquinone 
metabolites 
(Barnabe et al., 2002; Yee & 
Pritsos, 1997) 
 
1.3. Molybdo-flavoenzyme structure 
AO and XO are complex metalloflavoenzymes that contain one flavin adenine 
dinucleotide (FAD) two non-identical iron sulfur centers [2Fe-2S] and a molybdenum 
cofactor (Moco) as prosthetic groups (Borges et al., 2002; Garattini et al., 2008; 
Garattini et al., 2003; Nishino, 1994; Palmer et al., 1969). The active form of the 
molybdo-flavoenzymes enzymes are homodimers comprising of two identical 
subunits of approximately 150 kDa. This is schematically illustrated in figure 9, with 
each subunit divided into three distinct domains as follows: an N-terminus which has 
a 20 kDa domain with two [2Fe-2S] clusters, a 40 kDa flavin adenine dinucleotide 
(FAD) binding domain, and an 85 kDa C-terminal domain harbouring the Moco and 
the substrate-binding sites (Garattini et al., 2003; Garattini & Terao, 2012; Hille, 
2005; Hughes et al., 1992; Kisker, 1997; Mendel & Bittner, 2006; Wollers, 2008). 
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N-terminus C-terminus
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Fe-S-Fe-S
Domain
FAD
Domain MoCo Domain
 
 
Figure 9: Schematic diagram of the domain structure of the molybdenum centre in enzymes 
of the XDH/AO enzyme family.  
The N-terminus domain binds the two Fe2S2 clusters, the middle domain harbours the FAD 
binding site and the C-terminus domain is the location of the Mo-pterin cofactor (Mendel and 
Bittner, 2006). 
 
A further insight into the domain structure of molybdo-flavoenzymes was provided by 
the successful crystallization of mammalian molybdo-flavoenzymes (Enroth et al., 
2000; Romao et al., 1995; Truglio et al., 2002). X-ray crystallography data 
determined that each subunit of the bovine XO and XDH enzymes may be separated 
into three sub-domains. The first sub-domain (residues 1-165) at the N-terminus 
contains both the iron-sulphur cofactors. It is associated with the FAD-binding domain 
(residues 226-531) by a long segment of amino acids (residues 166-225). Another 
linker segment (residues 532-861) then, connects this sub-domain to the molybdenum 
cofactor binding domain (residues 590-1,332), which is spatially located close to the 
interfaces of the iron sulphur and FAD binding domains (Figure 10) (Enroth et al., 
2000). Aldehyde oxidoreductase a related molybdenum-containing bacterial enzyme 
from Desulfovibrio gigas has also been crystallised and its structure reported at 2.25Å 
resolution (Rebelo et al., 2000; Romao et al., 1995). These crystal structures have 
unlocked a wealth of information revealing previously unknown structural details 
about these enzymes.  
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Figure 10: Crystal structures of bovine milk XOR dimer with the three domains represented 
in different colours. Iron sulfur-center domain (residues 3–165; red), FAD domain (residues 
226–531; green) and Mo-pterin cofactor domain (residues 590–1331; blue) (Enroth et al., 
2000). The active site occurs between the two Lys569 and Lys551 residues. Used with 
permission from Professor Takeshi Nishino.  
 
1.4. Molybdenum cofactor and the catalytic mechanism of molybdo-
flavoenzymes. 
Molybdenum itself is biologically inactive unless bound to a tricyclic pterin 
compound where it then forms molybdenum cofactor (Moco) (Figure 11). Moco is 
situated at the active site of all molybdenum enzymes (Mendel & Bittner, 2006). The 
pterin structure coordinates to the molybdenum metal by an enedithiolate side chain 
(Hille, 2005). The molybdo-flavo enzymes, AO and XO, contain an active site that is 
believed to be in a five-coordinate complex with two enedithiolate ligands of the 
molybdopterin cofactor, one oxo group, one sulfide group, and one hydroxyl or water 
molecule. This coordination results in a square pyramidal geometric structure and is 
the site for substrate binding and enzyme inhibition (Brondino et al., 2005 ). 
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Figure 11: Molybdenum cofactor. The active site structure is attached to the pyranopterin 
compound by way of two enedithiolate side chains (red colour) to produce the molybdenum 
cofactor (Brondino et al., 2005). 
 
The function of the cofactor appears to be the transfer of electrons out of the 
molybdenum centre after the oxidation reaction has taken place. This results in the 
reduction of molybdenum from Mo (VI) to Mo (IV) (Hille, 2005). A proposed 
electron transfer sequence proceeds a shown below (Figure 12) (Hille & Nishino, 
1995; Nishino & Okamoto, 2000), where Fe/S I and Fe/S II are two distinct iron-
sulfur centers.  
 
Mo-pterin Fe/S- I Fe/S- II  FAD 
Electron Movement 
 
Figure 12: Proposed sequence of electron flow out of the molybdenum centre of molybdo-
flavoenzymes. Based on Hille & Nishino, 1995; Nishino & Okamoto, 2000. 
 
In general, mononuclear molybdo-flavoenzyme enzymes catalyze oxygen atom 
transfer reactions (Brondino et al., 2005 ; Hille & Sprecher, 1987). In the case of 
molybdo-flavoenzymes, this is done through the hydroxylation of carbon centers of 
substrates containing N-heterocycle or aldehyde functional groups (Figure 13) where 
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the oxygen atom incorporated into the product ultimately comes from water and not 
from molecular oxygen (O2), which is in contrast to a mono-oxygenase reaction 
(Hille, 2005).  
 
H2O R- OHR-H 2H+ 2e-
Substrate Water 
Molecule
Oxidized
Substrate
Protons Reducing 
Equivalents
 
 
Figure 13: Oxygen atom transfer reaction by molybdo-flavoenzymes.  
General oxidation reaction catalyzed by molybdo-flavoenzymes producing an oxidized 
substrate and two reducing equivalents (Beedham, 2001; Hille, 2005; Hille & Sprecher, 
1987). 
 
In the case of an aldehyde substrate the product is a carboxylic acid and xanthine the 
product is a uric acid (Figure 14). 
H H
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Figure 14: Oxygen atom transfer reaction molybdo-flavoenzyme involving an aldehyde and 
xanthine. Based on Hille & Nishino, 1995; Okamoto et al., 2004. 
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The close relationship between AO and XOR implies a common mechanism of action 
for these two enzymes. Due to the increasing availability of crystal structures for some 
molybdo-flavoenzymes, the chemistry of the mechanism is now better understood 
(Choi et al., 2004). There have been two proposed mechanisms for the xanthine 
oxidoreductase enzyme. The two mechanisms differ in the source of the labile oxygen 
atom. The alternate mechanisms illustrate either the oxygen from the oxo group 
(Mo=O) or the oxygen from the hydroxyl group (Mo-OH) as the catalytically labile 
(least stable) oxygen from the active site of the enzyme (Klaassen & Curtis, 2008; Xia 
et al., 1999). The oxygen used as the labile one defines which oxygen atom is 
ultimately transferred to the substrate (Hille, 2002). Until about 1996, most 
researchers believed it was the Mo=O group that donated its oxygen to the substrate as 
an electrophile and the oxo ligand was revived from a water molecule (Fetzner, 2000; 
Hille, 2002). Subsequent experiments from other researchers have, however agreed 
with the evidence that supports the Mo-OH group as containing the labile oxygen 
(Bernhardt et al., 2006; Choi et al., 2004; Hille, 2005). The agreed mechanism using 
xanthine as the example substrate is shown in figure 15. This oxygen atom transfer 
reaction begins with an active site base abstracting the hydrogen from the Mo-OH 
group. The group then proceeds to initiate nucleophilic attack at the C-8 position of 
the xanthine substrate (Figure 15) (Choi et al., 2004). The hydroxylation at C-8 
position on xanthine then yields uric acid. At the same time, a hydride transfer takes 
place from the C-8 position on the xanthine substrate to the MoVI=S group. This then 
leads to a reduction of the molybdenum atom from (VI) to (IV) oxidation states. Loss 
of the proton from the sulphur and electron transfer produces transient formation of 
the Mo (V) intermediate. Water then enters the reaction, the oxidation product 
dissociates, and its position on the molybdenum centre is replaced by a water or 
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hydroxyl group. This then results in an increase in oxidation state of the molybdenum 
metal from Mo (V) to Mo (VI). In a similar manner AO can convert aldehydes to the 
corresponding carboxylic acid via a base-assisted nucleophilic attack of the Mo-OH 
on the substrate carbonyl with concomitant hydride transfer to the Mo=S (Figure 16).  
An important amino acid residue that is involved in this process is glutamic acid. For 
the reaction mechanisms of XOR and AO, the O- of Glu/1261 lies within a hydrogen 
bond length of the Mo atom (Cao et al., 2011; Huber et al., 1996; Metz & Thiel, 
2009). This Glu residue has a role in catalysis as a Lewis-base, since it promotes the 
nucleophilicity attack of Mo-O- on the carbon to be hydroxylated and concomitant 
hydride transfer to the Mo=S group to give an initial intermediate that that can be 
formulated as product (uric acid in the case of xanthine as substrate) (Cao et al., 2011; 
Huber et al., 1996).  
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Figure 15: The reaction mechanism for XOR with xanthine as a substrate.  
The active site base abstracts proton form the Mo-OH group which then undertakes 
nucleophilic attack on the C-8 position of the xanthine substrate with concomitant hydride 
transfer to Mo=S. Formation of paramagnetic species followed by displacement of product by 
hydroxide form solvent returns the active site to original state. The Glu residue important for 
the mechanism of catalysis is also shown (Choi et al., 2004; Pauff et al., 2009; Xia et al., 
1999). 
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Figure 16: A general reaction mechanism of the AO enzyme with an aldehyde substrate.  
A base-assisted nucleophilic attack of the Mo-OH on the substrate carbonyl with concomitant 
hydride transfer to the Mo=S which leads to the conversion of the aldehyde to its 
corresponding carboxylic acid. The Glu residue important for the mechanism of catalysis is 
also shown (Garattini et al., 2008; Hille, 2005). 
During substrate oxidation the molybdenum atom is initially reduced from Mo (VI), in 
oxidized enzyme to the Mo (IV) state to produce two electrons (Beedham, 1998; Bray, 
1975; Hille, 2005; Hille & Nishino, 1995). In vivo, molecular oxygen serves as the 
electron acceptor for AO. XOR, on the other hand, exists primarily in the 
dehydrogenase form in vivo and its electron acceptor is NAD+ (Beedham, 1998; Hille 
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& Nishino, 1995). The enzymes function by being alternately reduced by the substrate 
and then re-oxidised by their respective electron acceptors. In vitro, potassium 
ferricyanide and 2, 6-dichloroindophenol (DCIP) have proven to be effective artificial 
electron acceptors for these enzymes (Krenitsky et al., 1972; Slef & Stadtman, 2000). 
Within the enzyme structure, flavin adenine dinucleotide (FAD) is the site where 
electrons are transferred to molecular oxygen where they produce either hydrogen 
peroxide (H2O2) by a two-electron reduction or a superoxide anion (O2•-) by one-
electron reduction in XOR and AO catalysis (Figure 17). With the XDH enzyme 
NAD+ is reduced to NADH at the FAD site (Beedham, 1998, 2001; Hille, 2005; Hille 
& Nishino, 1995; Mendel & Bittner, 2006). These two pathways are illustrated below 
(Figure. 17). 
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Figure 17: Reduction pathways occurring in molybdoflavoenzymes (Beedham, 1998; Hille, 
1996).  
The three different reduction pathways occur at the FAD site in the enzymes structure. The O2 
reactions occur with AO and XO. The NAD+ reaction occurs with the XDH enzyme. 
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1.5. Species variation in molybdo-flavoenzyme activity. 
AO and XOR are widely distributed among molluscs, crustaceans, insects, bacteria, 
fungi and all vertebrate classes (Beedham, 2001; Garattini et al., 2008; Garattini et al., 
2003; Glatigny & Scazzocchio, 1995; Krenitsky et al., 1972; Moura et al., 1976; 
Pometto & Crawford, 1983; Romao et al., 1995; Schrader et al., 1999; Turner et al., 
1987; Woolfolk & Downard, 1977; Wurzinger & Hartenstein, 1974; Xu & Johnson, 
1995; Yasuhara et al., 2002). The activity of AO between animal species varies 
depending on the substrate considered. Sugihara et al. found the activity of AO in 
monkey is higher than human when using N1-methylnicotinamide and benzaldehyde 
as substrates (Sugihara et al., 1997). Klecker et al. (2006) found the activity of AO is 
highest in mouse towards zebularine substrate than monkey and human (Klecker et 
al., 2006). Species differences have also found when using cinchonidine as a substrate 
where rabbits have higher AO activity than monkey (Fukiya et al., 2010). In contrast, 
monkey AO has a higher reductase activity toward zonisamide as a substrate than 
rabbit (Kitamura et al., 2001). Higher reductase activity was observed with rabbits AO 
towards naphthalene 1, 2-oxide and benzo [a] pyrene-4, 5-oxide as model substrates of 
epoxide compounds than the AO of rat (Hirao et al., 1994). In contrast, Kitamura and 
Tatsumi (1984) found the AO reductase activity of rabbits, hogs, guinea pig, hamster, 
rat and mice had similar reduction activity towards nicotinamide N-oxide as a 
substrate (Kitamura & Tatsumi, 1984). 
1.5.1. Vertebrate molybdo-flavoenzymes  
The AOX and XOR genes of mammals are variable and species specific. Vertebrates 
are characterized by a number of active AO genes that ranges from 1 to 4 (Dickinson, 
1971; Garattini et al., 2008, 2009; Garattini et al., 2003; Garattini & Terao, 2011, 
2012; Lindsley & Zimm, 1992 ; Terao et al., 2009; Terao et al., 2006). Rodents (rat 
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and mice) have four of AO genes and one XOR gene (Garattini et al., 2008; Garattini 
et al., 2003; Garattini & Terao, 2011; Terao et al., 2009). Of these two species and 
amongst all vertebrates mouse AOs are the best characterised. Table 4 summarizes the 
tissue distribution and substrate specificity of mouse AOs. In contrast to rodents other 
mammalian species have a reduced complement of functional MFE genes, bovine 
(Bos taurus) has three AO genes and one XOR, while dogs (Canis familiaris) have 
two AO and one XOR (Terao et al., 2006). Humans have only one functional AO 
gene (AOX1) and one XOR gene (Garattini et al., 2008; Garattini et al., 2003; 
Garattini & Terao, 2012). The chicken (Gallus gallus) has two AO genes (AOX1 and 
AOH) and one XOR (Terao et al., 2006). Interestingly, unlike humans and most other 
mammals, where AO activity is found in the liver, dogs and chickens do not express 
an AO enzyme in hepatic tissue. A summary of the current knowledge of MFEs in 
non-rodent species is given on table 5. 
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Table 4: Summary of the substrate specificity and tissue distribution of molybdo-
flavoenzymes in Mus musculus.  
The old nomenclature of AO enzyme for mouse (previous name) as used in the public 
databases (GeneBank) and publications up until 2008 and new nomenclature of mouse 
aldehyde oxidase adopted by Garattini et al, (2008) from 2008 onwards. 
 
Old enzyme 
nomenclature 
of AO/XOR 
New enzyme 
nomenclature 
of AO/XOR 
Tissue distribution Known substrates References 
AOX1 Aox1 
Liver, lung, heart, 
kidney, testis, brain, 
eye, spinal cord and 
spleen 
Butyraldehyde, 
nicotinamide, octanal, 
phenanthridine phthalazine, 
retinaldehyde,  pyridoxal, 
vanillin,  
2-hydroxpyrimidine 
 
(Garattini et al., 2008, 
2009; Garattini et al., 
2003; Garattini & Terao, 
2011, 2012; Kurosaki et 
al., 1999; Kurosaki et al., 
2004; Moriwaki et al., 
1996; Vila et al., 2004; 
Wright et al., 1999) 
AOH1 Aox3 Liver, lung and testis 
Benzaldehyde, 
butyraldehyde, octanal, 
phthalazine, 
retinaldehyde,  
2-hydroxpyrimidine 
(Garattini et al., 2008, 
2009; Garattini et al., 
2003; Garattini & Terao, 
2011, 2012; Kurosaki et 
al., 1999; Kurosaki et al., 
2004; Moriwaki et al., 
1996; Terao et al., 2001; 
Terao et al., 2000; Tomita 
et al., 1993; Vila et al., 
2004; Wright et al., 1999) 
AOH2 Aox4 
Skin, stomach, 
Haderian gland, 
sebaceous gland, 
epidermis,eye, 
pancreas, brain and 
esophagus 
Phenanthridine, 
retinaldehyde 
(Garattini et al., 2008, 
2009; Garattini et al., 
2003; Garattini & Terao, 
2011, 2012; Holmes, 
1979; Kurosaki et al., 
2004; Sasai & De 
Robertis, 1997; Terao et 
al., 2001; Terao et al., 
2000; Vila et al., 2004) 
AOH3 Aoxl1 Skin, Bowmans gland 
and olfactory mucosa 
 Benzaldehyde, octanal,  
phthalazine retinaldehyde,  
2-hydroxpyrimidine  
(Garattini et al., 2008; 
Garattini & Terao, 2011, 
2012; Kurosaki et al., 
2004; Terao et al., 2009; 
Vila et al., 2004) 
XOR Xdh 
Liver, muscle, 
mammary glands, 
oesophagus, stomach, 
duodenum, jejunum, 
lleum, colon, rectum, 
lung, kidney, heart, 
small intestine and 
spleen 
Hypoxanthine, xanthine  
(Falciani et al., 1994; 
Garattini et al., 2008; 
Kurosaki et al., 1995; 
Kurosaki et al., 1996; 
McManaman et al., 1999; 
McManaman et al., 2002 ; 
Terao et al., 1992; Terao 
et al., 2006; Yoshimura & 
Oka, 1989) 
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Table 5: Summary of molybdo-flavoenzymes in non-rodent mammalian species.  
Species Tissue distribution 
of XOR AO 
Tissue 
distribution 
of AO 
References 
Human 
(Homo sapiens) 
Liver, lung, mammary 
gland, kidney, spleen, 
stomach, skeletal 
muscle and milk 
AOX1 Liver, lung and brain 
(Beedham, 2001; 
Garattini et al., 2008; 
Garattini et al., 2003; 
Garattini & Terao, 2011, 
2012; Krenitsky et al., 
1974; Minoshima et al., 
1995; Moriwaki et al., 
2001; H. Peretz et al., 
2007; Terao et al., 1998) 
Rhesus monkey 
(Macaca mulatta) 
Liver, small intestine, 
brain and testis 
AOX1, AOH2  
and AOH3 
Liver and nasal 
mucosa 
(Fukiya et al., 2010; 
Garattini et al., 2008; 
Garattini & Terao, 2011, 
2012; Hoshino et al., 
2007; Krenitsky et al., 
1974; Sugihara et al., 
1997; Tawa et al., 2011) 
Bovine 
(Bos taurus) 
Liver, heart,  mammary 
gland and milk 
AOX1, AOH2  
and AOH3 
Liver, eye, 
kidney, testis, 
lung, spleen and 
ciliary body 
(Beedham, 2001; Calzei 
et al., 1995; Garattini et 
al., 2008; Shimada et al., 
1989; Terao et al., 2006) 
Horse 
(Equus caballus) 
Liver, skeletal muscle, 
lung and small intestine 
AOX1, 
AOH1, AOH2 
 and AOH3 
Liver 
(Garattini et al., 2008; 
Prichard et al., 1991; 
Räsänen et al., 1993; 
Seeley et al., 1984) 
Dog 
(Canis lupus 
familiaris) 
Spleen, skin, nasal 
mucosa, lacrimal glands 
and oesophagus 
AOH2  
and AOH3 
Nasal mucosa, 
lacrimal glands, 
testis, skin and 
oesophagus 
(Garattini et al., 2008; 
Krenitsky et al., 1974; 
Terao et al., 2006; Vila et 
al., 2004) 
Baboon 
(Papio ursinus) Liver and intestine  AOX1 
Liver. heart, 
kidney and 
intestine extract 
(Garattini et al., 2008; 
Holmes & Vandeberg, 
1986) 
Chicken 
(Gallus gallus) 
Liver, lung, brain, skin, 
muscle, spinal cord, 
thymus, trachea, spleen, 
pancreas, stomach, 
adrenal gland and testis 
AOX1  
and AOH 
Kidney brain, 
skin, muscle, 
thymus, trachea, 
lung, spleen, 
pancreas, 
stomach, 
adrenal gland 
and testis 
(Garattini et al., 2008; 
Nishino & Nishino, 1989; 
Nishino et al., 1989; 
Terao et al., 2006) 
 
1.5.2. Insect molybdo-flavoenzymes  
In Drosophila melanogaster XDH is a general component of peroxisomes (Beard & 
Holtzman, 1987) and is encoded by the rosy (ry or Xdh) gene (Tiveron et al., 1991). 
AO and pyridoxal oxidase (PO) enzymes in D. melanogaster are encoded by aldox 
and lpo structural loci (Keller & Glassman, 1964) and were identified in many adult 
Drosophila tissues (Cypher et al., 1982) using heptaldehyde and 2, 4, 5-
trimethoxybenzaldehyde as specific substrates for AO and PO, respectively (see table 
6) (Cypher et al., 1982).  
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Table 6: Distribution of aldehyde oxidase and pyridoxal oxidase in adult Drosophila 
melanogaster  tissues. + present and - : absent. Based on Cypher et al., 1982.  
Tissue AO present PO present 
Brain + - 
Corpora allata + - 
Alimentary canal + - 
Anterior midgut (ventriculus) + - 
Cardia, corp and oesophagus + + 
Malpighian band + - 
Posterior midgut - - 
Pyloric region + + 
Rectal valve and rectum + - 
Salivary gland - - 
Salivary duct + - 
Circulatory system + - 
Hemolymph + - 
Lymph glands + - 
Nephrocytes and abdominal + - 
Fat body + - 
Endocyte + - 
oviduct + + 
Musculature - - 
Spermatheca + + 
Uterus + + 
Vas deferens + + 
As well as in addition to studies in Drosophila, AO has been found in antennae of 
tobacco hawk moth (Manduca sexta), cabbage armyworm (Mamestra brassicae), 
polyphemus silkmoth (Antheraea polyphemus) and domestic silkworm (Bombyx mori) 
(Maibeche-Coisne et al., 2004; Merlin et al., 2005; Rybczynski et al., 1989; 
Rybczynski et al., 1990). In M. sexta , A. polyphemus and B. mori this AO is involved 
in the chemo-reception of pheromonal stimuli in the antennae by its transformation of 
aldehyde pheromones such as bombykal (Rybczynski et al., 1989; Rybczynski et al., 
1990). In addition to enzyme activities XOR and AO genes have been investigated in 
several insects. Drosophila melanogaster has one XDH and four AO genes (Adams et 
al., 2000; Dickinson & Gaughan, 1981; Garattini et al., 2003) and silkworm (Bombyx 
mori) has two XDH and six AO genes (Komoto et al., 1999; Pelletier et al., 2007). 
The current knowledge of the numbers of XOR and AO genes and MFE substrates for 
insects are summarised in table 7. At present the association of substrate specificity 
with individual insect AO genes is unknown.  
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Common and scientific name XOR gene XOR substrates AOX gene AO substrates* References 
Cabbage armyworm  
(Mamestra brassicae) - - MbrAOX - 
 
(Garattini et al., 2008; Garattini et al., 
2003; Merlin et al., 2005) 
European blowfly 
(Calliphora vicina) CvXOR Hypoxanthine - - 
(Merlin et al., 2005; Rocher-
Chambonnet et al., 1987) 
Fruit fly  
(Drosophila melanogaster) 
 
DmXOR 
Xanthine, 
2-amino-4-
hydroxypterdine, pterin, 
aminohydroxypteridine 
and 
salicylaldehyde 
DmAOX1-4  
Acetaldehyde, 
 benzaldehyde, anisaldehyde, 
 p-chlorobenaldehyde, 
cinnamaldehyde, citral, citronellal, 
dimethylaminobenzaldehyde, 
heptaldehyde, hexaldehydehyde,  
p-hydroxybenzaldehyde,  
m-hydroxybenzaldehyde,  
o-hydroxybenzaldehyde, 
salicylaldehyde and vanillin 
(Adams et al., 2002; Bentley & 
Williamson, 1982; Browder & 
Williamson, 1976; Chovnick et al., 
1990; Courtright, 1967; Cypher et al., 
1982; Doyle et al., 1996; Garattini et 
al., 2008; Garattini et al., 2003; Keith 
et al., 1987; Reaume et al., 1991; 
Rushlow & Chovnick, 1984; Wahl et 
al., 1982; Wurzinger & Hartenstein, 
1974) 
Honey bee 
(Apis mellifera) - - AmelXDH - (Pelletier et al., 2007) 
Mediterranean fruit fly 
(Ceratitis capitata) CecaXOR - - - 
(Merlin et al., 2005; Pelletier et al., 
2007) 
Mosquito 
(Culex quinquefasciatus)  
 
CqXOR Hypoxanthine CqAOX 
Acetaldehyde, 
 benzaldehyde and  
heptaldehyde  
(Coleman et al., 2002) 
Mosquito 
(Anopheles gambiae)  AgamXDH - AgamAOX - 
(Merlin et al., 2005; Pelletier et al., 
2007) 
Mosquito 
(Aedes aegypti) 
 
- - AaegAOX  (Merlin et al., 2005) 
Silkworm 
(Bombyx mori) 
BmXOR1 
and 
BmXOR2 
Hypoxanthine BmAOX1-6  Benzaldehyde and bombykal 
(Garattini et al., 2003; Kamoto et al., 
2003; Komoto et al., 1999; Pelletier 
et al., 2007; Rybczynski et al., 1990; 
Terao et al., 2001; Yasukochi et al., 
1998) 
Table 7: Summary of known AO and XOR genes and substrates in insects. * Substrates for individual enzymes not known 
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1.6. Molybdenum cofactor biosynthesis and molybdenum cofactor 
sulfuration.  
As well as the structural genes that encode AO and XOR there are also several genes 
involved in the biosynthesis of a sulfurated molybdenum cofactor that are essential for 
the formation of functionally active molybdo-flavoenzyme holoenzymes. MoCo 
biosynthesis (Figure 18) requires six gene products in humans, plants, and fungi 
(Garattini et al., 2003; Mendel & Bittner, 2006; Mendel & Hansch, 2002) and 
involves a conserved pathway (Garattini et al., 2003; Mendel & Bittner, 2006; Mendel 
& Hansch, 2002; Schwarz et al., 2009), which can be divided into 4 stages in humans: 
The reaction in stage 1 involves the conversion of GTP to the sulphur-free pterin 
precursor Z (Hille, 2005; Mendel & Bittner, 2006; Schwarz et al., 2009) mediated by 
MOCS1A and MOCS1B proteins (Mendel & Bittner, 2006; Reiss et al., 1999; Reiss 
& Johnson, 2003). The second stage of MoCo biosynthesis requires the integration of 
two sulfur atoms into the precursor Z for the formation of in MPT dithiolate and is 
initiated by the enzyme MPT synthase (Mendel & Bittner, 2006; Reiss & Johnson, 
2003) which contains two subunits, MOCS2A and MOCS2B, encoded in humans by 
the gene mocs2 (Garattini et al., 2003; Mendel & Bittner, 2006; Reiss, 2000; Reiss & 
Johnson, 2003). MPT is then activated by a sulfotransferase protein which is encoded 
by the gene mocs3 (Johnson et al., 1989; Reiss & Johnson, 2003). In stage 3, the 
incorporation of Mo into MPT, which necessitates the uptake of molbydate (the form 
in which organisms accept Mo), takes place, thus forming MoCo. Gephyrin (protein 
encoded by the gene GEPH) then catalyses the insertion of the molybdenum atom into 
the molybdopterin to create an active molybdenum cofactor suitable for use in sulphite 
oxidase (Garattini et al., 2003; Hille, 2005; Mendel & Bittner, 2006; Reiss, 2000). 
Finally a sulphur atom needs to be added to MoCo in order for AO and XOR to utilise 
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the cofactor (Mendel & Bittner, 2006). This is achieved by the enzyme molybdenum 
cofactor sulfurase (MCS) (Ichida et al., 2001). 
Gephyrin
Molybdenum cofactor sulfurase
GTP cyclohydrolase I and II
MPT synthase 
sulfurase
O
incorporated into sulfite oxidase
incorporated into AO and XOR
Molybdenum cofactor plus sulfur atom
H
H
H
S
L-cysteine
L-alanine
S-insertion
MoCo
Mo-insertion
Mo
Mo
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Figure 18: Summary of molybdenum cofactor synthesis based on Mendel & Bittner, 2006.  
32 
 
1.6.1. Identification of the molybdenum cofactor sulfurase gene and protein. 
Molybdenum enzymes are divided into two subgroups. The first group contains 
enzymes with a dioxo-molybdenum centre (MoCo with two additional oxo-ligands 
and a protein-derived cysteinyl sulphur bound to the enzymes) like sulphite oxidase 
and nitrate reductase (NR) that carry two oxygen atoms at the molybdenum. The 
second group enzymes that contains AO and XOR have a monooxo-molybdenum 
centre and possess one oxygen atom, a terminal inorganic sulfur atom instead of the 
oxygen atom (Figure 19) (Hille, 1996; Mendel & Hansch, 2002) and one hydroxyl 
group ligated to the pterin-chelated molybdenum of the active enzyme (Wollers et al., 
2008). This unique sulfur moiety was discovered using maroon-like (ma-l) D. 
melanogaster mutants that are deficient in XDH and AO but retain SO activity. The 
ma-l mutant gave the first clue as to how sulphur incorporation occurred (Forrest et 
al., 1956; Forrest et al., 1961; Hille et al., 2011) This was attributable to the 
requirement of a terminal sulphur ligand of the molybdenum cofactor by AO and 
XDH. In contrast, sulfite oxidase was unaffected in ma-l mutant because of the sulfite 
oxidase does not require a terminal sulphur ligand on the cofactor (Bogaart & Bernini, 
1981; Hille et al., 2011). The activities of AO, XOR and pyridoxal oxidase were 
reconstituting in the extracts of ma-l flies by resulphuration with sulfide/dithionite 
treatment (Wahl et al., 1982). It was surmised that ma-l mutants had a lesion in post-
translational sulfuration which was essential for the activity of AO, XDH and 
pyridoxal oxidase, but not of sulfite oxidase. Coughlan et al. found that the enzyme 
deficiency could be replicated by treating wild type enzyme extracts with cyanide. 
This suggested that sulphur is converted to thiocyanate in the presence of cyanide 
(Coughlan et al., 1980) and was characterised to be an inorganic sulfide ion which is a 
terminal ligand of the molybdenum atom. As well as cyanide treatment spontaneous 
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loss of this sulfur also occurs under a variety of conditions generating a desulfo 
enzyme in which the terminal sulphide is replaced by a terminal oxo-ligand resulting 
in an inactive enzyme (Wahl & Rajagopalan, 1982). In addition to the earlier studies 
on Drosophila  the activities of XDH and AO from crude extracts of Arabidopsis 
thaliana  Aba3 AO/XDH null-mutants was restored in vitro by anaerobic treatment 
with sulfite/dithionite, this indicated that these plants were also defective in the final 
sulfuration step of XDH and AO (Bittner et al., 2001). As the sulfuration reaction was 
heritable this suggested evidence for the genetic control of the incorporation of the 
cyanolyzable sulfur of Mo hydroxylases. The protein responsible for the sulfur 
incorporation into the molybdenum cofactor of XDH and AO was named 
molybdenum cofactor sulfurase (Figure 19).  
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Figure 19: Domain structure and function of Moco sulfurase Aba3. Based on Schwarz et 
al., 2009, contains an N-terminal NifS-like domain that binds pyridoxal phosphate (PLP) via a 
conserved lysine residue and desulfurates L-cysteine to L-alanine, thereby generating a 
cysteine persulfide.  
The persulfide sulphur generated by the NifS-like domain is transferred to the C-terminal 
domain for the conversion of bound desulfo-molybdenum cofactor into sulfurated 
molybdenum cofactor, which is required to activate XDH and AO enzymes. 
 
It was not until 2000 that a gene and protein were identified that was responsible for 
this activity. In 2000 the Drosophila melanogaster and Aspergillus nidulans MCS 
cDNAs were cloned. The Drosophila  gene was mapped to the X chromosome with a 
total length of 3.5kb with a coding region of 2.7kb spread over four exons (Amrani et 
al., 2000). With the knowledge of the Drosophila  gene homologous genes were 
cloned from other species. MoCo sulphurases have been cloned from bovine (MCSU) 
(Watanabe et al., 2000), human (HMCS) (Ichida et al., 2001), A. nidulans (hxB) 
(Amrani et al., 1999) and A. thaliana (Aba3) (Xiong et al., 2001). Of the MCS genes 
cloned the best studied is Aba3 from the plant Arabidopsis thaliana . Comparison of 
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the NH2-terminal domain of Aba3 with other proteins indicated that it shares 
significant similarities to NifS-like cysteine desulphurases in a pyridoxal-5-phosphate 
(PLP)-dependent mechanism of trans-sulfuration  (Bittner et al., 2001; Hille, 2005; 
Hille et al., 2011; Mendel & Bittner, 2006; Mendel & Hansch, 2002; Schwarz et al., 
2009) (Figure 20).  The C-terminal domain does not exhibit striking similarities to any 
other protein apart from other molybdenum cofactor sulphurase in other species and a 
mitochondrial amidoxine-reducing enzyme (Havemeyer, 2006). Molecular analysis of 
three Aba3 mutants in Arabidopsis thaliana  identified mutations in both the N-
terminal domain and C-terminal domain. These plants have strongly reduced XDH 
and AO activities but normal SO and nitrate reductase activities which are caused by a 
substitution of arginine 723 by a lysine within the C-terminal domain of the Aba3 
protein (Wollers et al., 2008). The biochemical and pathological consequences of this 
genetic lesion was a lack of abscisic aldehyde to abscisic acid (Aba) conversion which 
related to simultaneous loss of AO and XDH activities, which resulted to total loss of 
seed dormancy, wilty phenotype and impaired stress response in the MCS deficient 
plants (Seo et al., 2000). Further investigations demonstrated that the NH2-terminal 
domain of Aba3 transfers sulphur from L-cysteine to yield elemental sulphur, which is 
immediately bound as persulphide to a conserved protein cysteinyl residue within the 
domain (Wollers et al., 2008). Recently Lehrke et al. (2012) confirmed these results 
by a structure of NifS-like domain of Aba3 which indicated that Cys428 and Cys435 are 
conserved and bound as persulphide (Lehrke et al., 2012). Co-incubation of Aba3 C 
terminus carrying sulphurated molybdenum cofactor with partially active XDH and 
AO resulted in the stimulation of their enzymatic activities. This data suggested that 
the C-terminal domain of Aba3 might act as a scaffold protein where pre-bound 
desulpho-molybdenum cofactor is converted into sulphurated cofactor prior to the 
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activation of XDH and AO (Wollers et al., 2008). The domain structure and proposed 
mechanism of MCS is shown in figure 19. 
1.7. Molybdo-flavoenzyme deficiencies. 
Molybdo-flavoenzymes deficiencies with particular emphasis on hereditary 
xanthinuria, which is directly related to one of the research objectives described in this 
thesis. 
1.7.1. Hereditary xanthinuria. 
Xanthinuria is an inherited deficiency of XOR, which results in the inability to convert 
xanthine and hypoxanthine to uric acid (Dent & Philpot, 1954 ; Holmes & 
Wyngaarden, 1989). Hereditary xanthinuria can be subdivided into two types. 
Hereditary xanthinuria type I is characterised by a lack of XOR whereas the type II 
disease is characterised by a dual deficiency of AO and XOR. Hereditary xanthinuria 
type II is distinguished from hereditary xanthinuria type I by the oral administration of 
the AO substrates allopurinol, N1-methylnicotinamide or pyrazinamide. Hereditary 
xanthinuria type I patients show a normal ability to oxidise these compounds to 
oxipurinol, 2- and 4-pyridonecarboxamides and 5-hydroxypyrazinamide respectively 
whereas patients with hereditary xanthinuria type II show a defective ability to oxidise 
these compounds indicating a dual deficiency of both AO and XOR because 
allopurinol and pyrazinamide are substrates for XOR and AO and N1-
methylnicotinamide substrate for AO (Levartovsky et al., 2000; Reiter et al., 1990; 
Yamamoto et al., 1989; Yamamoto et al., 1991). Hereditary xanthinuria type I is 
caused by a defect in the structural gene for XOR so only XOR is absent (Borucka et 
al., 2010; Gok et al., 2003; Simmonds et al., 1995). 9 different mutations that cause 
hereditary xanthinuria type I have been identified that are summarised in table 8. With 
regards mutations that cause hereditary xanthinuria type II following the cloning of 
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the Drosophila  MCS, the gene was identified in mammals by the study of a herd of 
cattle in Japan affected by xanthinuria type II. The bovine MCS gene has an open 
reading frame of 2547 nucleotides, which encodes a protein of 849 amino acids. This 
amino acid sequence was 40% identical to the Drosophila molybdenum cofactor 
sulfurase protein (Wahl et al., 1982; Watanabe et al., 2000). When compared to the 
sequence obtained from the affected offspring in the herd a three base pair deletion 
from nucleotides 769-771 resulting in the loss of tyrosine 257 was identified 
(Watanabe et al., 2000). The following year the human MCS gene was cloned and a 
nonsense mutation that causes hereditary xanthinuria type II in two independent 
xanthinuric patients from the Kanto region of Japan identified (Table 8) (Ichida et al., 
2001). Later the first mutation in the C-terminal domain of HMCS was identified in a 
Bedouin-Arab child and a Jewish female (Peretz et al, 2007). A list of known 
hereditary xanthinuria type II mutations is summarised in table 8. Mutations that lead 
to the genetic deficiency of XOR or dual AO/XOR deficiency in eukaryotes with their 
phenotypes are listed in tables 8 and 9. 
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Species Disease/ Mutant Gene/protein affected Mutations Symptoms 
Humans 
(Homo sapiens) 
Xanthinuria 
type I 
Lack only XOR/XDH 
activity or mutation in 
gene encoding XOR 
c.682C>T,  resulting in p.Arg228X (Ichida et al., 1998). 
c.2164A>T, resulting in p.Lys722Tyr in exon 20 (Gok et al., 2003). 
A heterozygous deletion resulting in p.Pro214GlnfsX4 (Stiburkova et al., 2012). 
p.Arg825X, p.R825X and p.R881X (Stiburkova et al., 2012). 
c.445C>T, resulting in p.Arg149Cys (Sakamoto et al., 2001).  
c.1658insC translation frameshift predicting a truncated protein of 569 amino acids 
with an altered C-terminal amino acid sequence as compared 1333 amino acids of the 
native protein (Levartovsky et al., 2000).  
514G>A resulting in p.Gly172Arg (Levartovsky et al., 2000). 
 3326A>C resulting in p.Asp1109Thr (Levartovsky et al., 2000).   
3662A>G resulting in p.His1221Arg (Kudo et al., 2008). 
c.2810C>T, resulting in p.Thr910Met (Arikyants et al., 2007). 
 
Xanthinuria and the 
accumulation of xanthine calculi 
in renal tubules that leads to 
renal dysfunction and 
hypouricemia results from 
decreased uric acid production. 
Humans 
(Homo sapiens) 
Xanthinuria 
type II 
Lack of activity of both 
XOR and AO due to a 
mutation or mutations 
in the MCS gene 
c.1255C>T, resulting in p.Arg419X (Ichida et al., 2001). 
c.466G>C, resulting in p.Ala156Pro (Yamamoto et al., 2003). 
c.1034insA resulting in p.Gln347fs*379, which leaded to an inactive HMCS protein 
because the truncated protein lacks the important Cys430 residue in the Nifs like 
domain, and the entire C-terminal domain (H. Peretz et al., 2007). 
c.2326C>T, resulting in p.Arg776Cys. is essential for core structure of the C-terminal 
domain of the HMCS at this site may contribute clarifying the mechanism of MoCo 
sulfuration (H. Peretz et al., 2007). 
  
Xanthinuria and the 
accumulation of xanthine calculi 
in renal tubules that leads to 
renal dysfunction and 
hypouricemia results from 
decreased uric acid production. 
Appear a defective ability to 
oxidise allopurinol and 
pyrazinamide are substrates for 
XOR and AO and N1-
methylnicotinamide is substrate 
of AO indicating a dual 
deficiency of both AO and XOR 
Bovine 
(Bos taurus) 
Xanthinuria 
type II 
Lack in both XOR and 
AO activity due to 
mutation in MCS gene 
c.769-771delTAC resulting in p.Tyr257del (Watanabe et al., 2000). 
Xanthinuria and increased 
xanthine secretion in the urine 
related with lethal growth 
interruption at approximately  
6 months of age. 
 
Table 8: Genetic deficiency of mammalian molybdo-flavoenzymes.  
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Species Disease/ Mutant Gene/protein affected Mutations Symptoms 
Fruit fly 
(D.melanogaster) 
Model for xanthinuria  
type I 
(rosy mutants) 
Lack XOR activity due to 
mutation in gene encoding 
XOR (rosy locus) 
There are more than 200 rosy mutant strains are available, of which at 
least 23 have been sequenced. Four popular strains used are: 
1) The ry506 strain mutation is a deletion of approximately 2/3 of the 
3'-end of the XDH gene (Hughes et al., 1992; Reaume et al., 1989). 
2) The ry606 strain p.Glu89Lys, this mutation is located in the iron-
sulphur domain of the XDH gene (Gray et al., 1991; Hughes et al., 
1992; Lee et al., 1987). 
3) The ry544 strain p.Gly1011Glu, this mutation is located in the pterin 
molybdenum cofactor domain of the XDH gene (Gray et al., 1991; 
Hughes et al., 1992; Lee et al., 1987).  
4) The ry406 strain p.Gly348Glu, this mutation is located in the flavin 
domain of the XDH gene (Gray et al., 1991; Hughes et al., 1992; 
Lee et al., 1987).  
Dull brown eye colour, which darkens 
with adult age due to a partial 
deficiency of the red pteridine 
pigments compared to relatively 
normal wild type.  
 
Fruit fly 
(D.melanogaster) 
Model for xanthinuria 
 type II 
 (maroon-like  mutants) 
Lack in both XOR and AO 
activity due to mutation in 
MCS gene 
Unknown 
 
Reddish brown eye colour from a 
reduction in the red (drosopterin) 
pigments, loss in activity of XDH 
(Amrani et al., 2000; Bentley & 
Williamson, 1982; Finnerty et al., 
1970; Forrest et al., 1961). 
 
 
Silkworm 
 (Bombyx mori) 
Model for xanthinuria  
type I Mutation in BmXDH gene 
The ogz mutant has both an insertion and a deletion mutation. The 
deletion removes 386/822 amino acid residues (47% of the length) of 
the og protein, while the insertion inserts 47-bp, both at the C-terminal 
part, which caused premature stop codons and leads to the absence of 
XDH activity (Komoto, 2002; Komoto et al., 2003). 
Translucent mutant phenotype and 
accumulation of hypoxanthine and 
xanthine. High mortality during pupal 
period and low viability of moths. 
Causes sterility in females. 
 
Silkworm  
(Bombyx mori) 
Model for xanthinuria 
 type II Mutation in MCS gene 
A 2.1 kb deletion containing the transcription initiation site, exons 1 
and 2 the 5' end of exon 3 of the MCS gene was found in ogz (Ozaki,s-
translucent) mutant, which caused a complete loss-of-function allele 
(Fujii et al., 1998; Fujii et al., 2010; Fujii et al., 2009; Komoto, 2002). 
Translucent mutant phenotype and 
accumulation of hypoxanthine and 
xanthine. High mortality during pupal 
period and low viability of moths. 
Causes sterility in females. 
Thale cress 
(Arabidopsis thaliana) 
Model for xanthinuria  
type II Mutation in ABA3 MCS gene 
Strong reduction in AO and XDH activities due to a substitution of 
p.Arg723Lys within the C-terminal domain of the ABA3 MCS protein 
(Heidenreich et al., 2005; Sagi et al., 2002; Wollers et al., 2008).  
Complete loss of AO and XDH 
activity. Loss of seed dormancy, loos 
stress tolerance and wilty phenotype  
Fungi 
(Aspergillus nidulans) 
Model for xanthinuria 
 type II Mutation in hxB gene 
c.334delG of a methionine codon resulted in a stop codon 9 bp 
downstream (Amrani et al., 2000; Anantharaman & Aravind, 2002; 
Yamamoto et al., 1991). 
Complete loss of AO and XDH 
activity. Unable to use hypoxanthine 
as a nitrogen source 
Table 9: Genetic deficiency of non- mammalian molybdo-flavoenzymes.  
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1.8. Molybdo-flavoenzyme deficiencies in insects  
AO and XOR enzyme deficiencies have been identified in two insect species, 
silkworm (Bombyx mori) and the fruit fly (Drosophila melanogaster) (Chovnick et al., 
1971; Chovnick et al., 1990; Edwards et al., 1977; Fujii et al., 2009; Komoto, 2002; 
Komoto et al., 2003). Although all the mutants are deficient in XDH activity, they are 
different from each other in molybdo-flavoenzyme activity. Drosophila melanogaster 
have been investigated for a number of years and first mutant that lacked both 
molybdo-flavoenzymes were discovered in 1956 (Forrest et al., 1956; Hadorn & 
Schwinck, 1956). These mutants lack both XOR and AO activity and retain SO 
activity (Wahl & Rajagopalan, 1982). Maroon-like locus (ma-l) homozygotes are 
completely deficient in XDH and AO activities (Finnerty et al., 1979; Kamdar et al., 
1997) and display a maroon eye colour compared to the bright red seen in wild type 
Drosophila  (Amrani et al., 2000; Finnerty et al., 1979; Wahl & Rajagopalan, 1982). 
The two most widely used ma-l mutant strains (mal-1 and mal-f1) were induced by X-
ray and nitrogen mustard respectively (Bridgesc & Brehme, 1944; Schalet, 1960). 
Many studies reported that mal-1 is able to complement mal-f1. Glassman and 
Pinkerton, (1960) as well as Ursprung, (1961) and Chovinck et al. (1968) have 
examined the complementation phenotype between mal-f1/mal-1 they found low 
XDH and PO activity in the heterozygotes (Chovnick et al., 1969; Glassman & 
Pinkerton, 1960; Ursprung, 1961). In insects the dual deficiency of XOR and AO has 
been extensively studied in silkworm. Ozaki,s translucent (ogz) silkworm mutant 
strains with deletions, insertion and amino acid substitution in the MCS gene have 
been identified that lack AO activity along with XOR activity (Fujii et al., 2009). The 
(ogz) mutation in the MCS gene leads to translucent larval skin because of the inability 
to synthesize uric acid, high mortality and sterility (see table 9) (Fujii et al., 2009).  
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 The rosy gene encodes the XDH apoprotein and rosy mutants show normal AO 
activity (Kidd et al., 1999). The reason for these mutants being termed rosy relates to 
adult wild type flies have a bright red colour whereas rosy mutants have a brick red 
eye colour (see figure 20) (Cote et al., 1986). Of the greater than 200 rosy strains of 
D. melanogaster currently available, at least 23 have been well characterised (Gray et 
al., 1991).  
 
Figure 20: Wild type eye colour on the left and ry506 mutant eye colour on the right.  
Photograph taken by Dr DJ Clarke. Used with permission. 
 
Maroon-like and rosy mutants both have the same dull red eye colour, are deficient in 
uric acid and have relatively high xanthine and hypoxanthine when compared with 
wild type strains. Maroon-like and rosy strains are unable to oxidise hypoxanthine 
levels to xanthine then to uric acid, or convert 2-amino-4-hydroxypterdine to 
isoxanthopterin, which are reactions catalyzed by the XDH. This is due to the absence 
of the XDH enzyme. In the ry506 strains the lack of the XDH enzyme is due to 
mutations in the XDH gene on chromosome 3 (see table 9) (Glassman & Mitchell, 
1959). The genetic lesion is different in the maroon-like strain and is associated with 
the lack of a functional MCS gene on chromosome X (Courtright, 1967; Finnerty et 
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al., 1979). In addition, to the deficiency of XDH the ma-l mutants are also defective in 
AO (Courtright, 1967) and pyridoxal oxidase (Forrest et al., 1961).  
1.9. Effects of molybdo-flavoenzymes deficiencies on oxidative stress 
and xenobiotic toxicity in D. melanogaster.  
1.9.1. Effect of molybdo-flavoenzymes deficiencies on oxidative stress and 
xenobiotic toxicity in D. melanogaster. 
Uric acid has been shown to be an effective in vitro scavenger of singlet oxygen, 
peroxyl radical and hydroxyl radical (Chow, 1988). As ry and ma-l strains cannot 
produce uric acid as they are deficient in XDH activity these strains provide a means 
for critical in vivo analysis of the role of uric acid in oxygen defence (Phillips & 
Hilliker, 1990). Biological models proposing an important antioxidant role of uric acid 
predict that urate-null mutants should be more susceptible to oxygen radicals. Hilliker 
et al. (1992) reported an investigation of the role of uric acid in oxygen defense in 
ry506 urate-null mutants. Hilliker et al. (1992) measured the toxic response of these 
mutants to oxygen stress imposed by exposure to radical generating redox cycling 
agents, ionizing radiation, and increased oxygen tension. The results clearly 
demonstrated the in vivo radical-scavenging role of urate and reveal a critical 
metabolic role of this classical molybdoenzyme-genetic system in Drosophila . 
Hilliker et al. reported that ry506 mutants are demonstrably impaired in their capacity 
to detoxify the active oxygen generated by such diverse agents as paraquat, hyperoxia, 
and ionizing radiation (Hilliker et al., 1992). In additional, Humphreys et al found ma-
l strain had paraquat hypersensitivity due to the lack of XDH activity, which leads to 
absence of uric acid (Humphreys et al., 1993). In this role, uric acid can act either by 
directly scavenging active oxygen species, in which case it is oxidized into a variety 
of products including allantoin, oxaluric acid and parabanic acid (Kaur & Halliwell, 
1990) or by binding radical-generating transition metals into poorly reactive 
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complexes (Davies et al., 1986). Hamatake et al. also demonstrated that the urate-null 
strain was more sensitive to environmental cigarette smoke (ECS) toxicity than wild 
type strains (Oregon-R) as assayed by survival and fecundity. They hypothesised that 
oxidative damage seems to be involved in the toxicity of ECS as uric acid plays a role 
as an important antioxidant in Drosophila (Hamatake et al., 2009). 
 In D. melanogaster, caffeine has been shown to cause premature aging and a 
reduction in lifespan especially in males (Kuhlmann et al., 1968). It also induces 
somatic damage and chromosome breakage (Kuhlmann et al., 1968). Caffeine also 
interferes with DNA metabolism (Nigsch et al., 1977) DNA replication (Boyd & 
Presley, 1974), maternal systems (Mendelson & Sobels, 1974) and is mutagenic 
(Bateman, 1969). Graf & Wurgler (1986) found that 4% w/v
 
caffeine media killed 
approximately 75% of exposed flies (Graf & Wurgler, 1986). Nikitin et al. 2008  
showed that the lifespan of Canton-S Drosophila melanogaster males is reduced with 
varying caffeine concentration (1.5-13 mM) (Nikitin et al., 2008). Zimmering et al. 
1977 that found that caffeine is lethal to adult D. melanogaster  (Zimmering et al., 
1977) and at lower concentration decreases longevity and fecundity in Drosophila 
prosaltans (Carrillo & Gibson, 2002; Itoyama et al., 1998). Zimmering et al. (1977) 
found a high mortality rate (100%) in the ry506 flies after three days exposure to 1.25-
2.5 mg/ml caffeine compared with wild type Canton-S in which the mortality rate was 
around 40%. This suggests that Drosophila  XDH is involved in the chemoprotection 
against caffeine. 
1.9.2. Effects of molybdo-flavoenzymes deficiencies on longevity of D. 
melanogaster. 
 It has been proposed that uric acid has important role as an antioxidant in vivo and 
singlet oxygen scavenger properties and it is important in determining species 
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longevity (Ames, 1983). A number of longevity investigations have been carried out 
with Drosophila  strains that are XOR-null. In 1989 Shepherd et al. (1992) observed 
that the mutant ry506 strain had a reduced lifespan when compared to a wild type strain 
because the mean survival for male ry506 was approximately half of wild type (ry+)  
(Shepherd et al., 1989). A further study was carried out with XOR-null strain (ry506), 
during this study male ry506 strains were observed to have a 20% reduced lifespan 
compared with the wild type strains (Oregon R). This study also demonstrated that 
ry506 flies had a reduced immune response to bacterial infection when compared to a 
wild type strain due to the important role XDH plays in the innate immune response 
(Kim et al., 2001).  
1.9.3. Effect of purine on molybdo-flavoenzymes deficiencies on D. melanogaster.  
Geer and Laurie-Ahlberg tested survival rate of male wild type (Oregon R) and ry506 
(null XDH) D. melanogaster in purine medium (Geer & Laurie-Ahlberg, 1984). 
Although the high concentration of purine was toxic to all strains, it was less toxic to 
the wild type than ry506 (Tiveron et al., 1991). This demonstrated XDH role in 
chemoprotection against purine as a toxic substance. 
1.10. Effect of molybdo-flavoenzymes deficiencies on temperature 
stress on D. melanogaster 
The effects of temperature on the survival and longevity of D. melanogaster  have also 
been investigated. Duncker serendipitously demonstrated the protection role of XDH 
in cold stress. Duncker et al. (1995) created transgenic Drosophila  by transforming ry8 
flies that are deficient in XDH activity with an antifreeze protein (AFP) gene using a 
vector with the xdh marker gene to restore wild type eye colour. A control experiment 
was also performed in which the vector only without the AFP gene was used to 
transform the flies. When the two types of flies were tested for cold tolerance the 
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surprising finding was that flies that hosted the AFP gene did not have a greater 
tolerance than those with the vector only. Thus the AFP had no effect. However when 
the ry8 were compared with transgenic flies with the vector it was found that they had 
a significantly increased temperature tolerance at 0 and -7°C implicating XDH as 
conferring this effect (Duncker et al., 1995). 
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1.11. Aims of the project. 
The use of organisms that are genetically deficient in physiological functions has 
greatly aided our understanding of many biological functions. At present despite 
MFEs role as detoxification enzymes there has been no study to date that has used 
mutant organisms to authenticate this in vivo. Although bovine and human mutants 
that have hereditary xanthinuria exist, toxicological studies with these organisms are 
obviously problematic and raise ethical issues. Despite knockout mice that are XOR 
or AO deficient being created (Garattini et al., 2008) they have not been used for such 
investigations and no dual mutants exist. The availability of Drosophila melanogaster 
that are models for both hereditary xanthinuria type I (XDH deficiency) and II (ma-l 
mutants with XDH and AO deficiency) provides an opportunity to scrutinize the role 
of these enzymes in detoxification and expand studies on their role in senescence and 
stress response. Drosophila melanogaster is ideal for such studies due to their well 
understood biology, short lifespan and low cost in carrying out experimentation. 
The aims of this study are as follows: 
(a) Determine the molecular basis for dual deficiency of AO and XOR in ma-l 
mutants. 
(b) Determine the role of XOR and AO in the biotransformation of compounds in 
vivo and in vitro using MFE-deficient, transgenic and wild type Drosophila 
melanogaster. 
(c) Determine the role of MFEs in detoxification by examining the effects of 
exogenous and endogenous compounds in MFE-deficient, transgenic and wild type 
Drosophila melanogaster. 
(d) Determine the effect of MFEs deficiencies on lifespan and temperature stress in 
MFEs mutant, transgenic and wild type Drosophila melanogaster. 
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2.0. Materials and methods. 
All chemicals and reagents were obtained from Fisher Scientific and Sigma / Aldrich 
Chemical Company Ltd, Poole, UK. Mobile phase reagents and solvents were 
obtained from various companies but were all for HPLC grade purity. 
 2.1. Animal studies. 
2.1.1. Drosophila melanogaster strains used for research. 
Drosophila melanogaster strains were obtained from the Bloomington Drosophila 
Stock Centre, Indiana University (USA). All these strains and mutations were those as 
described in (Lindsley & Zimm, 1992 ). 
 The following strains were obtained from Bloomington Drosophila  Stock Centre: 
Bloomington stock numbers are in parentheses 
 Canton-S (1): Normal wild type Drosophila melanogaster (parental strain). 
 ry506 (225): Strain deficient in XOR activity. 
 mal-1 (3973) and mal-f1 (180): Strains deficient in MCS activity. 
 Transgenic T1 and T2 strains: ry506 mutant strain transformed with a normal 
Drosophila  XOR   gene in Carnegie 20 vector. 
2.1.2. Drosophila melanogaster media. 
All fly strains stocks were housed at 250C in controlled incubators with 12/12 h 
light/dark cycle and maintained on standard agar medium as follows: 
 
 
 
 
48 
 
Table 10: Chemicals used for preparing agar medium (Ashburner, 1989). 
Chemicals Amount for 250 ml of medium 
Agar no. 2: (agar (15.0 g/L), peptone (vegetable) (5.0 
g/L) and vegetable extract (3.0 g/L) from Sigma / Aldrich 
Chemical Company Ltd, Poole, UK  
3.75g 
Dried baker’s yeast 21.5g 
Tap water 250 ml 
Sucrose 20.0 g 
Antifungal chemicals  
Nipagen (Ethyl 4-hydroxybenzoate) 2.0 ml (2 g/20 ml in ethanol) 
CBZ (Carbendazim solution) 7.5 ml (8 mg/ 100 ml in ethanol) 
 
All the above ingredients with the exception of the anti-fungal compounds were 
weighed and dissolved in 250 ml of water and autoclaved. After autoclaving the 
medium, it was cooled to approximately 450C and the antifungal chemicals were 
added and mixed. The medium was then poured into about 5 to 6 autoclaved bottles 
(height: 7 cm; diameter: 2.5 cm) (Figure 21) or 30 autoclaved vials (height: 12.5 cm; 
diameter: 5 cm) for lifespan and temperature stress studies. Care was taken to ensure 
no bubbles formed while pouring and that the media depth was approximately 3 cm in 
bottles and 1.5 cm depth in vials. Following aliquoting of media this was left to set 
and vials and bottles were kept at ambient temperature for 2 days covered with paper 
towels to ensure all moisture left on the side of the bottles was eliminated. 
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Figure 21: Bottle container for D. melanogaster  media. 
 
2.1.3. Procedure for transferring Drosophila melanogaster to new media bottles 
and vials. 
A small amount of diethyl ether was poured in the base of the etherising container 
(Figure 22) and kept in it for few minutes so that it filled with ether vapour. After that, 
the glass bottle with Drosophila melanogaster was inverted over the funnel without 
the wooden cork so all Drosophila fell in to the funnel. To ensure the majority of flies 
were transferred the bottom of the bottle was slapped two times by hand. The plastic 
container and the funnel were then closed so that Drosophila  did not fly out. Once all 
Drosophila melanogaster  were etherised (usually after about 15-20 seconds), they 
were transferred into appropriate glass bottle or vial for further study. While etherising 
                 Sponge bung 
                 Glass bottle 
               Medium 
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the Drosophila melanogaster care must be taken so that they don’t die. For 
maintenance of fly stocks new bottles of media were prepared weekly and all flies 
transferred.  
 
Figure 22: Container used for etherising flies. 
 
2.2. Drosophila melanogaster lifespan tests. 
Newly eclosed male wild type and mutant Drosophila  strains were collected into glass 
vials containing approximately 5 ml of food medium as described in section 2.1.2. The 
vials were covered with sponge bungs and the flies were then left in medium vials 
overnight in a 25°C incubator to ensure they had recovered from the ether anaesthetic. 
Eclosing individuals were sequestered daily and male Drosophila  were transferred to 
a fresh glass vial containing 5 ml of fly medium as described in section 2.1.3. Lifespan 
studies were carried out in a 12 hour light/dark cycle at 250C to mimic the natural 
conditions of the Drosophila , with a total of 100 newly eclosed males (10 per vial) 
    Funnel 
 Wooden cork 
Plastic container 
Cotton with a few       
drops of   ether 
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tested for each longevity experiment. Bradley and Simmons (1997) studied ten 
different types of Drosophila; they found that lifespan increased when metabolic 
wastes did not exist in the media, so this factor affecting on the lifespan was corrected 
by frequent renewal of the media every 4 days (Bradley & Simmons, 1997). Transfer 
of flies into new vials with media was done by simply tapping the glass vial 
containing the flies on the bench so that all the flies dropped to the bottom of the vial, 
quickly removing the sponge bung and inverting the vial and gently tapping the flies 
into new vial. The new vial was then rapidly closed with a sponge bung. 
2.3. Heat and cold shock experiments. 
The same procedure was used as with the lifespan test except for the fact that 100 flies 
(3 days old) from each strain were placed in 5 vials with 20 flies per vial. These vials 
were sealed with a plastic leak-proof cap and immersed for 1, 2, 4 or 6 hours  in a 
temperature (-3 ± 0.5°C, 0 ± 0.5°C, 37 ± 0.5°C and 39 ± 0.5°C) controlled circulating 
water bath to a depth such that vial’s water seal cap plug was below water level (Golic 
& Lindquist, 1989). The controls from each strain were placed in the same sealed vials 
in an incubator at 25°C to make sure that there was enough oxygen after 6 hours. 
After each time the vials were removed and checked under the microscope for the 
number of flies paralysed (Gong & Golic, 2006). The flies were put into vials with 
media overnight to recover in a 25°C incubator. The next day the numbers of deaths, 
if any, were counted adult; flies that were able to fly, walk or stand were scored as 
alive (Overgaard & Sorensen, 2008).  
2.4. Drosophila melanogaster toxicity tests. 
All toxicity experiments were carried out at 25°C in a 12 hour light/dark cycle with 3 
days old flies being used. The flies were collected and transferred to medium (see 
standard medium in section 2.1.2) containing different concentration of the AO and 
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XOR substrates used to evaluate chemoprotection by XOR and AO. All these 
substrates were made up in concentrations from 0 mM to 100 mM in distilled water or 
in appropriate solvents (Table 11). As the higher concentrations were close to the 
saturation point of some of the compounds the solutions were placed in a sonicating 
bath to increase dissolution of the compound. All the final concentrations of these 
xenobiotics were prepared by dilution with water before adding the dry ingredients for 
the normal culture medium (as standard medium in section 2.1.2). Care was taken to 
ensure uniform distribution of the chemicals by vigorously shaking in the culture 
medium. Vials with media were then left to dry for 2 days before use. For the 
experiments the vials were incubated at 250C and the number of survivors recorded 
every 24 hours. Twenty flies were added to each vial and the survivors were 
transferred to new vials containing the same concentration of xenobiotics every four 
days. Control experiments were carried out using appropriate solvents as controls. 
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Table 11: A list of the xenobiotics used in toxicity experiments. Comments and appropriate 
solvents are indicated.  
Xenobiotics 
(stock concentration) Comment 
AO and XOR 
substrate Solvent 
6-Mercaptopurine 
(100 mM) Anti-cancer drug AO/XOR 
10 mM  NaOH 
sonicating 
Allopurinol 
(0.5M) Hyperuricemia drug  XOR/AO 
10 mM  NaOH 
Sonicating 
Caffeine 
(100 mM) Drug and food industry - 
10 mM  NaOH 
sonicating 
Cinchonine 
(100 mM) Anti-malarial drug AO 
dH2O 
drops of 0.1M HCl 
N1-Methylnicotinamide 
(100 mM) 
Endogenous vitamin 
metabolite AO 
dH2O  
sonicating 
Paraxanthine 
(0.5 M) Metabolite of caffeine XOR 
10 mM  NaOH 
sonicating 
Phenanthridine 
(100 mM) Environmental pollutant AO Absolute ethanol 
Pyrazinamide 
(100 mM) Tuberculosis drug AO/XOR 
10 mM NaOH 
sonicating 
Theobromine 
(100 mM) 
The primary 
methylxanthine in chocolate XOR 
10 mM  NaOH 
sonicating 
Theophylline 
(100 mM) Asthma drug XOR 
10 mM  NaOH 
sonicating 
Vanillin 
(0.5 M) Food industry AO dH2O (heated to 70
0C) 
2.4.1. Survival rate. 
Survival rates were calculated for all strains by comparing results from control and 
xenobiotics supplemented medium for each strain. 
Survival rate =  
 
 
2.5. Analysis of the in vivo metabolism of molybdo-flavoenzyme 
substrates by Drosophila melanogaster. 
Drosophila melanogaster (3 days old) were maintained on media containing various 
xenobiotics listed in table 11 and were removed from incubator and etherised. The 
whole flies were then immediately frozen at -80˚C for HPLC analysis of metabolites. 
20 flies weighing approximately 20 mg were placed in a 1.5 ml polypropylene 
Eppendorf tube and 180 µl of phosphate buffer saline (PBS) [0.2g of KCl 8g of NaCl 
0.36g of Na2HPO4.2H2O and 0.4g of KH2PO4 in 1000 ml of dH2O, pH 7.4] was 
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added. This was homogenised with a plastic homogeniser, vortexed for 30 sec and 
centrifuged for 5 min at 10,000 xg.  The supernatant was then removed and 20 µl was 
injected onto the HPLC. To confirm the individual peak retention time, 50 µl from 
each sample was spiked by mixing with 50 µl of 0.5 mM of working standard solution 
mixtures of individual compounds. Control assays were also performed on flies 
maintained on standard media without xenobiotics. 
2.5.1. HPLC analysis of the xenobiotic substrates and metabolites. 
Analysis of purine compounds, drugs and their metabolites were carried out by 
reverse HPLC. Using Beckman Coulter System GoldTM 127 Solvent HPLC Module 
(dual pump) and a programmable UV detector (module 166) or a programmable diode 
array detector (module 168) with injector equipped with a 20 µl sampling loop. The 
analytical columns used were either: a Kromasil (25 cm X 4.6 mm, 5µm; RP-C18), 
Hypersil ODS (25 cm X 4.6 mm, 5µm; RP-C18), LiChrosphere® (25 cm X 4 mm, 
5µm; RP-C18) or Spherisorb® (5µm CNRP 4.6 X 15 cm; RP-C18). A guard column 
(5µm) with same stationary phase was used upstream of the analytical column. The 
columns were obtained from Phenomenex, UK and Captial HPLC limited, UK. The 
mobile phases were filtered through a 0.45µm filter before use. Isocratic and gradient 
system were used to develop the best conditions for the separation components and 
most highly sensitive method for the determination of the different compounds in 
biological samples. In order to achieve this, HPLC methodologies were developed to 
allow the necessary enzyme assays to be performed using only very small amounts of 
a sample that were available. The mobile phase reagents and solvents were all HPLC 
grade purity. 
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2.5.2. Analytical procedure. 
2.5.2.1. Preparation of standards of calibration curves. 
A 5 mM individual stock solution of AO and XOR substrates and products were 
prepared in appropriate solvent (see table 11). After preparing the stock solutions a 
working standard solution of 1 mM were prepared by dilution with water. 
Quantification was done using six standards prepared from stock solution with dH2O 
ranging from 0.01 to 0.1 mM. These were injected onto the HPLC starting with the 
lowest concentration and were converted to (0.2 to 2 nmol/l); see figures 2-10 in 
appendix 1. All stock's solutions were stored at 40C with the exception of vanillin and 
N1-methylnicotinamide which were stored at -200C.  
2.5.2.2. Validation  
2.5.2.2.1. Methods accuracy and precision. 
Calibration standard injected on the same day were taken into calculation for intra-day 
accuracy and precision. This is a measure of the distribution of individual 
measurements around the mean. This parameter was assessed by repeated analysis of 
the same solution and expressed as the relative standard deviation (RSD) otherwise 
known as the coefficient of variation (CV). % RSD for retention time was calculated 
by dividing the standard deviation by the mean of retention time of three replicates in 
the same day (Ghassan et al., 2010; Miller & Miller, 2005). The accuracy of the assay 
was calculated by comparison of the nominal analyte concentration to the actual 
concentration obtained from the linear regression line within the concentration range 
investigated (0.01mM to 0.1 mM) (Accuracy = nominal concentration / actual 
concentration x 100). By using slope, intercept and the correlation coefficient (RSQ or 
r
2) for the linearity of the calibration curve was determined for each analyte.  
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2.5.2.3. Detection and Quantification limits. 
For the linearity for the results, the lower limit of Quantification (LOQ) and limit of 
detection (LOD) were determined for each analyte. According to international 
conference on harmonisation (ICH) guidelines, the LOD is defined as the lowest 
concentration of an analyte in a sample that can be detected but not quantified. The 
LOQ is the lowest amount of analyte in a sample that can be quantitatively determined 
with suitable precision and accuracy under the standard operational conditions of the 
method (ICH, 1994). The lower LOQ and LOD of samples was defined as the lowest 
added analyte concentration to the biological sample that can be measured with a low 
RSD and an accuracy of 100 ± 20% that can be discriminated significantly from the 
basal concentration of analyte in biological samples. The ICH has listed two options 
available to calculate both the LOD and the LOQ of an assay. One of these options are 
expressed as a concentration at a specified signal to noise ratio, usually 3:1 and 10:1 
for the signal to noise ratio for LOD and LOQ respectively (ICH, 1994). The LOD 
and the lower of LOQ were calculated from the mean of the slope (S) and standard 
deviation (SD) of the intercept of three calibration curves using the liner regression 
linear method. The LOD and LOQ are calculated according to the following 
equations: The LOD = 3.3 (SD/S) and the LOQ = 10 (SD/S) (ICH, 1994; Miller & 
Miller, 2005).  
2.5.3. HPLC assay of the purine based, N-heterocyclic and aldehydes substrates. 
All endogenous purines and exogenous methylxanthine compounds (caffeine, 
theobromine, theophylline, paraxanthine and 6-mercaptopurine), purine analogs 
(allopurinol and oxipurinol), aldehydes (vanillin, retinal and pyridoxal) and N- 
heterocyclic compounds (phenanthridine, quinidine, cinchonine, pyrazinamide, 
methotrexate and N1-methylnicotinamide) were purchased from Sigma Aldrich and 
reagents required for the preparation of the HPLC mobile phases were all of HPLC 
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grade purity. Initial stock solutions were prepared as 5mM solutions and were 
weighed into a flask and dissolved in appropriate solvents (see table 11). To ensure 
dissolution all stock solutions were sonicated for approximately 1 minute to dissolve 
any residue chromatograms in the solution. 1mM stocks were prepared by diluting the 
5 mM stocks with distilled H2O. Stock solutions were stored at 4C° in fridge. All 
mobile phases and HPLC methods for above compounds were summarized in tables 
12 and 13. 
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Analyte 
How 
analyte 
dissolved 
Chromatograph column Mobile phases Gradient/ Isocratic Flow rate ml/min Wavelength Reference 
6-mercaptopurine and 
 6-thioxanthine 
10 mM 
NaOH 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with guard 
column 5µm 
A: water H2O with addition of 0.1% 
v/v of glacial acetic acid. Solvent 
B: acetonitrile 
Gradient see 
figure 23 
Flow rate was time 
programmed with the 
variation in the solvent 
which was as follows 
in figure 23 
355 nm 
Modified 
from 
(Begas et al., 
2007) 
Allopurinol and 
oxipurinol 
10 mM 
NaOH 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with guard 
column 5µm 
A: water H2O with addition of 0.1% 
v/v of glacial acetic acid. Solvent 
B: acetonitrile. 
Gradient see 
figure 24 
Flow rate was time 
programmed with the 
variation in the solvent 
which was as follows 
in figure 24 
280 nm 
Modified 
from (Begas 
et al., 2007) 
Caffeine, theobromine, 
theophylline, 
paraxanthine,  
1-methylxanthine,  
3-methylxanthine and  
7-methylxanthine 
10 mM 
NaOH 
sonicating 
Kromasil 5µm (25cm x 4.6 
mm, C18) with guard 
column 5µm 
A: water H2O with addition of 0.1% 
v/v of glacial acetic acid. Solvent 
B: acetonitrile 
Gradient see 
figure 23 
Flow rate was time 
programmed with the 
variation in the solvent 
which was as follows 
in figure 23 
280 nm 
Modified 
from 
(Begas et al., 
2007) 
N1- 
methylnicotinamide 
dH2O 
sonicating 
Water Spherisorb® 5um 
(CNRP 4.6 x 150 mm; 
C18)  
A: 0.1% v/v of formic acid 
B: acetonitrile 
Gradient see 
figure 25 0.8 254 nm 
(Szafarz et 
al., 2010) 
N1- 
methylnicotinamide 
dH2O 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with guard 
column 5µm 
A: water H2O with addition of 0.1% 
v/v of glacial acetic acid. Solvent 
B: acetonitrile 
Gradient see 
figure 23 
Flow rate was time 
programmed with the 
variation in the solvent 
which was as follows 
in figure 23 
280 nm (Begas et al., 2007) 
Phenanthridine and 
6(5H)-phenanthridone 
Absolute 
ethanol 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with guard 
column 5µm 
A: water H2O  
B: acetonitrile. 
Gradient see 
figure 26 1.5 254 nm 
Modified 
from 
(LaVoie et 
al., 1985). 
 
Table 12: Summary of in vivo and in vitro HPLC analysis of purines, purines analog and N-heterocyclic substrates and products  
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Analyte How analyte dissolved 
Chromatograph 
column Mobile phases 
Gradient/ 
Isocratic Flow rate ml/min Wavelength Reference 
Cinchonine dH2O drops of 0.1M HCl 
Hypersil ODS 5µm (25 
cm x 4.6 mm, C18)  
A: of 0.4% w/v 
CH3COONH4,  
pH 3.27 
B: acetonitrile 35% v/v. 
Isocratic 1.0 248 nm (Beedham et al., 1992) 
Methotrexate Absolute ethanol 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with 
guard column 5µm 
A: 0.1 M CH3COONH4, 
methanol (87:5 % v/v), 
 pH 5.5 
B: acetonitrile 8% v/v 
Isocratic 1.5 305 nm (Jordan et al., 1999) 
Pyrazinamide 10 mM NaOH 
sonica-ting 
Kromasil 5µm (25cm x 
4.6mm, C18) with 
guard column 5µm 
A: 20 mM KH2PO4, 
 pH 5.2 
B: acetonitrile 5% v/v. 
Isocratic 0.8 268 nm (Kraemer et al., 1998) 
Pyrazinamide 10 mM NaOH 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with 
guard column 5µm 
A: water H2O with 
addition of 0.1% v/v of 
glacial acetic acid. Solvent 
B: acetonitrile 
Gradient see 
figure 23 
Flow rate was time 
programmed with the 
variation in the solvent which 
was as follows see figure 23 
268 nm 
Modified from 
(Begas et al., 
2007) 
Pyridoxal dH2O 
sonicating 
Kromasil 5µm (25cm x 
4.6mm, C18) with 
guard column 5µm 
A: 60 mM Na2HPO4,  
pH 6.5
 
B: methanol 25% v/v. 
Isocratic 0.8 315 nm 
Modified from 
(Talwar et al., 
2003) 
Retinal Absolute ethanol 
sonicating 
LiChrosphere® 5µm 
(25 cm x 4.0 mm, C18) 
with guard column 
5µm 
A: 30 mM CH3COONH4, 
pH 4.5 
B: acetonitrile 70% v/v. 
Isocratic 1.0 
378 nm  
diode array 
detector 
Modified from 
(Tsujita et al., 
1994) 
Vanillin dH2O 
 (heated to 70˚C) 
Kromasil 5µm (25cm x 
4.6mm, C18) with 
guard column 5µm 
A: 0.22 M KH2PO4,  
pH 2.9 
B: acetonitrile 15% v/v. 
Isocratic 1.5 285 nm 
(Panoutsopoulos 
& Beedham, 
2004) 
 
Table 13: Summary of in vivo and in vitro HPLC analysis of N-heterocyclic and aldehyde substrates and products  
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Figure 23: Diagram showing pump flow rate (red line) and pump gradient (blue line) change 
for purines. 
 
 
Figure 24: Diagram showing pump flow rate (red line) and pump gradient (blue line) change 
for allopurinol and oxipurinol. 
 
%B 
 
Minutes 
%B ml/min 
Minutes 
ml/min 
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Figure 25: Diagram showing pump flow rate (red line) and pump gradient (blue line) change 
for N1-methylnicotinamide. 
 
 
 
Figure 26: Diagram showing pump flow rate (red line) and pump gradient (blue line) change 
for phenanthridine and 6(5H)-phenanthridone. 
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2.5.4. In vitro analysis of Drosophila melanogaster molybdo-flavoenzymes activity. 
2.5.4.1. Preparation of cytosol from Drosophila. 
For the preparation of cytosol from D. melanogaster strains all steps were carried out 
at 0-40C. Approximately 0.7 g of frozen flies from each strain were weighed out and 
homogenised in 2.8 ml of cold buffer (0.25 M sucrose, 10 mM Tris HCL pH 7.4) with 
a motor-driven tissue grinder fitted with a Teflon pestle to produce a 20% w/v 
homogenate. The homogenate was then centrifuged at 40C for 15 minutes at 10,000 
xg, to pellet out the exoskeletons and nuclear/mitochondrial fractions of the 
homogenate. The supernatant was then removed and centrifuged for a further 60 
minutes at 40C at 105,000 xg to obtain the cytosolic fraction. This fraction was then 
collected separated into 0.5 ml aliquots and stored at -800C. The New Zealand white 
rabbit liver cytosol which was used to confirm the metabolite was prepared by 
Dr.D.J.Clarke. 
 
2.5.4.2. Gel filtration of Drosophila cytosol. 
Gel filtration was carried out in order to remove endogenous substrates such as 
purines and inhibitors, which may interfere with enzyme assays. A PD-10 gel 
filtration column was used (GE Healthcare Bio-Science, UK). Prior to use the column 
was allowed to drain before being equilibrated with 25 ml (5 column volumes) 50 mM 
Tris HCL pH 7.4. 1.5 ml of cytosol was then loaded onto the column and eluted with 
2.5 ml of 50 mM Tris HCL pH 7.4, the protein containing fraction was then collected, 
pooled and aliquoted into 0.5 ml fractions in 1.5 ml polypropylene Eppendorf tubes to 
avoid repeated freeze/thawing and stored at -80°C.  
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2.5.4.3. Assessment of in vitro biotransformation of the purines, non-purines, N-
heterocyclic and aldehydes substrates by Drosophila cytosol. 
Individual AO and XOR substrates listed in table 14 were incubated with gel filtered 
Drosophila cytosol as indicated in table 14 at 37°C for various time periods. In vitro 
incubations were composed of 50 µl D. melanogaster cytosol of all strains, 30 µl 
phosphate buffer saline (PBS) and 10 µl 0.1 mM of all substrates listed in following 
table. 10 µl NAD+ (0.67 mM) was used as an electron acceptor for XDH enzyme 
assays. At the end of the incubation time all polypropylene Eppendorf tubes were 
transferred into ice to stop the reaction. For all analytes the effect of mixing the 
analytes with fly extract was assessed by spiking extract with an analyte. In all cases 
no difference in retention time was found. Spiking was also carried out to confirm 
peak identity as well as spectrum scanning using diode array detection when 
appropriate. In all in vitro assays no spontaneous oxidation of any substrate was 
observed when control incubations were carried out without cytosol. 
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Substrate Stock  substrate 
concentration Volume of substrate added Volume of cytosol Volume of buffer  
Volume of NAD+  
(6.7 mM) 
1-methylxanthine 1mM 10 µl 50 µl cytosol 30 µl 10 µl 
3-methylxanthine 1mM 10 µl 50 µl cytosol 30 µl 10 µl 
6-mercaptopurine 1mM 10 µl 50 µl cytosol 40 µl 10 µl 
7-methylxanthine 1mM 10 µl 50 µl cytosol 30 µl 10 µl 
Allopurinol 1mM 10 µl 50 µl cytosol 40 µl - 
all-trans retinal 1mM 10 µl 50 µl cytosol 40 µl - 
Cinchonine 1mM 10 µl 50 µl cytosol 40 µl - 
Methotrexate 1mM 10 µl 50 µl cytosol 40 µl - 
N1- methylnicotinamide 1mM 10 µl 50 µl cytosol 40 µl - 
Phenanthridine 1mM 10 µl 50 µl cytosol 40 µl - 
Pyrazinamide 1mM 10 µl 50 µl cytosol 40 µl 10 µl 
Pyridoxal 1mM 10 µl 50 µl cytosol 40 µl - 
Vanillin 1mM 10 µl 50 µl cytosol 40 µl - 
Xanthine 1mM 10 µl 50 µl cytosol 30 µl 10 µl 
 
Table 14: Summary of in vitro HPLC assays with molybdo-flavoenzyme substrates. 
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2.6. Protein determination. 
The amount of protein in each sample was calculated using a modification of the 
method described by Smith et al. using bovine serum albumin (BSA) as standard 
(Smith et al., 1985). The bicinchoninic acid (BCA) based assay is available as a kit 
from Sigma-Aldrich Co.  
2.6.1. Bicinchoninic acid reagents. 
Reagents supplied in the Sigma-Aldrich Co. kit are: 
1. 1000 ml solution containing bicinchoninic acid, sodium carbonate (Na2CO3), 
sodium tartrate (Na2C4H4O6) and sodium bicarbonate (NaHCO3) in 0.1N NaOH (final 
pH 11.25).  
2.  25 ml solution containing 4% w/v copper (II) sulphate pentahydrate (CuSO4. 
5H2O). For preparation of a set of protein standards a 1mg/ml stock solution of bovine 
serum albumin (BSA) was prepared and this was then used to make the dilutions to be 
used for the calibration curve as shown in table 15 and figure 1 in appendix 1. 
Table 15: Dilution of BSA stock solution to give the required concentration to be used for the 
protein calibration standards. 
 
Final protein concentration 
(mg/mL) 
Volume BSA stock solution 
(µl) 
Distilled water 
(µl) 
0 0 100 
0.2 20 80 
0.4 40 60 
0.6 60 40 
0.8 80 20 
1.0 100 0 
 
2.6.2. Bicinchoninic acid methodology. 
1. The required amount of protein determination reagent was prepared by adding 1 
part CuSO4. 5H2O 4% w/v solution to 50 parts bicinchoninic acid solution. 
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2. Bovine serum albumin standards or gel-filtered cytosol of D. melanogaster  was 
diluted in duplicate at a 1:20 (20 µl cytosol + 380 µl PBS) dilution to get in middle of 
range of diluted standards. 
3. 15 µl of freshly protein determination reagent was added to 300 µl of diluted 
cytosol and vortexed. 
4. All tubes were incubated at 37°C for 30 minutes. 
5. The absorbance at 562 nm was then measured on a microplate reader and distilled 
water was used to zero the instrument. 
2.7. Spectrophotometric determination of molybdo-flavoenzymes 
activity. 
Spectrophotometric molybdo-flavoenzyme assays were conducted using a microplate 
reader spectrophotometer (BioTek) at 37ºC. All assays were carried out in triplicate in 
100 µl reaction volumes. All cytosol samples were frozen and thawed only once, and 
the spectrophotometric data were collected at 5 second intervals for 3 to 5 minutes 
using Gen5™ software on a Windows XP PC connected to the microplate reader 
spectrophotometer (BioTek). 
2.7.1. Spectrophotometric determination of dimethylaminocinnamaldehyde 
oxidase activity. 
The activity of the AO enzyme was tested by monitoring the disappearance of 
oxidation of dimethylaminocinnamaldehyde (DMAC) at 398 nm (Kurth & Kubiciel, 
1984). The reaction was carried out with 100 l volume as summarized in table 16. 
The specific activity was calculated using the molar extinction coefficient for DMAC 
which is 30,500 M-1cm-1. 
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Table 16: Dimethylaminocinnamaldehyde oxidase assay. 
Reagent Volume Final concentration 
1 mM DMAC (dissolved in absolute ethanol) 10 µl 0.1 mM 
50 mM Tris HCl pH 7.4 50 µl 25 mM 
Gel-filtered Drosophila  cytosol 40 µl  
 
2.7.2. Spectrophotometric determination of phenanthridine oxidase activity. 
The activity of the AO enzyme was tested by monitoring the oxidation of 
phenanthridine by an increase in absorbance at 322 nm (Johnson et al., 1984). The 
reaction was carried out with 100 l as summarized in table 17. The specific activity 
was calculated using the molar extinction coefficient for phenanthridinone, which is 
6,400 M-1cm-1. 
Table 17: Phenanthridine oxidase assay. 
Reagent Volume Final concentration 
1 mM phenanthridine (dissolved in absolute 
ethanol) 
10 µl 0.1 mM 
50 mM Tris HCl pH 7.4 50 µl 25 mM 
Gel-filtered Drosophila  cytosol 40 µl  
 
2.7.3. Spectrophotometric determination of vanillin oxidase activity. 
The activity of the AO enzyme was tested by monitoring the disappear of oxidation of 
vanillin at 310 nm (Panoutsopoulos et al., 2004). The reaction was carried out with 
100 l volume as summarized in table 18. The specific activity was calculated using 
the molar extinction coefficient for vanillin, which is 8,854 M-1cm-1. 
Table 18: Vanillin oxidase assay. 
Reagent Volume Final concentration 
1 mM vanillin (dissolved in hot water) 10 µl 0.1 mM 
50 mM Tris HCl pH 7.4 50 µl 25 mM 
Gel-filtered Drosophila  cytosol 40 µl  
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2.7.4. Spectrophotometric determination of xanthine oxidoreductase (XOR) 
activity. 
The oxidation of xanthine to uric acid was assayed by monitoring the increase in 
absorbance at 295 nm with the electron acceptors NAD+ and O2 (Waud & 
Rajagopalan, 1976). The reaction was carried out with 100 l volume as summarized 
in table 19. The specific activity was calculated using the molar extinction coefficient 
for uric acid, which is 9,600 M-1cm-1. 
Table 19: The assay set used for XOR activity in D. melanogaster .  
Example of XDH activity assay Example of the XDH blank 
Reagent Volume Final 
concentration Reagent Volume 
Final 
concentration 
1.5 mM xanthine in 
10 mM NaOH 10 µl 0.15 mM 10 mM NaOH 10 µl 1 mM 
100 mM Tris HCL, 
pH 7.5 20 µl 20 mM 
100 mM Tris 
HCL, pH 8 20 µl 20 mM 
6.7 mM NAD+ 10 µl 0.67 mM 6.7 mM NAD+ 10 µl 0.67 mM 
Drosophila  gel-
filtered cytosol 60 µl  
Drosophila  gel-
filtered cytosol 60 µl 
 
XDH activity was calculated by subtracting the blank measurements from the XDH assay. 
 
2.7.5. Determination of specific activity. 
Specific activity is expressed as the number of nmoles of substrate transformed per 
min per mg of protein at incubation temperature. The number of nmoles of substrate 
biotransformed per min was then calculated from the absorbance change observed per 
min using the relationship: 
c = A/єl where c = concentration (mM), A = absorbance, l = path length of absorbing 
solution in cm, є = molar extinction coefficient. The light path for 100µl in a 
microplate was 0.681cm. 
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2.8. Determination of optimum conditions of molybdo-flavo enzymes. 
As the rate of enzyme activity may be changed according to the reaction conditions 
(pH, temperature and substrate concentration) that affect the activity of molybdo-flavo 
enzymes these were investigated.  
 2.8.1. Determination of optimum pH of buffer. 
The pH stability of AO and XDH were analyzed by incubation at 37˚C for 5 min at 
different pH values 5.6, 6.5, 7, 7.5 and 8 using sodium phosphate buffer (50 mM final 
concentration). The assay was carried out at constant substrate 0.1mM final 
concentration for DMAC and 0.15mM final concentration for xanthine and the cytosol 
volume 40 µl for the DMAC oxidase assay and 60 µl for the XDH assay. 
2.8.2. Temperature dependence of AO and XDH activities in Drosophila extracts. 
The activities of AO and XDH were measured at different temperature. The aliquots 
of filtered cytosol were incubated at 20, 25, 30, 37, 45 and 50˚C for 30 min in a 
thermocycler machine (PCR machine) with a heated lid to prevented losses due to 
refluxing. After incubation the cytosols were removed from heating and cooled in ice 
for 5 min. The cooled cytosol extracts were then centrifuged at 13,000 xg for 5 min 
and the precipitate discarded. The assays was carried out at 0.1 mM final substrate 
concentration of DMAC for AO activity and 0.15 mM final concentration of xanthine 
for XDH activity, as described in tables 16 and 19.  
2.8.3. Determination kinetic parameters (Km) and maximum velocity (Vmax) for 
molybdo-flavo enzymes enzyme at different substrate concentrations.  
The rate of oxidation of varying concentrations of substrate of AO and XDH were 
monitored over the first two minutes of reactions. The enzyme was diluted to provide 
suitable reaction rates over an appropriate range of substrate concentrations were used. 
The substrates concentrations in the assay were 25 – 100 µM for the AO substrates, 
DMAC, vanillin and phenanthridine and XDH substrate, xanthine. Typically 40 µl of 
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cytosol solution was added to each assay. The initial velocity V, corresponding to 
each substrate concentrations [S] was determined by measurement of the gradient of 
the line recorded on the curve and expressed as the change in absorbance/time. An 
Eadie Hofstee V/[S] versus [S] was then plotted (Figure 27). The intercept on the 
ordinate axis is Vmax; the slope is Km. The line of best fit through the points on plot 
was determined using linear regression by least squares method using Microsoft Excel 
(Microsoft Office). All determinations were carried out using BioTek microplate 
reader at 37ºC. 
 
 
Figure 27: A plot of the Eadie- Hofstee.  
The plot was used to define the Vmax of the enzyme-catalysed reaction and the Km constant for 
the AO and XDH enzymes. 
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2.9. DNA analysis 
2.9.1 Bioinformatics. 
Alignment of sequences and primer design was performed using Genejockey™ 
(Biosoft, Cambridge). In some cases primers had to be manually designed and 
checked for primer dimer and hairpin loop formation using Amplify©, a freeware 
program obtained from Bill Engles, Department of Genetics, University of Wisconsin, 
USA. Both programs were run on an Apple Macintosh computer. DNA sequences 
were obtained from the National Center for Bioinformatics website (NCBI) situated at 
(http://www.ncbi.nlm.nih.gov/). After the primers were designed a BLAST alignment 
was carried out online at (http://www.ncbi.nlm.nih.gov/), this program aligns the 
inputted sequences with all of the sequences found on the NCBI database. Primers 
were discarded if they were found to bind to the target gene in more than one place, or 
if they bound to other genes found in the Drosophila  genome. DNA sequences were 
translated using the genetic code as shown in appendix 1. The one letter and three 
letter amino acid codes are also listed in appendix 2.  
2.9.2. Extraction of DNA from Drosophila melanogaster. 
This was carried out using a Qiagen DneasyTM Tissue Kit according to the 
manufacturer’s instructions: 
Drosophila melanogaster strains were etherised for 60 seconds leading to death. 70 
mg of Drosophila melanogaster was then homogenised in 180 µl phosphate buffer 
saline (PBS) by using disposable plastic homogeniser to crush the flies. The 1.5 ml 
Eppendorf tubes containing the flies were then balanced and centrifuged at 10000 rpm 
for 5 minutes. The supernatants were then cautiously transferred using a pipette with 
autoclaved tips. The supernatants were then transferred into new and labelled 
eppendorf tubes. The centrifugation process was then repeated. About 130µl of the 
supernatants were carefully removed and put into new labelled 1.5 ml eppendorf 
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tubes. Care was taken when the supernatants were removed to avoid getting some of 
the precipitants in them. The new fractions were then used for DNA extraction. 20 µl 
proteinase K and 200 µl buffer AL was added to the supernatants which were then 
incubated at 70ºC for 10 minutes. 200 µl ethanol was then added to the samples which 
were vortex mixed and the mixture pipetted into DNeasy spin column. Samples were 
then centrifuged at 6000 rpm for 1 minute. 500 µl buffer AW1 was then added and the 
sample centrifuged for 1 minute at 6000 rpm. 500 µl of AW2 of buffer was added then 
and the sample was centrifuged at 13000 rpm for 3 minutes, the flow-through was 
then discarded. The DNeasy spin column was then placed in a new collection tube and 
the DNA was eluted in 200 µl buffer AE with centrifugation at 6000 rpm for 1 minute. 
For storage the DNA solution was placed at - 70.    
 2.9.3. Polymerase chain reaction cloning of molybdenum cofactor sulfurase gene. 
The following materials and methods were used in the cloning process for the 
Drosophila melanogaster molybdenum cofactor sulfurase gene.   
2.9.4. Polymerase chain reaction. 
Polymerase chain reaction (PCR) reagents were from Promega, UK and it consisted of 
25mM MgCl2, dNTPs, PCR buffer, and Taq DNA polymerase.  Distilled autoclaved 
water was used for dilution. Disposable tips, 1.5ml eppendorf and 0.5 ml PCR tubes 
were used with appropriate labelling. All pipetting steps were carried out in a sterile 
environment, and all the pipette tips and tubes used were autoclaved before use. All 
reagents were vortexed before use and all samples vortexed after being pipetted. The 
dNTPs mix, PCR buffer, primer solutions, 25mM MgCl2 and Drosophila  strain 
samples were thawed before use, and kept on ice. The following (Table 20) shows the 
primers used in the PCR of the molybdenum cofactor sulfurase gene. 
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Table 20: Summary of the primers designed for the PCR cloning of the Drosophila 
molybdenum cofactor sulfurase gene. Nucleotide sequences and localization of the primers 
designed for the PCR amplification of Drosophila  MCS gene.  
Primer 
Code 
Primer Sequence* 
5'-3' 
bp at which 
primers start 
and finish** 
Expected 
Product 
Size 
Code for 
PCR 
product 
DMCS1F TATTGGTGAGCAGTGTG -323 575 bp mal-1 DMCS1R ACACGGATGAACTCACTTGAATCG +898 
 
DMCS2F TTCCAGCGAAGAAGAGTATG +495 
732 bp mal-2 DMCS2R AGCACTGAGGTGTGGTTCTC +1227 
 
DMCS3F AGCCGAGGTCTTCCAGAA +1642 780 bp mal-3 DMCS3R TTCAGCAACGGCGGCAAT +2422 
 
DMCS4F AGCCGAGGTCTTCCAGAA +1642 1103 bp mal-4 DMCS4R GTCGGCACACCTTGCTTACGCATT +2745 
 
DMCS5F CTGCCATTCCTCTCCATTGTCG +1760 662 bp mal-5 DMCS5R TTCAGCAACGGCGGCAAT  +2422 
 
DMCS6F CTGCCATTCCTCTCCATTGTCG +1760 985 bp mal-6 DMC6R GTCGGCACACCTTGCTTACGCATT +2745 
 
DMCS7F AATACTCCTGCGGACTGG +2126 615 bp mal-7 DMCS7R GCACACCTTGCTTACGCA +2741 
 
DMCS8F GACAACTATTCAGGACG +2300 447 bp mal-8 DMC8R CTGTCGGCACACCTTGCTTA +2747 
 
DMCS9F GACAACTATTCAGGACG +2300 883 bp mal-9 DMCS9R TAGTGATGTAGATGCCGAATCGCA +3183 
*reading 5'-3' ** bp at which the 5` base of the primer binds in relation to the A of the initiator codon 
being +1.  
 
2.9.5. The PCR protocol. 
The PCR protocol was as outlined in the table below. All reactions are run for 35 
cycles in total volume 50 µl. 
Table 21: Summary of the volumes and concentrations of each component used in PCR 
reaction of the molybdenum sulfurase cofactor gene. 
Component Final Volume Final concentration 
Autoclaved distilled water 30-33µL - 
5X Green GoTaq® Flexi Buffer (Promega.UK). 10µL 1x 
MgCl2  Solution (25 mM; Promega.UK) 3-6µL 1.5-3mM 
dNTP Mix (10 mM each nucleotide) 1µL 200 µM (each nucleotide) 
Primer mix (50 pmoles/µL each primer forward 
and reverse; MWG Biotech, Ebersberg, 
Germany) 
0.5µL  0.1 µM (each primer) 
Go Taq® DNA polymerase (5U/µl); 
Promega.UK) 0.5µL 2.5 Unit/50µL 
Genomic DNA template  1.0µL ~ 0.5 µg/50µL 
A typical PCR reaction was carried out using the following conditions: 
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Cycle 1 
 1. Denature 94°C for 3 minutes 
 2. Anneal 42-65°C for 1 minute  
 3. Extend 72°C for 1 minute/kb 
Cycles 2-35 
           1. Denature 94°C for 1 minute 
 2. Anneal 45-67°C for 1 minute  
 3. Extend 72°C for 5 minutes  
 
The number of cycles were 35 cycle and the whole PCR procedure took 
approximately 2 hr and 30 min. The success of the PCR was evaluated by agarose gel 
electrophoresis.  
2.9.6. Agarose gel electrophoresis. 
Agarose gel electrophoresis was carried out according to the methods described by 
Maniatis et al., 1982. For a 1% w/v agarose gel, 1 g of agarose was added to 100 ml 
0.5 X TBE (44.5 mM Tris, 44.5 mM boric acid, 1 mM EDTA pH 8).  This mixture 
was then heated in a microwave oven until all the agarose was dissolved. The heated 
mixture was allowed to cool to 60ºC and 1µl of 10mg/ml ethidium bromide was 
added. This was poured into a 11 x 14 cm gel tray, and a 2 mm wide well former 
inserted and the gel allowed to set for approximately 30 minutes. The gel was then 
placed into a horizontal gel electrophoresis apparatus with the wells at the anode side. 
0.5 X TBE was then poured into the tank until the gel was submerged to a depth of 2-
3 mm.  For reactions containing the 5X Green GoTaq® Flexi Buffer, the reaction was 
loaded directly onto the gel after amplification. In order to approximate the size of the 
PCR products 4 l of 1 kb DNA ladder purchased from Promega (Southampton, UK.) 
was mixed with 1 l loading dye. This 1 kb ladder produced 13 fragments of 250 bp, 
500 bp, 750 bp, 1,000 bp, 2,000 bp, 2,500bp, 3,000 bp, 4,000 bp, 5,000 bp, 6,000 bp, 
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8,000 bp and 10,000 bp. The PCR products or size markers were loaded into 
individual wells of the gel and electrophoresed for 1 hour and 15 minutes at 100 V, 
200 mA. The gels were then visualised on an UV transilluminator with wavelength 
254 nm and photographs taken as a record. 
2.9.7. Preparation of PCR samples for sequencing. 
The PCR samples were prepared for sequencing using the QIAquickTM purification kit 
(Qiagen; UK). All centrifugation steps were carried out in a benchtop microcentrifuge 
at 13000 rpm. The method followed manufacturers instructions as follows: 
 200 µl of buffer PB were added to 40 µl PCR products and mixed. This was then 
applied to the QIAquickTM column and centrifuged for 60 seconds. The flow through 
was discarded and 750 µl of buffer PE added to the column. This was centrifuged for 
60 seconds and the flow through discarded then centrifuged again for another 60 
seconds. Finally the QIAquickTM column was placed into a clean tube and 50 µl buffer 
EB applied to the centre of the membrane and centrifuged for 60 seconds to elute the 
DNA. Once the PCR product has been purified into a sterile 1.5 ml tube then 
appropriate reverse and forward primers were used to sequence the purified PCR 
products. 10 pmol/µl stock of the reverse or forward primer was prepared by pipetting 
10 µl of primer 100 pmol/ µl stock and 90µl of sterile distilled water into an 
Eppendorf tube and vortexed. 1.5µl of a single 10 pmol/ µl primer stock was then and 
put into a sterile tube containing each of the purified PCR samples (40 µl) for reverse 
and forward direction sequencing. All purified samples were stored at -20°C until 
required for sequencing.  
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2.10. Statistical analysis. 
2.10.1. Chi2 Statistical Tests. 
Using a Chi2 statistical test (χ2), it was determined whether or not the frequency 
distribution of the collected data was as a result of a something occurring by chance. 
Using the formula: 
χ2 = ∑ (Observed value-Expected value) 2/ Expected value. 
The expected value was calculated as follows: 
E = (Total of column x Total of row)/Overall total. 
The degree of freedom (df) was calculated as follows: 
df = (Number of rows-1) x (Number of columns-1). 
For these results, the critical values (5% significance or P  < 0.05) for χ2 were 3.84, 
5.99, and 7.82, since there were 1, 2, and 3 degrees of freedom respectively.  The null 
hypothesis (H0) was accepted if the calculated value was less than the critical value, 
while H0 was rejected and the alternative hypothesis (H1) accepted if the calculated 
value was more than the critical value. A Yates correction value of 0.5 was used when 
the df was 1. H0 states that there is no significant difference between the observed and 
expected values, while H1 states that there is a significant difference between the 
observed and expected values. 
2.10.2. T-test two tailed. 
The results were calculated as the mean ± standard deviation (SD) for the number of 
experiments. Statistical significance between samples group were compared by a t-test 
two tailed. Values with P  < 0.05 were considered statistically significant. The t- test is 
the parametric test for calculating the significance of a small sample mean because the 
distributions of small sample are not normal. 
A one sample t-test has the following null hypothesis: 
    μ (mu) = the population mean, c = hypothesized value.  
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  3. Results.  
This results section is split into 6 main sections as follows. Firstly sections 3.1 and 3.2 
spectrophotometric and HPLC assays were used to assess molybdo-flavoenzymes 
mediated biotransformation in wild type, transgenic and MFEs deficient Drosophila . 
Toxicological and metabolite assays are then described to determine the 
chemoprotective role of AO and XOR in wild type and genetically deficient 
Drosophila melanogaster in sections 3.3. The effect of MFEs deficiencies on lifespan 
and the effects of cold and heat shock were studied as described in sections 3.4 and 
3.5. Finally, the cloning and DNA sequencing of the molybdenum cofactor sulphurase 
(MCS) gene in wild type and mutant strains are subsequently described in section 3.6. 
3.1. Quantification of molybdo-flavoenzyme activity in wild type and 
mutant Drosophila melanogaster strains.   
3.1.1. Investigation of molybdo-flavoenzyme activities in Canton-S Drosophila 
strains using spectrophotometric assays. 
Several spectrophotometric assays were used to measure the relative reaction rates of 
the molybdo-flavoenzymes to be studied. These assays were designed to specifically 
measure the rate of biotransformation of one N-heterocyclic AO substrate 
(phenanthridine) and two aldehyde compounds (vanillin and 
dimethylaminocinnamaldehyde (DMAC). XOR was measured with or without NAD+ 
in the assay using its endogenous substrate xanthine. Assays were performed at 37˚C 
as described in materials and methods section 2.7 with 50 µl of Canton-S cytosol and 
0.1 mM final substrate concentration. In order to remove endogenous inhibitors 
cytosol was gel filtered on a Sephadex G25 column prior to XOR assays. DMAC and 
vanillin oxidase assays monitored substrate disappearance at 398 and 310 nm 
respectively (see Figure 28a and 28b). Phenanthridine oxidase and XOR were 
monitored by following product formation of 6(5H)-phenanthridone and uric acid at 
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322 and 295 nm respectively (Figure 28c and 28d). All assays showed linear reaction 
kinetics under the conditions used. Omission of NAD+ from the XOR assay resulted in 
no detectable production of uric acid reflecting the previously documented lack of 
activity of invertebrate XOR with oxygen as electron acceptor (Garattini et al., 2003).  
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 (a)                                                                         (b) 
 
(c)                                                                          (d) 
Figure 28: Spectrophotometric assay of aldehyde oxidase and xanthine dehydrogenase 
activities using Canton-S strain cytosol at 37˚C with AO and XDH substrates. 
 (a) DMAC oxidase activity assay. (b) Vanillin oxidase activity assay. (c) Phenanthridine 
oxidase activity assay. (d) Xanthine oxidase activity assay. For all assays 100 µM final 
substrate concentrations were used. For the XDH assay 670 µM NAD+ was used as the 
electron acceptor. For analysis conditions see section 2.7. 
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3.1.2. Effect of pH and temperature on Drosophila molybdo-flavoenzymes 
activity  
In the initial assays 37˚C was used for assays but in order to determine if this was the 
optimum temperature to use a series of experiments were performed. In order to test 
effect of temperature on the activity of Drosophila  AO and XDH this was measured as 
at different incubation temperatures. The rate of reaction of Drosophila  AO with 
DMAC rose gradually with increasing temperature from 20˚C to 37˚C, then fell to 
zero at 45˚C as shown in figure 31. In contrast Drosophila  XDH had approximately 
80% of the activity at 45˚C versus 37˚C (Figure 29).  As the maximum reaction rate 
was obtained at 37˚C for both enzymes, this temperature was therefore selected for all 
assays.  
 
Figure 29: Effect of the assay incubation temperature on of Canton-S strain AO and XDH 
activity.  
Enzyme activity was measured at 37˚C, pH 7.5. 0.1 mM DMAC was used as the substrate in AO 
assays. 0.15 mM xanthine and 0.67 mM NAD+ were in XOR substrate assays. Each point represents the 
mean ± S.D. of three experiments with pooled cytosol from ~1000 animals.  
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and 8.0 as described in section 2.8.1. The maximum activity of AO and XDH were 
found between pH 7 and 7.5 as shown figure 30.  
 
 
Figure 30: Effect of the pH on Canton-S strain AO (blue line) and XDH activity (red line).  
AO activity was measured at 37˚C. 0.1 mM DMAC was used as the substrate in AO assay. 0.15 mM 
xanthine and 0.67 mM NAD+ was used as a substrate XOR substrate assays. Each point represents the 
mean ± S.D. of three experiments with pooled cytosol from ~1000 animals.  
 
3.1.3. Comparison of MFE activity in wild type and mutant Drosophila 
melanogaster strains 
Once the assays were optimised, AO and XDH activities were measured in the wild 
type and mutant strains. The results from the DMAC, vanillin and phenanthridine 
oxidase assays were collated from all Drosophila strains and are summarised in the 
following table 22. Both Canton-S and ry506 had activity towards all three AO 
substrates tested. The results demonstrate the significantly higher (P  < 0.05) vanillin 
oxidase activity which is present in the rosy strains in comparison to Canton-S strain 
tested (Table 22). In contrast mal-1 and mal-f1 showed no DMAC, vanillin and 
phenanthridine oxidase activity. XOR activity was absent in ry506 and maroon-like 
strains. In order to determine that there was definitely no activity present in maroon-
like strains for phenanthridine and vanillin as substrates a HPLC assay was performed 
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with these substrates. This is shown in figure 31, where no product was detected even 
after extended incubation periods. Similarly no uric acid production was detected 
using a HPLC assay with both ry506 and ma-l strains (Figure 32).  
 
Table 22: Dimethylaminocinnamaldehyde, phenanthridine, vanillin and xanthine oxidase 
activities in Drosophila cytosol of different strains.  
Drosophila  
strains 
DMAC 
oxidase activity 
(nmol/min/mg 
protein) 
(100 µM) 
Phenanthridine 
oxidase activity 
(nmol/min/mg 
protein) 
(100 µM) 
Vanillin  
oxidase activity 
(nmol/min/mg 
protein) 
(100 µM) 
Xanthine 
dehydrogenase 
activity 
(nmol/min/mg 
protein) 
(100 µM) 
Canton-S 1.18  0.06 0.98  0.06 1.68  0.06 1.21  0.09 
ry506 1.20  0.07 0.90  0.07 2.22*  0.16 N.D. 
mal-1 N.D. N.D. N.D. N.D. 
mal-f1 N.D. N.D. N.D. N.D. 
Activities were determined as described in materials and methods (section 2.7.1). The activities are 
shown as nmol substrate hydroxylated/min/mg protein and are expressed as means    S.D. of 3 sets of 
pools of animals. The result of pooled cytosol from ~ 1000 male flies. N.D. – not detectable; (*P  < 0.05 
t-test two tailed are marked with asterisks), n = 3. 
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Figure 31: HPLC analysis of the in vitro biotransformation of vanillin and phenanthridine by 
Canton-S, rosy and maroon-like strains cytosol.  
HPLC chromatograms are offset on the vertical axis to allow comparison between different 
Drosophila  strains. (a) HPLC chromatogram of the in vitro oxidation of vanillin to vanillic 
acid by Canton-S, rosy and maroon-like cytosol after 20 minutes incubation time at 37°C. 
Lower HPLC chromatogram is ma-l strain. The middle chromatogram is Canton-S strain. The 
upper chromatogram shows oxidation of vanillin to vanillic acid for rosy strain. Analytes were 
injected onto a C-18 column (Kromasil 5 µm) and eluted with a 0.22 M KH2PO4: acetonitrile 
system (85: 15) as mobile phase. The wavelength of the detection was 285 nm. (b) HPLC 
chromatogram the in vitro oxidation of phenanthridine by Canton-S, rosy and maroon-like 
cytosol after 30 minutes incubation time at 37°C. Lower HPLC chromatogram is ma-l strain. 
The middle chromatogram is Canton-S strain. The upper chromatogram is rosy strain. 
Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted with water: 
acetonitrile gradient system as described in section 2.5.3 as mobile phase. The wavelength of 
the detection was 254 nm.   
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Figure 32: HPLC analysis of the in vitro biotransformation of xanthine by Canton-S, rosy and 
maroon-like cytosol after 120 minutes incubation time at 37°C.  
Lower HPLC chromatogram is Canton-S strain. The middle chromatogram is rosy strain .The 
upper chromatogram is ma-l strain. HPLC chromatograms are offset on the vertical axis to 
allow comparison between different Drosophila strains. Analytes were injected onto a C-18 
column (Kromasil 5 µm) and eluted with a 0.1% v/v glacial acetic acid: acetonitrile gradient 
system as described in section 2.5.3 as mobile phase. The wavelength of the detection was 
280 nm. 
 
3.1.4. Spectrophotometric determination of the kinetic parameters for aldehyde 
oxidase and xanthine oxidoreductase in Drosophila strains.  
Kinetic parameters of AO for the oxidation of DMAC, phenanthridine and vanillin 
were measured for AO in Canton-S and rosy strains. Mean values of Km and Vmax of 
AO and XDH were determined using Eadie Hofstee (Figures 33 and 34), due to this 
plot being superior to other methods of plotting data (Houston et al., 2003). Eadie 
Hofstee plots of the data obtained gave good correlation coefficients (r2) > 0.97 
(Figures 33 and 34). The results obtained in the present study shows the at all 
substrates used were found to be good substrates of Drosophila  AO (Table 23). Km 
values of AO substrates were observed with DMAC (50 ± 5.4 µM), phenanthridine 
(80 ± 9.1 µM) and vanillin (303 ± 11.7 µM) respectively for Canton-S strain cytosol. 
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Relatively low Vmax values were obtained with phenanthridine (1.78 ± 0.38 
nmol/min/mg protein) and DMAC (1.80 ± 0.35 nmol/min/mg protein). The highest 
Vmax was obtained from Canton-S cytosol with vanillin (7.58 ± 2.11 nmol/min/mg 
protein) (Table 23). The enzyme kinetic parameters for AO and XDH are listed in 
table 23. Similar Km and Vmax values were obtained for DMAC and phenanthridine as 
substrates for Canton-S and ry506 strains. Km values for DMAC and phenanthridine 
were ~6 and ~4 fold lower than that for vanillin as a substrate. Interestingly vanillin 
oxidase activity in the ry506 strain was significantly different than the Canton-S strain. 
The Km was approximately 15% lower and the Vmax was approximately 5% higher in 
the ry506 strain compared with the Canton-S strain (see figures 33 and 34). 
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Figure 33: Eadie- Hofstee plot of AO and XDH activities in Canton-S Drosophila  strain.  
 (a) AO-catalyzed oxidation DMAC. (b) AO-catalyzed oxidation vanillin. (c) AO-catalyzed oxidation phenanthridine. (d)  XDH-catalyzed oxidation xanthine. 
The substrates concentrations were 25-100 µM of AO and XDH substrates. The typical results are from three independent experiments. 
. 
y = -0.05x + 1.8 
R² = 0.9788 
0 
0.5 
1 
1.5 
2 
0 5 10 15 20 25 30 
sp
e
c
if
ic
 a
c
ti
v
it
y
 
n
m
o
l/
m
in
/
m
g
 p
ro
te
in
 
V/S (ml/min/mg protein)  
(a) y = -0.3037x + 7.536 
R² = 0.9838 
0 
2 
4 
6 
8 
10 
12 
0 5 10 15 20 25 
sp
e
ci
fi
c 
a
ct
iv
it
y
 
n
m
o
l/
m
in
/
m
g
 p
ro
te
in
 
V/S (ml/min/mg protein)  
(b) 
y = -0.0809x + 1.7852 
R² = 0.9809 
0 
0.5 
1 
1.5 
2 
0 5 10 15 20 
sp
e
c
if
ic
 a
c
ti
v
it
y
 
n
m
o
l/
m
in
/
m
g
 p
ro
te
in
 
V/S (ml/min/mg protein)  
(c) y = -0.0271x + 1.5373 
R² = 0.9718 
0 
0.5 
1 
1.5 
2 
0 10 20 30 40 
sp
e
c
if
ic
 a
c
ti
v
it
y
 
n
m
o
l/
m
in
/
m
g
 p
ro
te
in
 
V/S (ml/min/mg protein)  
(d) 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Eadie- Hofstee plot of AO activity in ry506 Drosophila  strain.  
(a) AO-catalyzed oxidation DMAC. (b) AO-catalyzed oxidation vanillin. (c) AO-catalyzed oxidation phenanthridine. The substrates concentrations 
were 25-100 µM. The typical results are from three independent experiments. 
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Table 23: Kinetic constants for molybdo-flavoenzyme substrates by Drosophila  strains 
cytosol. 
Strains substrates 
Km** 
(µM) 
Vmax 
nmol/min/mg protein 
Canton-S 
DMAC 
Phenanthridine 
Vanillin 
Xanthine 
50 ± 5.4 
80 ± 9.1 
303 ± 11.7 
27 ± 4.1 
1.80 ± 0.35 
1.78 ± 0.38 
7.58 ± 2.11 
1.53  ± 0.17 
ry506 
DMAC 
Phenanthridine 
Vanillin 
Xanthine 
49 ± 5.1  
82 ± 9.3 
261* ± 11.2 
N.D. 
1.75 ± 0.37 
1.79 ± 0.42 
7.93 ± 1.42 
N.D. 
mal-1 
DMAC 
Phenanthridine 
Vanillin 
Xanthine 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
mal-f1 
DMAC 
Phenanthridine 
Vanillin 
Xanthine 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
The oxidation rates of DMAC, phenanthridine and vanillin were measured 
spectrophotometrically at 37˚C with molecular oxygen as an acceptor. The oxidation rate of 
xanthine by for xanthine dehydrogenase was measured spectrophotometrically at 37˚C with 
NAD+ as an acceptor. Km and Vmax were calculated from linear oxidation rates using Eadie-
Hofstee plots. All correlation coefficients (r2) > 0.97. The value shown are the mean ± S.D., 
obtained from three separate pooled cytosol fractions for each Drosophila strains, each 
experiment being conducted in triplicate. Substrates concentration = 100 µM. The wavelength 
used for the DMAC, phenanthridine, vanillin and xanthine oxidase assays were 398, 322, 310 
and 295 nm respectively. N.D. – not detectable; (*P  < 0.05 t-test two tailed are marked with 
asterisks), **n = 3  
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3.2. Quantification of molybdo-flavoenzyme activities in wild type 
and mutant Drosophila melanogaster strains by HPLC assays. 
As the majority of MFEs substrates and products cannot be quantificated by 
spectrophotometry, HPLC assays were used to measure MFEs oxidation rates for 15 
substrates.  
3.2.1. Validation  
3.2.1.1. Methods accuracy and precision of HPLC assays. 
 The precision of the various HPLC assays was determined by injecting five 
concentrations (0.01, 0.02, 0.03, 0.05 and 0.1 mM) of all AO and XOR substrates and 
the products listed in materials and methods section 2.5.2.2, three times on the same 
day to determine the intra-day variation. The intra-day variation assessed as the 
coefficient of variation in peak area ratio. The relative standard deviation (%RSD) 
calculation for retention time was described in section 2.5.2.2.1. The lower the value 
is the better the assay performance. At lower level it was below 3.5% for 3 replicates, 
see table 2 in appendix 3. The accuracy of the assay was calculated by comparison of 
the nominal analyte concentration to the actual concentration obtained from the linear 
regression line within the concentration range investigated (0.01 mM to 0.1 mM), see 
table 3 in appendix 3. Table 3 (in appendix 3) showed that the intra-day values ranged 
between 95.1-105.6%. The precision of all concentrations of analytes was 
approximately less than ± 5%. The calibration graphs obtained with these HPLC 
methods were linear over the concentration range used and the (r2) values were 0.92 to 
0.99 for each analyte when plotted for the mean peak area for three injections against 
the actual concentration (Figures 2-17 in appendix 3). This demonstrates that these 
HPLC methods are precise and repeatable and can be successfully used to analyze 
MFE catalysed biotransformations in this study.  
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3.2.1.2. Detection and quantification limits 
In addition to accuracy and precision tests the limit of detection (LOD) and the limit 
of quantification (LOQ) were calculated for each of the analytes in section 2.5.2.3. 
The LOD of all substrates and products were ranged between 0.1-7 nmol and LOQ 
was ranged from 0.5 to 95 nmol. From these results, it can be concluded that the 
current HPLC methods are sufficiently sensitive to detect low concentrations of 
substrates and products of molybdo-flavoenzyme catalysed reactions enzymes. The 
results of linearity, limit of detection and limit of quantification are presented in table 
4 in appendix 3.  
3.2.2. HPLC analysis of the oxidation of purine based substrates by Drosophila 
melanogaster strains. 
 Prior to incubation with cytosol endogenous purines were removed by gel filtration 
using Sephadex G25 chromatography. The result obtained after incubation of Canton-
S cytosol with xanthine as a substrate of XDH with and without NAD+ present is 
shown on figure 35 a. No uric acid product was observed when NAD+ was absent 
from the assays. In order to confirm that this was due to XDH the XDH inhibitor 
oxipurinol (0.1 mM final concentration) was added to the incubation (Figure 35 b). 
This shows that there was no uric acid generated and the reaction was completely 
inhibited by oxipurinol. Even using the sensitive HPLC assay no XOR activity with 
xanthine as a substrate was found for any of the MFE deficient strains (ry506, mal-1 
and mal-f1) (as shown in figure 32). 
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Figure 35: HPLC analysis of the in vitro biotransformation of xanthine by Canton-S cytosol.  
(a) The chromatogram produced following zero and 120 minutes incubations are indicated by 
blue and red lines respectively. (b) HPLC analytes generated by Canton-S cytosol with 
xanthine and with and without oxipurinol. The chromatogram produced following 120 
minutes with oxipurinol (blue line) and 120 minutes (red line) incubation without oxipurinol. 
Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted with a 0.1% v/v 
glacial acetic acid: acetonitrile gradient system as described in section 2.5.3 as mobile 
phase. The wavelength of the detection was 280 nm.   
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With the major caffeine metabolite, 1-methylxanthine (1-MX) Canton-S cytosol 
shows that 1-methyl-uric acid (1-MU) was produced from 1-MX when NAD+ was 
present as an electron acceptor (Figure 36) No 1-MU was produced when NAD+ was 
absent (data not shown). 7.5 ± 1.4 nmol of 1-MU was produced/15 min/mg Canton-S 
cytosol. When similar assays were carried out with 3-methylxanthine (3-MX) and 7-
methylxanthine (7-MX) no methyl-uric acids were generated even with extended time 
periods. This suggests that 3-MX and 7-MX were not substrates for Drosophila  XDH. 
 
 
Figure 36: HPLC analysis of the in vitro biotransformation of 1-methylxanthine (1-MX) by 
Canton-S cytosol at 37°C.   
The blue line is a HPLC chromatogram from 120 minutes incubation and red line is a HPLC 
chromatogram for a zero minute incubation. Analytes were injected onto a C-18 column 
(Kromasil 5 µm) and eluted with a 0.1% v/v glacial acetic acid: acetonitrile gradient system 
as described in section 2.5.3 as mobile phase. The wavelength of the detection was 280 nm.   
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6-Mercaptopurine (6-MP) is a thiopurine anti-leukemia drug in which carbon 6 of 
purine has been substituted with a sulphur atom (Merck Index, 2006). In mammals 6-
MP is oxidized to 6-thiouric acid via 6-thioxanthine or 8-oxo-6-mercaptopurine by 
AO or XOR (Van Scoik et al., 1985)  although there is some controversy over the in 
vitro studies (Rashidi et al., 2007; Rowland et al., 1999). According to the in vitro 
experiments with Drosophila  cytosol in this study, 6-MP is not a substrate for either 
XOR or AO of Drosophila  melanogaster using NAD+ and O2 as electron acceptors 
respectively (shown figures 37 a and b).  In order to validate that the assay, rabbit liver 
cytosol was incubated with 6-MP and the products generated analysed by HPLC. This 
demonstrated that when rabbit cytosol was incubated with 6-MP it was oxidized to 6-
thiouric acid via 6-thioxanthine. This confirmed that the HPLC procedure and 
incubation conditions had successfully detected and resolved the expected 6-MP 
metabolites confirming the lack of detectable activity in Drosophila  cytosol towards 
this substrate was not due to experimental conditions (Figure 38).  
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Figure 37: HPLC analysis of analytes produced following the in vitro incubation of 6-
mercaptopurine with Canton-S cytosol with and without NAD+ at 37°C. 
 (a) HPLC chromatogram of analytes generated following incubation of 6-MP with Canton-S 
cytosol at 0, 60 and 240 minutes without NAD+. (b) HPLC chromatogram of analytes 
produced following the in vitro incubation of 6-MP with Canton-S cytosol at 0, 60 and 240 
minutes with NAD+. Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted 
with a 0.1% v/v glacial acetic acid: acetonitrile gradient system as described in section 2.5.3 
as mobile phase. The wavelength of the detection was 355 nm.   
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Figure 38: HPLC analysis of the in vitro biotransformation of 6-mercaptopurine by rabbit 
liver cytosol at 0 and 60 minutes. 
Blue line is HPLC chromatograms of a zero minute incubation. Red line is HPLC 
chromatograms of 60 minutes incubation. The green line is 6-thioxanthine standard. HPLC 
chromatograms are offset on the vertical axis to allow comparison between incubation times. 
Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted with a 0.1% v/v 
glacial acetic acid: acetonitrile gradient system as described in section 2.5.3 as mobile 
phase. The wavelength of the detection was 280 nm.    
 
Allopurinol was also tested as a substrate with and without NAD+ in the incubations 
with Canton-S strain cytosol. The results shown in figure 41 indicate that the product 
oxipurinol was formed with O2 as an electron acceptor and that product formation was 
increased approximately 3 fold following NAD+ addition (Figure 39 and Table 24). 
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Figure 39: HPLC analysis of the in vitro biotransformation of allopurinol by Canton-S 
cytosol strain at 37°C with and without NAD+.   
(a) Incubation with NAD+. Blue line is HPLC chromatograms from analytes from a zero 
minute incubation. Red and green lines are analytes from 30 and 120 minutes. (b) Incubation 
without NAD+. Blue line is HPLC chromatograms of a zero minute incubation. Red and green 
lines are 30 and 120 minutes. HPLC chromatograms are offset on the vertical axis to allow 
comparison between different incubation times. Analytes were injected onto a C-18 column 
(Kromasil 5 µm) and eluted with a 0.1% v/v glacial acetic acid: acetonitrile gradient as 
described in section 2.5.3 as mobile phase. The wavelength of the detection was 280 nm.   
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The chromatogram (Figure 40) shows that XOR-null rosy strain cytosol can also 
convert allopurinol to oxipurinol. In comparison, at the same incubation course for the 
rosy strain cytosol, there was a lower in the amount of product, when was compared 
with Canton-S strain. Using the sensitive HPLC assay no oxipurinol was produced 
with allopurinol as a substrate by MFE deficient strains cytosol (maroon-like). 
 
 
Figure 40: HPLC analysis of the in vitro biotransformation of allopurinol by ry506 cytosol 
strain.  
 Blue line is a zero minute incubation. Red and green lines are analytes from 30 and 120 
minutes incubations. HPLC chromatograms are offset on the vertical axis to allow comparison 
between the different incubation times. Analytes were injected onto a C-18 column (Kromasil 
5 µm) and eluted with a 0.1% v/v glacial acetic acid: acetonitrile gradient system as described 
in section 2.5.3 as mobile phase. The wavelength of the detection was 280 nm.  
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The enzyme activity of the in vitro allopurinol oxidation in the different Drosophila 
melanogaster strains are presented in the following table.  
Table 24: Allopurinol oxidase activity in cytosol of Drosophila melanogaster strains.  
Enzyme activity in cytosolic Drosophila strains 
(nmol converted in 30 minutes per mg protein  
of Drosophila cytosol strains) 
Canton-S  
with NAD+ 
Canton-S  
without NAD+ ry
506
 mal-1 mal-f1 
10.5 ± 1.5 3.5 ± 0.4 3.6 ± 0.6 N.D. N.D. 
Data represents mean ± S.D. of three independent experiments. N.D.: not detectable. 
 
3.2.3. HPLC analysis of D. melanogaster strains with non purine and N-
heterocyclic compounds.  
The substrates used to evaluate AO activity in this research included the exogenous 
(drugs): cinchonine (anti-malaria drug), methotrexate (anti-cancer drug) and 
pyrazinamide (tuberculosis drug). In vitro incubations with Canton-S, ry506 and ma-l 
strains were carried out at several incubation times using cytosol with 0.1 mM final 
substrate concentration.  
The pyrazinamide was incubated with Canton-S with and without NAD+ and HPLC 
analyses were carried out. After incubation with Canton-S cytosol with or without 
NAD+ the HPLC chromatogram showed a small putative 5-hydroxypyrazinamide 
peak (Figure 41 a and b). This indicated that it was a substrate using both conditions 
tested. Because of the 5-hydroxypyrazinamide is not commercially available, it was 
not possible to identify it due to the low level of 5-hydroxypyrazinamide in complex 
biological matrix. No results were detected by LC-MS. The chromatogram (Figure 42) 
showed that the XOR-null ry506 strain can also convert pyrazinamide to 5-
hydroxypyrazinamide with O2 as an electron acceptor indicating AO involvement in 
its conversion. 
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Figure 41: HPLC analysis of the in vitro biotransformation of pyrazinamide by Canton-S 
cytosol strain at 37˚C with and without NAD+.  
(a) Incubation with NAD+ (b) Incubation without NAD+. Red and black are representative 
chromatograms produced at a zero and 240 minutes respectively. HPLC chromatograms are 
offset on the vertical axis to allow comparison between different incubation times. Analytes 
were injected onto a C-18 column (Kromasil 5 µm) and eluted with a 20 mM KH2PO4: 
acetonitrile (95: 5) as mobile phase. The wavelength of the detection was 268 nm.   
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Figure 42: HPLC analysis of the in vitro biotransformation of pyrazinamide by ry506 
Drosophila melanogaster  cytosol at 37˚C.  
Blue line is a HPLC chromatogram of a zero minute incubation. Black line is a HPLC 
chromatogram at 240 minutes incubation. HPLC chromatograms are offset on the vertical axis 
to allow comparison between different incubation times. Analytes were injected onto a C-18 
column (Kromasil 5 µm) and eluted with a 20 mM KH2PO4: acetonitrile (95: 5) as mobile 
phase. The wavelength of the detection was 268 nm.    
When the N-heterocycle cinchonine was incubated with Drosophila  cytosol from 
Canton-S and rosy strains one metabolite of cinchonine was detected by HPLC 
(Figure 43). Because its metabolite 2-cinchoninone is not commercially available; LC-
MS was used to check the identity of the cinchonine metabolite. Unfortunately due to 
the low level of 2-cinchoninone in complex biological matrix no result was obtained 
to confirm its identity.   
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Figure 43: HPLC analysis of the in vitro biotransformation of cinchonine to 2'-cinchoninone 
by rosy cytosol.  
Blue line is a HPLC chromatogram of a zero minute incubation. Red line is a HPLC 
chromatogram at 120 minutes incubation. HPLC chromatograms are offset on the vertical axis 
to allow comparison between different incubation times. Analytes were injected onto a C-18 
column (Kromasil 5 µm) and eluted with a 0.4% w/v CH3COONH4: acetonitrile (65: 35) as 
mobile phase. The wavelength of the detection was 248 nm.   
 
When methotrexate was tested as a substrate to the Drosophila  cytosol no detectable 
hydroxylation of methotrexate (MTX) was observed with Drosophila  cytosol even 
with extended incubations of 8 hrs (Figure 44 a). In contrast control incubations with 
rabbit cytosol showed demonstrable activity by oxidation MTX to its metabolite (7-
hydroxymethotrexate) (Figure 44 b). These results confirmed that Drosophila  AO has 
no activity toward MTX as a substrate.  
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Figure 44: HPLC analysis of analytes produced following the in vitro incubation of 
methotrexate with Drosophila  and rabbit liver cytosol.  
(a) Canton-S cytosol. (b) Rabbit liver cytosol. Blue line is a HPLC chromatogram of a zero 
minute incubation. Black line is a HPLC chromatogram at 120 minutes and red line for 480 
minutes incubation. HPLC chromatograms are offset on the vertical axis to allow comparison 
between different incubation times. Analytes were injected onto a C-18 column (Kromasil 5 
µm) and eluted with a 0.1 M CH3COONH4: acetonitrile (92: 8) as mobile phase. The 
wavelength of the detection was 305 nm.   
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When cinchonine, methotrexate and pyrazinamide were incubated with maroon-like 
(mal-1 and mal-f1) cytosol even for extended incubation periods, HPLC analyses 
carried out did not detect any metabolites being formed.  
The enzyme activity of the in vitro pyrazinamide and cinchonine oxidation in the 
different Drosophila strains is presented in table 25.  
Table 25: Pyrazinamide and cinchonine oxidase activity in cytosol of Drosophila 
melanogaster  strains. 
AO and XOR 
substrate 
Enzyme activity in cytosolic Drosophila strains 
(nmol converted in 120 minutes per mg protein  
of Drosophila cytosol strains) 
Canton-S 
without NAD+ 
Canton-S with 
NAD+ ry
506
 mal-1 mal-f1 
Pyrazinamide 16.8 ± 5.0 36.0 ± 11.0 34.8 ± 10.6 N.D. N.D. 
Cinchonine 27.6 ± 10.2 - 24.0 ± 10.8 N.D. N.D. 
Data represents mean ± S.D. of three independent experiments. -: not tested. N.D.: not detectable. 
 
3.2.4. HPLC in vitro analysis of D. melanogaster strains with endogenous vitamins 
and vitamin metabolites. 
The endogenous vitamins B6 (pyridoxal), A (all-trans retinal) and nicotinamide B3 
metabolite (N1-methylnicotinamide) were also tested as a substrate of the different 
Drosophila  strains. Pyridoxic acid and retinoic acid were formed by the action of AO 
in Canton-S and ry506 strains. Canton-S and ry506 strains had similar activity towards 
these compounds whereas ma-l strains had no detectable activity (Figure 45 and Table 
26).  
Two N1-methylnicotinamide products (Figure 46) were observed that were probably 
N1-methyl-2-pyridone-5-carboxamide (2-PY) and N1-methyl-4-pyridone-3-
carboxamide (4-PY) as previously observed with rat and mice (Kitamura et al., 2008; 
Shibata et al., 1988; Stanulovic & Chaykin, 1971; Sugihara et al., 2006).  
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Figure 45: HPLC analysis of the in vitro biotransformation of endogenous compounds 
(pyridoxal and all-trans retinal) by Canton-S cytosol.  
HPLC chromatograms are offset on the vertical axis to allow comparison between different 
incubation times. (a) Incubation Canton-S cytosol with pyridoxal at 37 °C for 0 (blue line) and 
60 minutes (red line). Analytes were injected onto a C-18 column (Kromasil 5 µm) using 
methanol: 60 mM Na2HPO4 (25: 75) as mobile phase. The wavelength of the detection was 
315 nm. (b) Incubation Canton-S cytosol with all-trans retinal. Blue line is a zero minute 
incubation and red line for 60 minutes incubation. Analytes were injected onto a C-18 column 
(LiChrosphere 5 µm) and eluted with a 30 mM CH3COONH4: acetonitrile (30: 70) as mobile 
phase. The wavelength of the detection (DAD) was 378 nm.   
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Figure 46: HPLC analysis of the in vitro biotransformation of N1-methylnicotinamide by 
Canton-S cytosol.  
(a) HPLC chromatogram of the oxidation of N1-methylnicotinamide by Canton-S cytosol at a 
zero minute incubation (blue line) and 120 minutes incubation (black line). (b) HPLC 
chromatogram of the oxidation of N1-methylnicotinamide by maroon-like cytosol. Blue line is 
a HPLC chromatogram of a zero minute. Red line is a HPLC chromatogram of 120 minutes 
incubation. HPLC chromatograms are offset on the vertical axis to allow comparison 
between different incubation times. Analytes were injected onto a C-18 column 
(Spherisorb; CNRP 5 µm) and eluted with a 0.8 % v/v formic acid: acetonitrile 
gradient as described in section 2.5.3 as mobile phase. The wavelength of the 
detection was 254 nm.   
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When pyridoxal, all-trans retinal and N1-methylnicotinamide were incubated with 
maroon-like (mal-1 and mal-f1) cytosol even for extended incubation periods, no 
metabolites were detected.  
The enzyme activity of the in vitro endogenous vitamin oxidation in the different D. 
melanogaster strains is summarised in table 26.  
Table 26: The oxidase activity towards pyridoxal, all-trans retinal and N1-
methylnicotinamide by cytosol of Drosophila  strains. 
AO substrate 
Enzyme activity in cytosolic Drosophila strains 
(nmol converted in 10 minutes per mg protein  
of Drosophila cytosol strains) 
Canton-S  ry506 mal-1 mal-f1 
Pyridoxal 17.5 ± 1.8 16.6 ± 1.7 N.D. N.D. 
All-trans retinal  7.1 ± 0.5 7.5 ± 0.6 N.D. N.D. 
N1-methylnicotinamide  9.7 ± 1.9 9.9 ± 2.1 N.D. N.D. 
Data represents mean ± S.D. of three independent experiments. N.D.: not detectable. 
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3.3. Investigation of the chemoprotective role of molybdo-
flavoenzymes against xenobiotic toxicity 
The study of chemoprotective role of MFEs was performed by adding a variety of 
known AO and XOR substrates to Drosophila  media. Percentage survival was 
assessed over a one to five weeks time course depending on the compounds being 
scrutinised (see methods sections for protocol used). In addition to testing the toxicity 
of compounds analytical tests were also performed to assess the ability of the different 
Drosophila  strains to metabolise the compounds in vivo using the HPLC techniques 
developed for in vitro studies (section 2.5). All samples for HPLC assays were 
prepared and analysed by HPLC as described in section 2.5.4 with flies exposed to the 
potential toxicant for 4 days.  In order to check the effect of the fly extract on the 
retention time of compounds, extracts were spiked with each of the analytes. In all 
cases no difference in retention time was found. Spiking was also carried out to 
confirm peak identity as well as using a diode array detector (DAD) when appropriate.  
3.4.1. Endogenous purine content of Drosophila melanogaster strains. 
 Prior to assessing exogenous purine metabolism HPLC profiles were obtained for 
endogenous purine content of all Drosophila  strains. This is shown in figure 47. As 
expected there was a demonstrable lack of uric acid and elevated xanthine in ry506 and 
ma-l strains compared with wild type and transgenic strains (Cote et al., 1986; 
Finnerty et al., 1979).    
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Figure 47: HPLC analysis of endogenous purines in untreated Drosophila melanogaster 
strains.  
Canton-S (blue line), transgenic (green line), ry506 (black line) and maroon-like (red line). 
HPLC chromatograms are offset on the vertical axis to allow comparison between different 
Drosophila  strains. Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted 
with a 0.1% v/v glacial acetic acid: acetonitrile gradient as described in section 2.5.3 as 
mobile phase. The wavelength of the detection was 280 nm.   
  
 
Comparison of the purine levels of mutant Drosophila  strains (rosy and maroon-like) 
(Table 27) with the normal Drosophila  strain (Canton-S) indicated that the xanthine to 
hypoxanthine ratio was approximately 4 times the level of normal fly. The xanthine 
level of these mutants was 7 fold higher than in the normal strain, but no significant 
difference in the hypoxanthine level was seen. Rosy and maroon-like Mutant strains 
had no detectable uric acid.  
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Table 27: Xanthine, hypoxanthine and uric acid content of wild type, transgenic and mutant 
D. melanogaster  strains. 
 
Strains 
ry506 Maroon-like  Canton-S Transgenic 
Xanthine (nmol/fly) 0.69 ± 0.11 0.71 ± 0.10 0.11 ± 0.007 0.10 ± 0.005 
Hypoxanthine (nmol/fly) 0.19 ± 0.03 0.17 ± 0.02 0.16 ± 0.05 0.12 ± 0.03 
Uric acid (nmol/fly) N.D. N.D. 0.82 ± 0.12 0.80 ± 0.10 
Xanthine: hypoxanthine ratio 3.7 4.1 1.4 1.2 
N.D not detected. Data represents mean ± S.D. of three independent experiments. 
 
3.3.2. Investigation of the chemoprotective role of molybdo-flavoenzymes with 
purine and purine based drugs in D. melanogaster strains. 
Following analysis of endogenous purines Drosophila  were kept on either 20 mM or 
100 mM caffeine (1, 3, 7-trimethylxanthine), theophylline (1, 3-dimethylxanthine), 
paraxanthine (1, 7-dimethylxanthine) and theobromine (3, 7-dimethylxanthine) for up 
to 2 weeks. The results of the toxicity study are presented in figure 48.  All 
methylxanthines with the exception of paraxanthine tested were significantly more 
toxic to XOR-deficient rosy and ma-l strains than wild type (Canton-S) or transgenic 
(T1 and T2) strains at 20 mM see figure 48. As there was no toxic effect at 20 mM 
paraxanthine with any strain (data not shown) a 100 mM dose was used that showed a 
similar pattern of toxicity to the strains tested with XOR- deficient strains having a 
much more pronounced death rate.  
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Figure 48: Toxicity of methyl-xanthines to Drosophila melanogaster  strains (a) caffeine (20 mM), (b) theobromine (20mM), (c) theophylline (20 mM) and 
(d) paraxanthine (100 mM).  
Each vial contained twenty, 0-3 days old male flies, each point represents mean  SD of four sets of data. CS = Canton-S. T1and T2 = transgenic. 
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Analysis of metabolites obtained from all fly strains incubated with these 
methylxanthines indicated that apart from the methylated xanthine added to the media 
and the previously identified endogenous purines there were no peaks that represented 
any of the known eight caffeine metabolites used as standards. Peaks found at 12.6, 
13.3 and 15.0 minute retention times were unidentified compounds that also appeared 
in untreated fly extracts. Canton-S HPLC profiles are shown for illustration figures 49 
and 50. 
 
 
Figure 49: HPLC analysis wild type Canton-S Drosophila melanogaster extracts after 4 days 
treatment with caffeine.  
HPLC chromatograms are offset on the vertical axis to allow comparison between wild type 
Canton-S and caffeine metabolite and endogenous purine standards. Analytes were injected 
onto a C-18 column (Kromasil 5 µm) and eluted with a 0.1% v/v glacial acetic acid: 
acetonitrile gradient as described in section 2.5.3 as mobile phase. The wavelength of 
the detection was 280 nm. HPLC chromatograms of extracts from Canton-S treated for 4 
days with 20 mM caffeine in media (red line). 250µM caffeine metabolite and endogenous 
purine standards (blue line). Abbreviations: Ur = uracil; U = uric acid; HX = hypoxanthine; 
X = xanthine; 7X = 7-methylxanthine; 1U = 1-methyluric acid; 3-MX = 3-methylxanthine; 1X 
= 1-methylxanthine; 37X = 3,7-dimethylxanthine or theobromine; 17U = 1,7-dimethyluric 
acid; 17X = 1,7 dimethylxanthine or paraxanthine; 13X = 1,3-dimethylxanthine or 
theophylline and 137X = 1,3,7- trimethylxanthine or caffeine. 
 
 
 
 
 
 
 
 
 
 
A
bs
o
rb
a
n
ce
 
(28
0 
n
m
) 
Time (minutes) 
112 
 
 
 
 
Figure 50: HPLC chromatogram of purines found in Canton-S Drosophila  after 4 days of 
treatment with paraxanthine, theobromine and theophylline.  
Red line is untreated Canton-S Drosophila  and blue line is Canton-S treated with methyl-
xanthines. (a) paraxanthine, (b) theobromine and (c) theophylline. HPLC chromatograms are 
offset on the vertical axis to allow comparison between the treated and untreated flies. 
Analytes were injected onto a C-18 column (Kromasil 5 µm) and eluted with a 0.1% v/v 
glacial acetic acid: acetonitrile gradient as described in section 2.5.3 as mobile phase. The 
wavelength of the detection was 280 nm.   
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As well as the drugs theophylline and caffeine the toxicity of several other purine or 
purine analog drug substrates were assessed. On comparing the percentage survival of 
Canton-S and transgenic with ry506, mal-1 and mal-f1 strains treated with the anti-
leukemic drug 6-mercaptopurine the percentage survival of wild type and transgenic 
was slightly greater than ry506 and maroon-like strains (Figure 51). From statistical 
tests comparing the Canton-S (wild type), transgenic and mutant strains (ry506, mal-1 
and mal-f1) found a highly significant difference (P  < 0.05) between XDH active 
(Canton-S and transgenic) and XDH inactive mutant strains (ry506, mal-1 and mal-f1) 
(Appendix 4; Tables 3). HPLC of 6-mercaptopurine treated flies of all strains revealed 
no detectable metabolites after 4 days (data not shown).  
As well as 6-mercaptopurine the purine analog anti-gout drug allopurinol was tested. 
The percentage survival for all strains exposed to allopurinol containing media can be 
seen in figure 51. It was observed that the strains harbouring mutations in XOR or 
MCS genes had an increased sensitivity to the toxicity of allopurinol. 20 mM 
allopurinol was most toxic to maroon-like strains with the effect being much less 
pronounced with the ry506 strain. As there was a less pronounced effect on the rosy 
strain with 20 mM allopurinol, in order to investigate if allopurinol had a more 
pronounced effect at higher concentration 100 mM allopurinol was tested. This 
demonstrated that allopurinol at this elevated concentration led to all ry506 flies dying 
by day 15 whereas XOR-active strains (Canton-S and transgenic) had 100% 
survivorship at this time point.  
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Figure 51: Toxicity of 6-mercaptopurine and allopurinol to wild type, transgenic and mutant of Drosophila melanogaster  strains.  
(a) 6-mercaptopurine (20mM). (b) Allopurinol (20mM). (c) Allopurinol (100 mM). Each vial contained twenty, 0-3days old male flies, each point represents mean  SD of 
four sets of data. CS = Canton-S. T1and T2 = transgenic. 
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HPLC analysis of fly extracts demonstrated that Canton-S, transgenic and rosy strain 
generated oxipurinol (Figure 52) in 20 mM allopurinol media whereas the ma-l strain 
had no detectable metabolite.  
 
Figure 52: HPLC analysis of allopurinol metabolism in Drosophila melanogaster strains.  
The red line chromatogram is an extract from allopurinol treated Drosophila strains. The blue 
line chromatogram shows the sample of untreated Drosophila strains. (a) Canton-S, (b) 
transgenic and (c) rosy. Analytes were injected onto a C-18 column (Kromasil 5 µm) and 
eluted with a 0.1% v/v glacial acetic acid: acetonitrile gradient system as described in section 
2.5.3 as mobile phase. The wavelength of the detection was 280 nm.  Abbreviations: U = uric 
acid; HX = hypoxanthine; X = xanthine; Oxi = oxipurinol and Allo = allopurinol. 
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The quantification of allopurinol and oxipurinol in each of the strains is shown in table 
28. 
Table 28: Quantification of allopurinol and oxipurinol in fly extracts after 4 days of 20 mM 
allopurinol treatment. 
Strain nmol/fly % Metabolite (Oxipurinol) 
 
Allopurinol  Oxipurinol  
 
Canton-S 0.28 ± 0.04 0.70 ± 0.12 71.4 ± 10.5 
ry506 0.30 ± 0.05 0.41 ± 0.07 57.7 ±  8.6 
mal-1 0.91 ± 0.13 N.D - 
Data represents mean ± S.D. of three independent experiments. N.D.: not detectable.  
It was also observed that allopurinol caused approximately 50 % decrease in uric acid 
and significant increase in xanthine and hypoxanthine in untreated Canton-S (Figure 
52).  
3.3.3. Investigation of the chemoprotective role of molybdo-flavoenzymes with 
toxicity of non-purine based N-heterocyclic compounds in D. melanogaster 
strains. 
Several other non-purine based N-heterocyclic compounds were used in the toxicity 
studies. These included phenanthridine (an AO substrate and environmental 
pollutant), pyrazinamide (an AO and XOR substrate and anti-tuberculosis drug) and 
cinchonine (an AO substrate and anti-malarial). When these compounds were 
administered in fly media as described in section 2.4 the following graphs were 
obtained (Figure 53). This illustrates the percentage survival of Drosophila  strains 
after treatment with 20 mM concentration of these compounds in media. The maroon-
like strains appeared weaker as they had a higher mortality rate than that of the rosy, 
transgenic and wild type strains with all compounds. With phenanthridine and 
cinchonine there was no significant difference between ry506, transgenic and wild type 
strains (Appendix 4; Tables 3 and Figure 53). In contrast, pyrazinamide caused a 
faster death rate and highly significant difference (P  < 0.05) when the ry506 strain was 
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compared to the two MFE-active strains and there was slightly significant difference 
than ma-l strains (Appendix 4; Tables 3 and Figure 53).  
 
 
 
 
Figure 53: Toxicity of 20 mM phenanthridine, pyrazinamide and cinchonine to wild type, 
transgenic and mutant of Drosophila melanogaster  strains.  
(a) phenanthridine, (b) pyrazinamide and (c) cinchonine. Each vial contained twenty, 0-3days 
old male flies, each point represents mean  SD of four sets of data. CS = Canton-S. T1and T2 
= transgenic. 
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To determine the metabolic basis of the toxicities found the oxidation of 
phenanthridine, pyrazinamide and cinchonine with the different Drosophila 
melanogaster strains was examined in fly extracts. Both wild type (Canton-S) and 
rosy mutant (ry506) strains had significant quantities of 6(5H)-phenanthridone 
metabolite generated at day 4 of the experiment in contrast to the maroon-like strains 
that had no detectable metabolite (Figure 54 and Table 29). The quantification of 
phenanthridine and 6(5H)-phenanthridone in each strain is shown in table 29.    
Table 29: Quantification of phenanthridine and 6(5H)-phenanthridone in fly extract after 4 
days of 20 mM phenanthridine treatment. 
Strain nmol/fly % metabolite 
 (6(5H)-phenanthridone) 
 Phenanthridine  6(5H)-phenanthridone   
Canton-S 0.21 ± 0.04 0.19 ± 0.03 47.5 ± 6.0 
ry506 0.25 ± 0.03 0.21 ± 0.04 46.5 ± 5.8 
mal-1 0.75 ± 0.10 N.D. - 
Data represents mean ± S.D. of three independent experiments. N.D.: not detectable.  
 
Pyrazinamide, a drug used to treat tuberculosis is metabolised to 5-
hydroxypyrazinamide by the action of XOR and AO in mammals (Kitamura et al., 
2006; Moriwaki et al., 1997). All strains under pyrazinamide treatment showed a 
similar profile in that there were no clear peaks of 5-hydroxypyrazinamide metabolite 
with any strains (data not shown). All strains of Drosophila melanogaster treated with 
cinchonine that is a known mammalian AO substrate were also analysed for 
metabolites. Canton-S and ry506 strains showed a metabolite peak at a retention time of 
6.7 minutes in the chromatograms (see figure 54 as example of Canton-S strain). In 
theory this was 2-cinchoninone however due to the lack of commercial availability of 
this compound and the complexity of the biological sample that made the LC-MS 
result inconclusive it was therefore not possible to unequivocally identity the 
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metabolite found in this case. In contrast to Canton-S and ry506 strains there was no 
conversion of cinchonine to the putative 2-cinchoninone peak in maroon-like strains.  
 
Figure 54: HPLC analysis of phenanthridine and cinchonine biotransformation in Canton-S 
Drosophila melanogaster  strain. 
 (a) Phenanthridine biotransformation in Canton-S strain .The blue line is a chromatogram of 
the extract from phenanthridine treated Canton-S animals and the black line is a 
chromatogram of untreated Canton-S. Analytes were injected onto a C-18 column (Kromasil 5 
µm) and eluted with water: acetonitrile gradient system as described in section 2.5.3 as 
mobile phase. The wavelength of the detection was 254 nm. (b) Cinchonine biotransformation 
in Canton-S strain .The red line is a chromatogram of the extract from cinchonine treated 
Canton-S animals and the black line is a chromatogram of untreated Canton-S. HPLC 
chromatograms are offset on the vertical axis to allow comparison between different 
incubation times. Analyte injected onto a C-18 column (Kromasil 5 µm) eluted with a 0.4% 
w/v CH3COONH4: acetonitrile (65: 35) as mobile phase. The wavelength of the detection was 
248 nm.   
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3.3.4. Investigation of the chemoprotective role of molybdo-flavoenzymes with 
vanillin and N1-methylnicotinamide toxicity in D. melanogaster strains.  
The results from the N1-methylnicotinamide toxicity tests are shown in figure 55. 
Figure 55 demonstrates that the strains of Drosophila  lacking aldehyde oxidase are 
less able to survive in media containing N1-methylnicotinamide. When exposed to the 
N1-methylnicotinamide in the media, maroon-like strains had a highly significant 
decreased survivorship compared to all other strains tested (Appendix 4; Tables 3). At 
day 9 all maroon-like flies were dead, whereas there was 100% survival of all other 
strains at this time point. 
 
 
Figure 55: Toxicity of 20 mM N1-methylnicotinamide to wild type, transgenic and mutant of 
Drosophila melanogaster  strains.  
Each vial contained twenty, 0-3days old male flies, each point represents mean  SD of four 
sets of data. CS = Canton-S. T1 and T2 = transgenic. 
 
In order to test for the MFE-mediated metabolism of N1-methylnicotinamide HPLC 
analysis was performed. Strains of Drosophila melanogaster treated with N1-
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methylnicotinamide were analysed by HPLC. Quantification of N1-
methylnicotinamide and its metabolites in all Drosophila  strains treated with this 
compound revealed no detectable pyridine metabolites were detectable using the 
HPLC protocol described in section 2.5.3 (data not shown). 
To determine if vanillin was toxic to Drosophila  flies from each strain were exposed 
to vanillin in low and high concentrations (20 mM and 100 mM). The results of 
survivorship of the different Drosophila  strains when exposed to the 20 mM of 
vanillin demonstrated that it was not toxic to any strains at this concentration when 
monitored for up to three weeks (Figure 56) compared to the normal lifespan of all 
Drosophila  strains (see figure 56).  
 
Figure 56: Toxicity of 20 mM vanillin to wild type, transgenic and mutant of Drosophila 
melanogaster  strains.  
Each vial contained twenty, 0-3 days old male flies, each point represents mean  SD of four 
sets of data. CS = Canton-S. T1and T2 = transgenic. 
 
Interestingly, the average lifespan of all strains treated with 20 mM vanillin 
concentration appeared to be slightly increased compared with to their normal mean 
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lifespan (Figures 56 and 57). However, according to the statistical analysis (Table 30), 
it was observed that the mean lifespan of all strains treated with 20 mM vanillin were 
no significant difference (P > 0.05).  
 
 
 
Figure 57: Comparison of the effect of 20 mM vanillin on lifespan of Drosophila 
melanogaster  strains.  
Data represents mean ± S.D. of four sets of data. Data from table 32 for untreated flies 
(control) and figure 56. 
 
Table 30: Statistical difference of mean lifespan between 20 mM vanillin treated and 
untreated Drosophila  strains. 
χ2 value of Drosophila melanogaster lifespan 
Canton-S  
normal media 
T1  
normal media 
ry506  
normal media 
mal-1  
normal media 
mal-f1 
 normal 
media 
Canton-S 
 vanillin media 
T1  
vanillin media 
ry506  
vanillin media 
mal-1  
vanillin media 
mal-f1  
vanillin 
media 
0.60 0.46 0.96 0.86 1.0 
 (*P  < 0.05 by 05 by chi2 test is 3.84) indicates when a value is significantly different from the control 
value.  
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The effects of vanillin observed at 100 mM was that the strains harbouring mutations 
of XOR and AO (mal-1 and mal-f1) had a highly significant decreased survivorship 
when compared to the wild type, transgenic and ry506 strains (Figure 58 and Appendix 
4; Table 3). 
 
Figure 58: Toxicity of 100 mM vanillin to wild type, transgenic and mutant Drosophila 
melanogaster  strains.  
Each vial contained twenty, 0-3 days old male flies, each point represents mean  SD of four 
sets of data. CS = Canton-S. T1and T2 = transgenic. 
 
In order to test for the MFE-mediated metabolism of vanillin HPLC analysis was 
performed. Canton-S, transgenic and ry506 strains under vanillin treatment showed its 
metabolite vanillic acid (Figure 59). In contrast maroon-like strains displayed no 
detectable vanillic acid peak.  
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Figure 59: HPLC analysis of vanillin biotransformation in Drosophila melanogaster  strains.  
(a) HPLC chromatogram showing the difference between ry506 treated (red line) and untreated 
with vanillin (blue line). (b) HPLC chromatogram of an extract from mal-1 Drosophila  strain 
treated with vanillin. The blue line chromatogram shows the sample of untreated mal-1 
Drosophila . The red line is the treated sample. HPLC chromatograms are offset on the vertical 
axis to allow comparison between different Drosophila  strains. Analytes were injected onto a 
C-18 column (Kromasil 5 µm) and eluted with a 0.22 M KH2PO4: acetonitrile system (85: 15) 
as mobile phase. The wavelength of the detection was 285 nm.  
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The quantification of vanillin and vanillic acid in each of the strains is shown in table 
31.  
 
Table 31: Quantification of vanillin and vanillic acid in fly extract after 4 days of 20 mM 
vanillin treatment.   
Strain nmol/fly % Metabolic (Vanillic acid) 
 Vanillin  Vanillic acid   
Canton-S 1.11 ± 0.20 2.37 ± 0.41   68.1 ± 11.1 
ry506 0.67 ± 0.10 3.56 ± 0.63 84.1 ± 9.3 
ma-l 3.86 ± 0.72 N.D. - 
Data represents mean ± S.D. of three independent experiments. N.D: not detectable.  
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3.4. Lifespan Studies of molybdo-flavoenzymes-active and molybdo-
flavoenzymes-deficient Drosophila strains. 
 The effect of MFE deficiencies on lifespan of MFE-active (Canton-S and transgenic) 
and MFE deficient (ry506 and ma-l) strains of Drosophila  is shown in figure 60.  
 
 
Figure 60: The lifespan of Canton-S, transgenic, ry506, mal-1 and mal-f1 strains.  
Each vial = 20 male flies. Data represents mean ± S.D five sets of data. CS = Canton-S. T1= 
transgenic. 
 
The mean lifespan of all the strains tested are shown in table 28. According to the 
results, it was observed that the mean lifespan of the Canton-S, transgenic, ry506, mal-
1 and mal-f1 strains were 49.2 ± 10.4, 48.8 ± 9.3, 29.7 ± 7.1, 15.1 ± 3.2 and 15.1 ± 2.4 
days ± S.D respectively (Table 32). The graph shows the transgenic strains that have 
had the ry gene re-inserted (T1) have a lifespan which is similar to that of the Canton-
S strain lifespan. The statistical analysis of the results showed that there were no 
difference in lifespan of Canton-S and transgenic strains with each test resulting in P > 
0.05 values (Tables 32). The Canton-S strain survived for considerable longer than the 
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ry506 strain and maroon-like flies (mal-1and mal-f1). The P  values for longevity of 
ry506 and the maroon-like strains are lower than (P  < 0.05) value compared with 
Canton-S strain (Tables 32). In addition, the null XOR/AO strains (mal-1 and mal-f1) 
had a reduced lifespan when compared with that the XOR null strain (ry506) strain. 
There was also a high level of significant difference between the rosy and maroon-like 
strains (Table 32).  
 
Table 32: Mean lifespan and maximum life of wild type, transgenic and mutant strains.  
Strain N 
Maximum 
Life of last fly 
(Days) 
 
Mean lifespan 
Days ± SD 
χ2  value of Drosophila 
melanogaster mean lifespan 
    
Canton-S ry 506 
Canton-S 100 64  49.2 ± 10.4 - 5.72* 
T1 100 62 48.8 ± 9.3 0.004 5.22* 
ry506 100 45 29.7 ± 7.1 5.72* - 
mal-1 100 29 15.1 ± 3.2 27.66* 18.41* 
mal-f1 100 31 15.9 ± 2.4 28.11* 18.75* 
N: Total number of individuals. Data represents mean ± S.D. of 5 sets of data. Statistical results of 
mean lifespan between Drosophila  strains (*P  < 0.05 by chi2 test is 3.84) indicates when a value is 
significantly different from the control value. 
  
From the results the effect of XOR and AO enzymes on longevity of Drosophila is 
clear. It can be seen that the XOR null strain and the dual XOR/AO strains have a 
greatly reduced lifespan when compared with the type strain. The mean lifespan was 
approximately 15.9 ± 2.4 days for maroon-like and 29.7 ± 7.1 days for ry506 strains in 
comparison with 49.2 ± 10.4 days for the wild type strain.  
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3.5. Effect of heat and cold shock on Drosophila melanogaster strains.  
In the present study, the survivorship of wild type and mutant strains when they were 
exposed to heat and cold shock was investigated.  
3.5.1. Effect of 25, 37 and 39°C on Drosophila melanogaster strains. 
As expected all strains had 100% survival at 25°C. The mean percentage survival for 
all strains after the 37 and 39°C heat shock at 1, 2, 4 and 6 hours can be seen in figure 
61.  The temperatures and procedures used were according to that described by Gong 
and Golic (2005). All strains had no effect when were exposed to heat shock at 37°C 
for 2 hours. All the Canton-S flies survived at 4 hours but had a relatively high 
mortality rate at 6 hours (approximately 50%) at 37°C. The rosy strain had a 
significantly higher mortality rate after four hours (approximately 30%) and after six 
hours was approximately 60%. The heat shock at 37°C had a significant effect on the 
mortality of maroon-like strains; the survival rate of mal-1 and mal-f1 strains was 
approximately 40% and 37% respectively at 4 hours and all the flies were dead at 6 
hours. At the highest temperature of 39˚C at four and six hours found none of maroon-
like strains survived. The heat shock at 39˚C results showed that the ry506 strain had a 
significantly reduced percentage survival after 4 and 6 hours compared to the wild 
type Canton-S strain (shown figure 61). The rosy mutant strain at two hours at 39˚C 
appears to have a low percentage survival (approximately 60%) and mal-1 and mal-f1 
strains at the same duration appear to have a highly significant death levels with 
mortality being approximately 85% when, compared with Canton-S strain 
(approximately 20%).  
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Figure 61: The survival percentage of Drosophila  strains exposed to heat shock for different 
durations at 37 and 39˚C temperature.  
(*P  < 0.05 by chi2 test is 3.84) indicates when a value is significantly different from the 
control value. (a) at 37˚C. (b) at 39˚C.  
Statistical tests were carried out to check whether the effect of the heat shock on 
Drosophila melanogaster strains were significantly different. Table 33 presented the 
chi2 values between all strains. 
Table 33: Statistical difference in survival rate between wild type and mutant strains after 
exposure to the heat shock at 37 and 39˚C. 
 (*P  < 0.05 by chi2 test is 3.84) indicates when a value is significantly different from the control value.  
This indicated MFE-null strains were less able to survive at elevated temperature than MFE-
active strains. 
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Temperature degree and χ2  
value 
Strain 
Canton-S ry506 
ry506 ma-l mal-f1 mal-1 mal-f1 
37˚C at 4 hours   χ2  = 4.84* 26.76* 28.22* 22.75* 21.86* 
37˚C at 6hours   χ2  = 5.10* 37.98* 39.01* 35.31* 37.01* 
39˚C at 2hours   χ2  = 2.86 36.94* 35.80* 29.34* 28.11* 
39˚C at 4hours   χ2  = 6.00* 47.80* 48.17* 42.97* 41.99* 
39˚C at 6hours   χ2  = 4.59* 59.96* 61.10* 53.95* 52.77* 
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3.5.2. Effect of 0 and -3 °C cold shock on Drosophila melanogaster strains. 
The mean percentage survival for all wild type and mutant strains when exposed to 
cold shock temperatures (0 and -3°C) for different periods (1, 2, 4, and 6 hrs) is 
illustrated in the following graph (Figure 62). There was no significant differences 
observed when the various strains were exposed to cold shock at 0 and -3°C for 1 hr. 
Canton-S strain had a steady decreased in percentage survival rate from ~90% to 
~40%  between 1 to 6 hours and all flies were dead when exposed to cold shock 0°C  
after 6 hours. For the period from 2 to 6 hours the rosy and ma-l strains had a higher 
significant mortality rate being ~ 80% of rosy strain at 6 hours and all ma-l flies were 
dead when exposed to 0°C.  At -3°C cold shock temperature the mutant strains (ry506 
and ma-l) had a highly significant different mortality rate for ry506 after 4 hours 
(approximately 98%) and all flies were dead after 6 hours. All ma-l strains were dead 
after 4 hours at -3˚C (Figure 62).   
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Figure 62: The survival percentage of Drosophila  strains exposed to cold shock for different 
durations at 0 and -3˚C.  
(*P  < 0.05 by chi2 test) indicates when a value is significantly different from the control value. 
(a) at 0˚C. (b) at -3˚C. 
Statistical tests were carried out to check whether the effect of the cold shock on 
Drosophila melanogaster strains were significantly different. Table 34 presented the 
chi2 values between all strains. This indicated MFE-deficient strains were less able to 
survive cold shock than MFE-active strains. 
Table 34: Statistical difference in survival rate between wild type and mutant strains after 
exposure to the cold shock at 0 and -3˚C. 
Temperature degree and χ2  
value 
Strain 
Canton-S ry506 
ry506 ma-l mal-f1 mal-1 mal-f1 
0˚C at 2 hours   χ2  = 3.07 10.43* 9.79* 8.02* 8.70* 
0˚C at 4 hours   χ2  = 6.09* 37.97* 39.02 24.34* 25.12* 
0˚C at 6hours   χ2  = 11.41* 61.44* 60.71* 51.27* 50.98* 
-3˚C at 2hours   χ2  = 9.95* 49.05* 47.87* 27.42* 26.72* 
-3˚C at 4hours   χ2  = 5.33* 37.40* 36.98* 1.04 1.10 
 (*P  < 0.05 by chi2 test is 3.84) indicates when a value is significantly different from the control value.  
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3.6. Bioinformatics analysis of Drosophila molybdenum cofactor 
sulphurase (MCS) gene.  
In order to identify mutations in the MCS gene in mal-1 and mal-f1 strains 
bioinformatic analysis was performed in order to map intron/exon boundaries and to 
design PCR primers. This was necessary as there has been no publication detailing 
these. As the Drosophila  genome had been completely sequenced (Adams et al., 
2000) the gene sequence was available on the Genbank database (AC011758). Along 
with the complete gene, the cDNA sequence was also found and the two were then 
compared using bioinformatics software (see section 2.9.1). This showed that the 
coding sequence of the gene was split over 4 exons. The intron/exon boundaries were 
also deduced. Once the boundaries had been established primer pairs were designed in 
order to clone the complete sequence. Nine primer pairs were selected forming an 
overlapping contig covering the entire gene (Figure 63). 
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-647  gatgtaaatcgaataatcagctgtatgtgtaggctatcgtctagatgtgaaaacgaatttaatgttctgtagttaaaaaacattttataaatgttttaaataataagattgtagtttccaaaaattattgtcatacaattggccaattagccattagcaaccattttcctaacaccaattgtttgccaacactcagaacatatgtttgaatagccatgcaaagtgcacaacgactagttaata  
-404  ccgtacaatttgagtttaaaattctatgcaattcagagttaataattggaaaagatttggtaaaatgctacatctataatattggtgagcagtgtgagaatatgatatatatattacaataagcaaacataatgcacaagaagcttaataaattgagcttcgtaaaatatatattacaataagcaaacataatgcacaagaagcttaataaattgagcttcgtaaaatgtgtagggtggagta  
                                                                                                                                                                       +1  
-161  agttcaaagagaagtcaaagcaaatgctcaactgaacgtgatagttgatgtatactgtccgtggctttttccagCGAAGAAGAGTATGGCGCAACAAATGCAAGCCGGTCGCAAATAAATAAAGCCCGCTTTGCAGCCAACACGAATAGTTAGTTCCCAACATGACATCATATCGGCCGGAGTTCTCCGCATCGGAGCAGTCGCAAATAGACGCGGAATTCTCTAGATTGGCCAGTAAgtgga         
                                                                                                                                                                       MetThrSerTyrArgProGluPheSerAlaSerGluGlnSerGlnIleAspAlaGluPheSerArgLeuAlaSerAs      (26)   
 
+161  gaaccatggtgaaatacccagcgcaaacagataacgaacctaactatccgtctatcgaacaggcaaCAAGAGTGTTTACCTGGATCATGCGGGCACCACTCTCTATGCCGAGAGCCAGGTGACGGCCGCCGCGGAGCAACTGCAGCGCAATGTCATCTGCAATCCGCACACCTGCCGCCTCACCGGCGACTTCGTCGACCAGGTGCGATTCAAgtgagttcatccgtgtccacgagccaaaac  
                                                                        nLysSerValTyrLeuAspHisAlaGluThrThrleuTyrAlagluSerGlnValThrAlaAlaAlaGluGlnLeuGlnArgAsnValIleCysAsnArgHisThrCysArgLeuThrGlyAspPheValAspGlnValArgPheLy                               (75)                                                
 
+325  aaccattctccccctgtcattgggttgcccttgtgtggcgcttttattaataattatttatgtgcatatagcaatatcgtaaaatatccttatgtcgctgcttatcttcctcatttgtggttaagttgtttttagtaaaacttctattcatatacacttttttagAATACTGGAATTCTTTAACACCACCGCCGAAGATTACCATGTGATATTCACGGCGAATGCCACCGCTGCTTTGTCCCT  
                                                                                                                                                                           sIleLeuGluPhePheAsnThrThrAlaGluAspTyrHisValIlePheThrAlaAsnAlaThrAlaAlaLeuSerLe (101)      
 
+568  GGTGGCGGAAAACTTTGACTTTGGATCCTCTGGTGAGTTTCACTTCTGCCAGGAGAACCACACCTCAGTGCTGGGAATGCGGGAAAGGGTCCGGGAAAACGGTATATACATGCTGAGGGAGAATGAAATCTCTGGCGGAAAGCACAAGGCGAACGGGAAAGTTCACGAGGTGTCCGGAAAAACAGGAAACTCCTTGCTGACCTTTTCGGCCCAATGCAACTTTAGTGGTTACAAAATCCCACT  
      sValAlaGluAsnPheAspPheGlySerSerGlyGluPheHisPheCysGlnGluAsnHisThrSerValLeuGlyMetArgGluArgValArgGluAsnGlyIleTyrMetLeuArgGluAsnGluIleSerGlyGlyLysHisLysAlaAsnGlyLysValHisGluValSerGlyLysThrGlyAsnSerLeuLeuThrPheSerAlaGlnCysAsnPheSerGlyTyrLysIleProLe (182) 
 
+811  GGAAGTCATTGAGCAAATCCAAATCGATGGCTTGGCCAAGCCGGGAAAAGAGCTTTGGAGCTCTTTGGGAGAGAAGAAGAAGAATATGCACAACGATTACTATATCTGCCTGGATGCGGCGTCTTTTGTGGCCACCAGTCCGTTGGATCTGCAAAAGTATAGACCAGATTACGTGTGCCTTAGTTTCTACAAGATCTTCGGTTATCCCACGGGCGTGGGAGCCCTGCTCGTGAGTCGACGAGG  
      uGluValIleGluGlnIleGlnIleAspGlyLeuAlaLysProGlyLysGluLeuTrpSerSerLeuGlyGluLysLysLysAsnMetHisAsnAspTyrTyrIleCysLeuAspAlaAlaSerPheValAlaThrSerProLeuAspLeuGlnLysTyrArgProAspTyrValCysLeuSerPheTyrLysIlePheGlyTyrProThrGlyValGlyAlaLeuValValSerArgArgGl (263) 
 
+1054 AGCCGAGGTCTTCCAGAAGCGCCGCTTTTTTGGCGGTGGTACCATCAACTACGCATATCCGCATGCCATGGATTACCAGCTGAGAGAGACCTTCCATCAGCGCTACGAGGACGGCACCCTGCCATTCCTCTCCATTGTCGGGTTGCTCGAGGGCTTTCGAACGCTGGAGAGATTGGTGCCCAGAACGGACGAGTTTAGCACCATGGAGAGGATTTCCAGgtgattagataatgataagtctga  
      yAlaGluValPheGlnLysArgArgPhePheGlyGlyGlyThrIleAsnTyrAlaTyrProHisAlaMetAspTyrGlnLeuArgGluThrPheHisGlnArgTyrGluAspGlyThrLeuProPheLeuSerIleValGlyLeuLeuGluGlyPheArgThrLeuGluArgLeuValProArgThrAspGluPheSerThrMetGluArgIleSerAr                         (333) 
 
+1540 tgacttcagccttattttccaatcattgtattttcagACACGTCTTTGGTCTGGCCAAGTATCTGGAGGATCAGCTGCGCCAGCTGCATCATCCCAATGGTGAGCCCCTCGTGAAGCTGTACAATAAAGTGGGCTACCAAGACAAATCCCGGCAGGGTGGCATCGTGGCCTTTAACGTGCGCACTGAATCGGGTTCGTTTGTGGGATTCGGCGAGATCGCCTGTGTGGCTGCTCTGCACGGAA  
                                           gHisvalPheGlyLeuAlaLysTyrLeuGluaspGlnLeuArgGlnLeuHisHisProAsnGlyGluProLeuValLysLeuTyrAsnLysValGlyTyrGlnAspLysSerArgGlnGlyGlyIleValAlaPheAsnValArgThrGluSerGlySerPheValGlyPheGlyGluIleAlaCysValAlaAlaLeuHisGlyI (414) 
 
+1783 TACTCCTGCGGACTGGTTGCTTCTGCAACATCGGAGCCTGCCAATATTACCTAGGCCTCGATGAAGATGCTTTGGATGCGATTTACAAGCGAGCAGGTCGCATATGCGGCGACTACTTTGATCTGATCGATGGACAGCCGACGGGAGCGGTACGGGTATCTTTTGGCTATATGACAACTATTCAGGACGTAGACAAGCTGCTCCAGATGCTGCGCTCCAGTTATTTGGCAACCAAGCCGCTGC  
      leLeuLeuArgThrGlyCysPheCysAsnIleGlyAlaCysGlnTyrTyrLeuGlyLeuAspGluAspAlaLeuAspAlaIleTyrArgArgAlaGlyArgIleCysGlyAspTyrPheAspLeuIleAspGlyGlnProThrGlyAlaValArgValSerPheGlyTyrMetThrThrIleGlnAspValAspLysLeuLeuGlnMetLeuArgSerSerTyrLeuAlaThrArgProLeuG (495)     
 
+2026 AGCGGATTCAGTTCATCGAGGAGCAGGCGGAGCAATTGCCGCCGTTGCTGAAGGAGCGAGTCCAGCTCTTGAGGCCAAAACTATTGCAGATGGCCATATATCCGGTAAAGTCTTGTGCCGCCTTTAAGATCGAATTACCGGGCTCCTGGCCATTGACGGATCAAGGTTTGAAATATGACCGTGAGTGGATGATCGTGGACATGAATGGCATGGCGTTGACCCAGAAACGCTGCACGGAGTTGT  
      lnArgIleGlnPheIleGluGluGlnAlaGluGlnLeuProProLeuLeuLysGluArgValGlnLeuLeuArgProLysLeuLeuGlnMetAlaIleTyrProValLysSerCysAlaAlaPheLysIleGluLeuProGlySerTrpProLeuThrAspGlnGlyLeuLysTyrAspArgGluTrpMetIleValAspMetAsnGlyMetAlaLeuThrGlnLysArgCysThrGluLeuC (576)  
 
+2269 GCCTAATTAGGCCAGTGATTAAGGTTGACCAATTGGAGCTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCTGGATGACCAGGCAGCCGACACAGCAAAATGCGTAAGCAAGGTGTGCCGACAGCCCGTGGAAGGTTTGGATTGCGGCGATAGGGTTGCCCAGTGGTTAAGCGAAAACCTCGGCATGGAGGGCCTCCGTTTGCTTCGACAATCGGGCCAGAGAAACTCTTCCA  
                                                                                                                    TGCGTAAGCAAGGTGTGC 
                                                                                                                  AATGCGTAAGCAAGGTGTGCCGAC                                        
      ysLeuIleArgProValIleLysValAspGlnLeuGluLeuGlnPheGlyGluAsnSerThrIleSerValProLeuSerLeuAspAspGlnAlaAlaAspThrAlaLysCysValSerLysValCysArgGlnProValGluGlyLeuAspCysGlyAspArgValAlaGlnTrpLeuSerGluAsnLeuGlyMetGluGlyLeuArgLeuLeuArgGlnSerGlyGlnArgAsnSerSerL (638) 
 
+2512 AGGATCAGCAGAAGCTAAGTCTGGTTAATCAGGCCCAGTTCTTGCTGCTAAACAAGTCTTCCGTGCGATCGCTTCAATTTGAAGAGCCCCTCGACGAGACTGTGGATCGTTTTCGGGCAAATATCATCATCGACACGGGCAGTGCCTTTGAGGAGCTTACCTACAAGGCCCTGTCCATTGGGGGAATCCAATTTCAGGTGGAGGGTCCCTGCCAGCGCTGCGACATGATCTGCATTAACCAAA  
      ysAspGlnGlnLysLeuserLeuValAsnGlnAlaGlnPheLeuLeuLeuAsnLysSerSerValArgSerLeuGlnPheGluGluAspLeuAspGluThrValAspArgPheArgAlaAsnIleIleIleAspThrGlySerAlaPheGluGluLeuThrTyrLysAlaLeuSerIleGlyGlyIleGlnPheGlnValGluGlyProCysGlnArgCysAspMetIleCysIleAsnGlnA (729)   
 
+2755 GGACAGGCGAACGGTCGCCAGAAACCTTGACCACCATATCCCGCCTGCAGAAGGGTCGCATGCGATTCGGCATCTACATCACTAGGATCCCCCAGGACACAAAAGAACTGGAACCCAAGGAGCAACACATGACCTGCGGCGATGTTGTCCTTGTGGAATAAGCTCACTTTACATCACTTCAGCGTGGTTTTCTTCGTTCTTTGGTTCGTTGACCCGAAATGTTTCTATTGTACATAGTTTTAG  
      rgThrGlyGluArgSerProGluThrLeuThrThrIleSerArgLeuGlnLysGlyArgMetArgPheGlyIleTyrIleThrArgIleProGlnAspThrLysGluLeuGluProLysGluGlnHisMetThrCysGlyAspValValLeuValGluStp                                                                                   (782)   
 
+2998 CACAATATTCACTAAGTAATTCTCTATTACGTTGCATCACGTTTCGCACTTAGTTTGTTTTTTAAGTACTTCTGAAATAGGAATACGCAAACATTCTTAAAGAAACATTCAGGATAGCTTAAGTTCAAAGTAACCGGATACCTCTTGCCAGTGTCTTAAGCCTTTAAAAGGCCTTAATTGCAAAATAAACACATTGAAATCGatatgtatatacttgagttcttaggaagggtaatcgaacgt  
 
+3236 aaataacgcaacggcgtaaataaatgccgatttgaatccaggcgcccatttgaagaagtgacgagcagggctaccaacgaatcatggaaagcaaatttagcacaagttgcttaacatcaataatgataataatgaataaaaagcatcgcgatatcataacttcatatcacaacatatcataaaaattaatgattatattttcttgaaactgttaaagtctattaaattaccaaggctt       
 
 
Figure 63: Complete gene sequence for the MCS gene in Drosophila melanogaster  showing deduced amino acid sequence, exonic sequence shown in upper case black 
letters and intronic sequence shown in lower case black letters.  
Primer pairs are indicated in different colours and are presented in table 20 in section 2.9.3. The nucleotides are numbered from the transcription initiation site (position +1). 
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3.6.1. Design of PCR primers for the amplification of the Drosophila 
molybdenum cofactor sulpharase gene. 
Primers sequences were selected by using the computer programs as described in 
materials and methods section 2.9.1 to find primer pairs that would hybridise to 
regions located within 1 kb of each other. 
3.6.2. Optimisation of the PCR conditions for amplification of Drosophila 
molybdenum cofactor sulpharase gene. 
Once the PCR primers were designed PCR optimisation was achieved by using the 
basic components as listed in materials and methods (section 2.9.3), varying one 
component at a time. The basic variable components were the temperature the PCR 
was carried out at, the concentration of the primers and the concentration of the 
MgCl2. Table 35 shows a summary of the conditions used and the results obtained 
using DNA isolated from the wild type strain (Canton-S) of Drosophila melanogaster. 
The optimal conditions for each primer pair are highlighted in yellow. An agarose gel 
image showing the successfully amplified products for each of the primer pairs is 
shown in figure 64.   
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Table 35: Summary of the experimental conditions and outcomes of the PCR of the 
Drosophila  MCS gene. 
Primers set 
Annealing temperatures 
C 
Primer 
conc.* 
MgCl2 
conc.* 
Fragments Generated 
DMCS1 
50,52,54,56,58 0.5 pM 2 mM Several fragments 
50,52,54,56,58,60,62 0.5 pM 3 mM Several fragments 
57 0.5 pM 1.5 mM 570 bp fragment 
     
DMCS2 
47,49,51,53,55,57,60,62 0.5 pM 1.5 mM No fragments 
48,50,52,54,56,58,60,62 0.5 pM 3 mM Several fragments 
47,49,51,53,55,57 0.5 pM 2 mM Several fragments 
47,49,51,53,55,57,60,62 0.5 pM 2.5 mM Several fragments 
57,58,59,60,61,62 0.5 pM 3.5 mM Several fragments 
52,53,54,55,56 0.5 pM 1.5 mM Several fragments 
47,49,51,53,55,57 0.5 pM 1.5 mM Several fragments 
47,49,51,53,55,57 0.5 pM 3 mM Several fragments 
55 0.25 pM 1.5 mM 730 bp fragment 
     
DMCS3 
50,52,54,56,58 0.5 pM 2 mM Several fragments 
59 0.5 pM 1.5 mM 780 bp fragment 
     
DMCS4 55 0.5 pM 1.5 mM 1100 bp fragment 
DMCS5 57 0.5 pM 1.5 mM 660 bp fragment 
DMCS6 55 0.5 pM 1.5 mM 980 bp fragment 
     
DMCS7 
47,49,51,53,55,57,60,62 0.5 pM 1.5 mM Several fragments 
48,50,52,54,56,58,60,62 0.5 pM 3 mM Several fragments 
47,49,51,53,55,57 0.5 pM 2 mM Several fragments 
47,49,51,53,55,57,60,62 0.5 pM 2.5 mM Several fragments 
57,58,59,60,61,62 0.5 pM 3.5 mM Several fragments 
52,53,54,55,56 0.5 pM 1.5 mM Several fragments 
47,49,51,53,55,57 0.5 pM 1.5 mM Several fragments 
47,49,51,53,55,57 0.25 pM 2 mM Several fragments 
55 0.25 pM 1.5 mM 610 bp fragment 
DMCS8 55 0.5 pM 1.5 mM 440 bp fragment 
DMCS9 
50,52,54,56,58,60,62 0.5 pM 1.5 mM Several fragments 
53 0.25 pM 1.5 mM 880 bp fragment 
This table shows the optimisation process for primer sets from DMCS1 to DMCS9. It illustrates the 
temperatures used with each set of conditions and the optimised outcomes from each set of conditions 
used, indicated by yellow colour. *concentration. 
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Figure 64: Agarose gel electrophoresis of products obtained by PCR amplifying different 
regions of Canton-S Drosophila  molybdenum cofactor sulfurase gene.DMSC1-9 sets used 
from Table 27. 
Once the optimal conditions had been obtained for each of the nine primer sets, to 
confirm that the correct region of the Drosophila  genome had been amplified the nine 
products obtained were sequenced in both the forward and reverse directions. The 
DNA sequencing results from the nine amplified products were used to produce a 
contig of the wild type sequence. The contig sequence produced was compared to the 
known GenBank sequence. The coding region of the Canton-S wild type sequence 
was 99% identical to that of the known GenBank sequence (AC011758 Drosophila 
melanogaster, chromosome X, region 19C-19E, BAC clone and AF162681 
Drosophila melanogaster maroon-like protein (mal) gene, complete). A number of 
nucleotide changes were identified in the non-coding and coding regions of the gene 
(Figure 65). This confirmed that the region amplified was the Drosophila  MCS gene. 
The nucleotide sequence variations between Canton-S (wild type) DNA and database 
AC01178 and AF162681 were in intron 1 (IVSI-93C>T, IVSI-135A>T and IVSI-
151A>G), exon 3 (c.260T>A, c.808C>A and c.1196G>A) and exon 4 (c.1884A>C, 
c.2483A>C, c.2143C>A, c.2289G>T, c.2567C>T and c.2890C>T) (see figure 51).  
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Figure 65: Comparison of the nucleotide sequence of the Canton-S D. melanogaster  strain MCS gene (CSDMCS) obtained in this study with those on GeneBank.  
Nucleotide sequence alignment of the Canton-S D. melanogaster  MCS gene which was obtained from PCR products and compared with AC011758 D. melanogaster 
chromosome X region 19C-19E, BAC clone AF162681 D. melanogaster  maroon-like protein (ma-l) gene were aligned using CLUSTAL X program (Larkin et al., 2007). 
The MSC gene exonic sequences are highlighted in different colours and intronic sequence shown in lower case letters. The sequences in upper case italics are 5' and 3' 
untranslated sequences in the mRNA. The differences nucleotides highlighted in red text. AC011758 = D. melanogaster  chromosome X region 19C-19E BAC clone.  
AF162681 = D. melanogaster  maroon-like protein (ma-l) gene. 
 
CSDMCS   (-179) acccagaaacgctgcacggagttgtgcaagttcaaagagaagtcaaagcaaatgttcaactgaacgtgatagttgatgtatactgtccgtggctttctccagCGAAGAAGAGTATGGCGCAACAAATGCAAGCCGGTCGCAAAT 
AC011758 (-179) acccagaaacgctgcacggagttgtgcaagttcaaagagaagtcaaagcaaatgctcaactgaacgtgatagttgatgtatactgtccgtggctttttccagCGAAGAAGAGTATGGCGCAACAAATGCAAGCCGGTCGCAAAT 
AF162881 (-179) acccagaaacgctgcacggagttgtgcaagttcaaagaaaagtcaaagcaaatgttcaactgaacgtgatagttgatgtatactgtccgtggctttctccagCGAAGAAGAGTATGGCGCAACAAATGCAAGCCGGTCGCAAAT  
                ************************************** *************** ***************************************** *********************************************** 
CSDMCS   (-45)  AAATAAAGCCCGATTTGCAGCCAACACGAATAGTTAGTTCCCAACATGACATCATATCGGCCGGAGTTCTCCGCATCGGAGCAGTCGCAAATAGACGCGGAATTCTCTAGATTGGCCAGTAAgtggagaaccatggtgaaatac 
AC011758 (-45)  AAATAAAGCCCGCTTTGCAGCCAACACGAATAGTTAGTTCCCAACATGACATCATATCGGCCGGAGTTCTCCGCATCGGAGCAGTCGCAAATAGACGCGGAATTCTCTAGATTGGCCAGTAAgtggagaaccatggtgaaatac 
AF162681 (-45)  AAATAAAGCCCGATTTGCAGCCAACACGAATAGTTAGTTCCCAACATGACATCATATCGGCCGGAGTTCTCCGCATCGGAGCAGTCGCAAATAGACGCGGAATTCTCTAGATTGGCCAGTAAgtggagaaccatggtgaaatac 
                ************************************************************************************************************************************************ 
CSDMCS   (+243) ccagcgcaaacagataacgaacctaactatccgtctatcgaacaggcaaCAAGAGTGTTTACCTGGATCATGCGGGCACCACTCTCTATGCCGAGAGCCAGGTGACGGCCGCCGCGGAGCAACTGCAGCGCAATGTCATCTGCA 
AC011758 (+243) ccagcgcaaacagataacgaacctaactatccgtctatcgaacaggcaaCAAGAGTGTTTACCTGGATCATGCGGGCACCACTCTCTATGCCGAGAGCCAGGTGACGGCCGCCGCGGAGCAACTGCAGCGCAATGTCATCTGCA 
AF162681 (+243) ccagcgcaaacagatatcgaacctaactatccgtctatcgaacaggcaaCAAGAGTGTTTACCTGGATCATGCGGGCACCACTCTCTATGCCGAGAGCCAGGTGACGGCCGCCGCGGAGCAACTGCAGCGCAATGTCATCTGCA 
                **************** ******************************************************************************************************************************* 
CSDMCS   (+387) ATCCGCACACCTGCCGCCTCACCGGCGACTTCGTCGACCAGGTGCGATTCAAgtgagttcatccgtgtccacgagccaaaacaaccattctccccctgtcattgggttgcccttgtgtggcgcttttattaataattatttatg 
AC011758 (+387) ATCCGCACACCTGCCGCCTCACCGGCGACTTCGTCGACCAGGTGCGATTCAAgtgagttcatccgtgtccacgagccaaaacaaccattctccccctgtcattgggttgcccttgtgtggcgcttttattaataattatttatg   
AF162681 (+387) ATCCGCACACCTGCCGCCTCACCGGCGACTTCGTCGACCAGGTGCGATTCAAgtgagttcatccgtgtccacgagccaaaacaaccattctccccctgtcattgggttgcccttgtgtggcgcttttattaataattatttatg 
                ************************************************************************************************************************************************ 
CSDMCS   (+531) tgcatatagcaatatcgtaaaatatccttatgtcgctgcttatcttcctcatttgtggttaagttgtttttagtaaaacttctattcatatacacttttttagAATACTGGAATTCTTTAACACCACCGCCGAAGATTACCATG                                  
AC011758 (+531) tgcatatagcaatatcgtaaaatatccttatgtcgctgcttatcttcctcatttgtggttaagttgtttttagtaaaacttctattcatatacacttttttagAATACTGGAATTCTTTAACACCACCGCCGAAGATTACCATG 
AF162681 (+531) tgcatatagcaatatcgtaaaatatccttatgtcgctgcttatcttcctcatttgtggttaagttgtttttagtaaaacttctattcatatacacttttttagAATACTGGAATTCTTTAACACCACCGCCGAAGATTACCATG 
                ************************************************************************************************************************************************ 
CSDMCS   (+675) TGATATTCACGGCGAATGCCACCGCTGCTTTGTCCCTGGTGGCGGAAAACTTTGACTTTGGATCCTCTGGTGAGTTTCACTTCTGCCAGGAGAACCACACCTCAGTGCTGGGAATGCGGGAAAGGGTCCGGGAAAACGGTATAT 
AC011758 (+675) TGATATTCACGGCGAATGCCACCGCTGCTTTGTCCCTGGTGGCGGAAAACTTTGACTTTGGATCCTCTGGTGAGTTTCACTTCTGCCAGGAGAACCACACCTCAGTGCTGGGAATGCGGGAAAGGGTCCGGGAAAACGGTATAT 
AF162681 (+675) TGATATTCACGGCGAATGCCACCGCTGCTTTGTCCCTGGTGGCGGAAAACTTTGACTTTGGATCCTCTGGTGAGTTTCACTTCTGCCAGGAGAACCACACCTCAGTGCTGGGAATGCGGGAAAGGGTCCGGGCAAACGGTATAT 
                ************************************************************************************************************************************ *********** 
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CSDMCS   (+819) ACATGCTGAGGGAGAATGAAATCTCTGGCGGAAAGCACAAGGCGAACGGGAAAGTTCACGAGGTGTCCGGAAAAACAGGAAACTCCTTGCTGACCTTTTCGGCCCAATGCAACTTTAGTGGTTACAAAATCCCACTGGAAGTCA 
AC011758 (+819) ACATGCTGAGGGAGAATGAAATCTCTGGCGGAAAGCACAAGGCGAACGGGAAAGTTCACGAGGTGTCCGGAAAAACAGGAAACTCCTTGCTGACCTTTTCGGCCCAATGCAACTTTAGTGGTTACAAAATCCCACTGGAAGTCA 
AF162881 (+819) ACATGCTGAGGGAGAATGAAATCTCTGGCGGAAAGCACAAGGCGAACGGGAAAGTTTACGAGGTGTCCGGAAAAACAGGAAACTCCTTGCTGACCTTTTCGGCCCAATGCAACTTTAGTGGTTACAAAATCCCACTGGAAGTCA 
                ************************************************************************************************************************************************ 
CSDMCS   (+963) TTGAGCAAATCCAAATCGATGGCTTGGCCAAGCCGGGAAAAGAGCTTTGGAGCTCTTTGGGAGAGAAGAAGAAGAATATGCACAACGATTACTATATCTGCCTGGATGCGGCGTCTTTTGTGGCCACCAGTCCGTTGGATCTGC 
AC011758 (+963) TTGAGCAAATCCAAATCGATGGCTTGGCCAAGCCGGGAAAAGAGCTTTGGAGCTCTTTGGGAGAGAAGAAGAAGAATATGCACAACGATTACTATATCTGCCTGGATGCGGCGTCTTTTGTGGCCACCAGTCCGTTGGATCTGC  
AF162881 (+963) TTGAGCAAATCCAAATCGATGGCTTGGCCAAGCCGGGAAAAGAGCTTTGGAGCTCTTTGGGAGAGAAGAAGAAGAATATGCACAACGATTACTATATCTGCCTGGATGCGGCGTCTTTTGTGGCCACCAGTCCGTTGGATCTGC 
                ************************************************************************************************************************************************ 
CSDMCS   (+1107) AAAAGTATAGACCAGATTACGTGTGCCTTAGTTTCTACAAGATCTTCGGTTATCCCACGGGCGTGGGAGCCCTGCTCGTGAGTCGACGAGGAGCCGAGGTCTTCCAGAAGCGCCGCTTTTTTGGCGGTGGTACCATCAACTAC 
AC011758 (+1107) AAAAGTATAGACCAGATTACGTGTGCCTTAGTTTCTACAAGATCTTCGGTTATCCCACGGGCGTGGGAGCCCTGCTCGTGAGTCGACGAGGAGCCGAGGTCTTCCAGAAGCGCCGCTTTTTTGGCGGTGGTACCATCAACTAC 
AF162881 (+1107) AAAAGTATAGACCAGATTACGTGTGCCTTAGTTTCTACAAGATCTTCGGTTATCCCACGGGCGTGGGAGCCCTGCTCGTGAGTCGACGGGGAGCCGAGGTCTTCCAGAAGCGCCGCTTTTTTGGCGGTGGTACCATCAACTAC 
                ***************************************************************************************** ****************************************************** 
CSDMCS   (+1251) GCATATCCGCATGCCATGGATTACCAGCTGAGAGAGACCTTCCATCAGCGCTACGAGGACGGCACCCTGCCATTCCTCTCCATTGTCGGGTTGCTCGAGGGCTTTCGAACGCTGGAGAGATTGGTGCCCAGAACGGACGAGTT 
AC011758 (+1251) GCATATCCGCATGCCATGGATTACCAGCTGAGAGAGACCTTCCATCAGCGCTACGAGGACGGCACCCTGCCATTCCTCTCCATTGTCGGGTTGCTCGAGGGCTTTCGAACGCTGGAGAGATTGGTGCCCAGAACGGACGAGTT 
AF162881 (+1251) GCATATCCGCATGCCATGGATTACCAGCTGAGAGAGACCTTCCATCAGCGCTACGAGGACGGCACCCTGCCATTCCTCTCCATTGTCGGGTTGCTCGAGGG-TTTCGAACGCTGGAGAGATTGGTGCCCAGAACGGACGAGTT 
                 ***************************************************************************************************** ***************************************** 
CSDMCS   (+1395) TAGCACCATGGAGAGGATTTCCAGgtgattagataatgataagtctgatgacttcagccttattttccaatcattgtattttcagACACGTCTTTGGTCTGGCCAAGTATCTGGAGGATCAGCTGCGCCAGCTGCATCATCCC 
AC011758 (+1395) TAGCACCATGGAGAGGATTTCCAGgtgattagataatgataagtctgatgacttcagccttattttccaatcattgtattttcagACACGTCTTTGGTCTGGCCAAGTATCTGGAGGATCAGCTGCGCCAGCTGCATCATCCC 
AF162881 (+1395) TAGCACCATGGAGAGGATTTCCAGgtgattagataatgataagtctgatgacttcagccttattttccaatcattgtattttcagACACGTCTTTGGTCTGGCCAAGTATCTGGAGGATCAGCTGCGCCAGCTGCATCATCCC 
                 *********************************************************************************************************************************************** 
CSDMCS   (+1539) AATGGTGAGCCCCTCGTGAAGCTGTACAATAAAGTGGGCTACCAAGACAAATCCCGGCAGGGTGGCATCGTGGCCTTTAACGTGCGCACTGAATCGGGTTCGTTTGTGGGATTCGGCGAGATCGCCTGTGTGGCTGCTCTGCA 
AC011758 (+1539) AATGGTGAGCCCCTCGTGAAGCTGTACAATAAAGTGGGCTACCAAGACAAATCCCGGCAGGGTGGCATCGTGGCCTTTAACGTGCGCACTGAATCGGGTTCGTTTGTGGGATTCGGCGAGATCGCCTGTGTGGCTGCTCTGCA 
AF162881 (+1539) AATGGTGAGCCCCTCGTGAAGCTGTACAATAAAGTGGGCTACCAAGACAAATCCCGGCAGGGTGGCATCGTGGCCTTTAACGTGCGCACTGAATCGGGTTCGTTTGTGGGATTCGGCGAGATCGCCTGTGTGGCTGCTCTGCA 
                 *********************************************************************************************************************************************** 
AC011758 (+1683) CGGAATACTCCTGCGGACTGGTTGCTTCTGCAACATCGGAGCCTGCCAATATTACCTAGGCCTCGATGAAGATGCTTTGGATGCGATTTACAAGCGAGCAGGTCGCATATGCGGCGACTACTTTGATCTGATCGATGGACAGC 
AF162881 (+1683) CGGAATACTCCTGCGGACTGGTTGCTTCTGCAACATCGGAGCCTGCCAATATTACCTAGGCCTCGATGAAGATGCTTTGGATGCGATTTACAAGCGAGCAGGTCGCATATGCGGCGACTACTTTGATCTGATCGATGGACAGC 
CSDMCS   (+1683) CGGAATACTCCTGCGGACTGGTTGCTTCTGCAACATCGGAGCCTGCCAATATTACCTAGGCCTCGATGAAGATGCTTTGGATGCGATTTACAAGCGAGCAGGTCGCATATGCGGCGACTACTTTGATCTGATCGATGGACAGC 
                 *********************************************************************************************************************************************** 
CSDMCS   (+1827) CGACGGGAGCGGTACGGGTATCTTTTGGCTATATGACAACTATTCAGGACGTAGACCAGCTGCTCCAGATGCTGCGCTCCAGTTATTTGGCAACCAAGCCGCTGCAGCGGATTCAGTTCATCGAGGAGCAAGCGGAGCAATTG 
AC011758 (+1827) CGACGGGAGCGGTACGGGTATCTTTTGGCTATATGACAACTATTCAGGACGTAGACAAGCTGCTCCAGATGCTGCGCTCCAGTTATTTGGCAACCAAGCCGCTGCAGCGGATTCAGTTCATCGAGGAGCAGGCGGAGCAATTG 
AF162881 (+1827) CGACGGGAGCGGTACGGGTATCTTTTGGCTATATGACAACTATTCAGGACGTAGACAAGCTGCTCCAGATGCTGCGCTCCAGTTATTTGGCAACCAAGCCGCTGCAGCGGATTCAGTTCATCGAGGAGCAGGCGGAGCAATTG 
                 ******************************************************** ************************************************************************************** 
CSDMCS   (+1971) CCGCCGTTGCTGAAGGAGCGAGTCCAGCTCTTGAGGCCAAAACTATTGCAGATGGCCATATATCCGGTAAAGTCTTGTGCCGCCTTTAAGATCGAATTACCGGGCTCCTGGCCATTGACGGATCAAGGTTTGAAATATGACCG 
AC011758 (+1971) CCGCCGTTGCTGAAGGAGCGAGTCCAGCTCTTGAGGCCAAAACTATTGCAGATGGCCATATATCCGGTAAAGTCTTGTGCCGCCTTTAAGATCGAATTACCGGGCTCCTGGCCATTGACGGATCAAGGTTTGAAATATGACCG 
AF162881 (+1971) CCGCCGTTGCTGAAGGAGCGAGTCCAGCTCTTGAGGCCAAAACTATTGCAGATGGCCATATATCCGGTAAAGTCTTGTGCCGCCTTTAAGATCGAATTACCGGGCTCCTGGCCATTGACGGATCAAGGTTTGAAATATGACCG 
                 *********************************************************************************************************************************************** 
CSDMCS   (+2115) TGAGTGGATGATCGTGGACATGAATGGAATGGCGTTGACCCAGAAACGCTGCACGGAGTTGTGCCTAATTAGGCCAGTGATTAAGGTTGACCAATTGGAGTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCT  
AC011758 (+2115) TGAGTGGATGATCGTGGACATGAATGGCATGGCGTTGACCCAGAAACGCTGCACGGAGTTGTGCCTAATTAGGCCAGTGATTAAGGTTGACCAATTGGAGTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCT 
AF162881 (+2115) TGAGTGGATGATCGTGGACATGAATGGCATGGCGTTGACCCAGAAACGCTGCACGGAGTTGTGCCTAATTAGACCAGTGATTAAGGTTGACCAATTGGAGTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCT 
                 *************************** *******************************************************************************************************************  
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CSDMCS   (+2259) GGATGACCAGGCAGCCGACACAGCAAAATGTGTAAGCAAGGTGTGCCGACAGCCCGTGGAAGGTTTGGATTGCGGCGATAGGGTTGCCCAGTGGTTAAGCGAAAACCTCGGCATGGAGGGCCTCCGTTTGCTTCGACAATCGG 
AC011758 (+2259) GGATGACCAGGCAGCCGACACAGCAAAATGCGTAAGCAAGGTGTGCCGACAGCCCGTGGAAGGTTTGGATTGCGGCGATAGGGTTGCCCAGTGGTTAAGCGAAAACCTCGGCATGGAGGGCCTCCGTTTGCTTCGACAATCGG 
AF162881 (+2259) GGATGACCAGGCAGCCGACACAGCAAAATGCGTAAGCAAGGTGTGCCGACAGCCCGTGGAAGGTTTGGATTGCGGCGATAGGGTTGCCCAGTGGTTAAGCGAAAACCTCGGCATGGAGGGCCTCCGTTTGCTTCGACAATCGG 
                 ****************************** **************************************************************************************************************** 
CSDMCS   (+2403) GCCAGAGAAACTCTTCCAAGGATCAGCAGAAGCTAAGTCTGGTTAATCAGGCCCAGTTCTTGCTGCTAAACAAGTCTTCCGTGCGATCGCTTCAATTTGAGGAGCCCCTCGACGAGACTGTGGATCGTTTTCGGGCAAATATC 
AC011758 (+2403) GCCAGAGAAACTCTTCCAAGGATCAGCAGAAGCTAAGTCTGGTTAATCAGGCCCAGTTCTTGCTGCTAAACAAGTCTTCCGTGCGATCGCTTCAATTTGAAGAGCCCCTCGACGAGACTGTGGATCGTTTTCGGGCAAATATC 
AF162881 (+2403) GCCAGAGAAACTCTTCCAAGGATCAGCAGAAGCTAAGTCTGGTTAATCAGGCCCAGTTCTTGCTGCTAAACAAGTCTTCCGTGCGATCGCTTCAATTTGAAGAGCCCCTCGACGAGACTGTGGATCGTTTTCGGGCAAATATC 
                 **************************************************************************************************** ****************************************** 
CSDMCS   (+2547) ATCATCGACACGGGCAGTGCTTTTGAGGAGCTTACCTACAAGGCCCTGTCCATTGGGGGAATCCAATTTCAGGTGGAGGGTCCCTGCCAGCGCTGCGACATGATCTGCATTAACCAAAGCACAGGCGAACGGTCGCCAGAAAC  
AC011758 (+2547) ATCATCGACACGGGCAGTGCCTTTGAGGAGCTTACCTACAAGGCCCTGTCCATTGGGGGAATCCAATTTCAGGTGGAGGGTCCCTGCCAGCGCTGCGACATGATCTGCATTAACCAAAGCACAGGCGAACGGTCGCCAGAAAC 
AF162881 (+2547) ATCATCGACACGGGCAGTGCCTTTGAGGAGCTTACCTACAAGGCCCTGTCCATTGGGGGAATCCAATTTCAGGTGGAGGGTCCCTGCCAGCGCTGCGACATGATCTGCATTAACCAAA-CACAGGCGAACGGTCGCCAGAAAC 
                 ******************** ************************************************************************************************* ************************  
CSDMCS   (+2691) CTTGACCACCATATCCCGCCTGCAGAAGGTCGCATGCGATTCGAGCATCTACATCACTAGGATCCCCCAGGACACAAAAGAACTGGAACCCAAGGAGCAACACATGACCTGCGGCGATGTTGTCCTTGTGGAATAAGCTCACT                       
AC011758 (+2691) CTTGACCACCATATCCCGCCTGCAGAAGGGTCGCATGCGATTCGGCATCTACATCACTAGGATCCCCCAGGACACAAAAGAACTGGAACCCAAGGAGCAACACATGACCTGCGGCGATGTTGTCCTTGTGGAATAAGCTCACT 
AF162881 (+2691) CTTGACCACCATATCCCGCCTGCAGAAGGGTCGCATGCGATTCGGCATCTACATCACTAGGATCC------------------------------------------------------------------------------ 
                 *****************************************************************  
CSDMCS   (+2835) TTACATCATTCAGCGTGGTTTTCTTCGTTCTTTGGTTCGTTGACCCGAAATGTTTTTATTGTACATAGTTTTAGCACAATATCCACTAAGTAATTCTCTATTACGTTGCATCACGTTTCGCACTTAGTTTGTTTTTTAAGTAC 
AC011758 (+2835) TTACATCATTCAGCGTGGTTTTCTTCGTTCTTTGGTTCGTTGACCCGAAATGTTTCTATTGTACATAGTTTTAGCACAATATTCACTAAGTAATTCTCTATTACGTTGCATCACGTTTCGCACTTAGTTTGTTTTTTAAGTAC 
                 ******************************************************* ***************************************************************************************      
CSDMCS   (+2979) TTCTGAAATAGGAATACGCAAACATTCTTAAAGAAACATTCAGGATAGCTTAAGTTCAAAGTAACCGGATACCTCTTGCCAGTGTCTTAAGCCTTTAAAAGGCCTTAATTGCAAAATAAACACATTGAAATCGatatgtatat 
AC011758 (+2979) TTCTGAAATAGGAATACGCAAACATTCTTAAAGAAACATTCAGGATAGCTTAAGTTCAAAGTAACCGGATACCTCTTGCCAGTGTCTTAAGCCTTTAAAAGGCCTTAATTGCAAAATAAACACATTGAAATCGatatgtatat 
                 ***********************************************************************************************************************************************         
CSDMCS   (+3123) acttgagttcttaggaagggtaatcgaacgtaaataacgcaacggcgtaaataaatgccgatttgaatccaggcgcccatttgaagaagtgacgagcagggctaccaacgaatcatggaaagcaaatttagcacaagttgctt           
AC011758 (+3123) acttgagttcttaggaagggtaatcgaacgtaaataacgcaacggcgtaaataaatgccgatttgaatccaggcgcccatttgaagaagtgacgagcagggctaccaacgaatcatggaaagcaaatttagcacaagttgctt 
                 *********************************************************************************************************************************************** 
CSDMCS   (+3267) aacatcaataatgataataatgaataaaaagcatcgcgatatcataacttcatatcacaacatatcataaaaattaatgattatattttcttgaaactgttaaagtctattaaattaccaaggcttgaaagtggtgagggagt 
AC011758 (+3267) aacatcaataatgataataatgaataaaaagcatcgcgatatcataacttcatatcacaacatatcataaaaattaatgattatattttcttgaaactgttaaagtctattaaattaccaaggcttgaaagtggtgagggagt 
                 *********************************************************************************************************************************************** 
CSDMCS   (+3411) ttgtatcaatactccaaaaatggcatggaagcattttctttcattcattgatttaggacatccttctatcttaaagctgtacggattaattggtaccttgttttttgggcttaggtagagcttttatggtctatttatttgtt         
AC011758 (+3411) ttgtatcaatactccaaaaatggcatggaagcattttctttcattcattgatttaggacatccttctatcttaaagctgtacggattaattggtaccttgttttttgggcttaggtagagcttttatggtctatttatttgtt 
                 *********************************************************************************************************************************************** 
CSDMCS   (+3463) atataaagcaaacctaagattgaaaactgcagcaaattaactgttgagacca 
AC011758 (+3463) atataaagcaaacctaagattgaaaactgcagcaaattaactgttgagacca 
                 ****************************************************       
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3.6.3. Identification of the mutations responsible for molybdenum cofactor 
sulfurase deficiencies in Drosophila melanogaster.  
Once the wild type MCS sequence was confirmed, DNA was extracted from both the 
mal-1 and mal-f1 strains. The MCS region was the amplified in both strains and the 
PCR products were sequenced and compared to the sequence data obtained from the 
wild type strain. 
3.6.3.1. Identification of the mutations responsible for the MFE-deficiency 
observed in the mal-1 Drosophila strain. 
 
Figure 66 shows a region of the sequence data obtained from primer set DMCS-8 
compared to the same region of the wild type sequence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mal-1: 
 
Wild type: 
 
 
Figure 66: Comparison of the DNA sequencing electrophoretograms obtained from 
the wild type and the mal-1 D. melanogaster  strains using primer set DMCS-8.  
Top electrophoretrogram shows sequence obtained from mal-1 strain. Bottom 
electrophoretrogram shows sequence obtained from wild type strain. The red box 
highlights a 6 bp insertion in mal-1 and the red arrow indicates the point of insertion in 
wild type. 
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Comparison of the sequence data obtained from the mal-1 strain revealed a 6 bp 
insertion within exon 4 of the MCS gene (Figure 67). The mutation was identified at 
nucleotide position c.2123_2124insCTACCA from the AUG initiator codon in the 
predicted mRNA transcript of the mal-1 mutant. Translation of the predicted mRNA 
indicated that the 6 bp insertion resulted in the in-frame p.Ile577_Tyr578insLeuPro 
(Figure 67). 
 
(a) 
DMCS/mal-1 (+2094) TTGAGGCCAAAACTATTGCAGATGGCCATACTACCATATCCGGTAAAGTCTTGTGCCGCC 
CSDMCS     (+2094) TTGAGGCCAAAACTATTGCAGATGGCCATA-----ATATCCGGTAAAGTCTTGTGCCGCC 
                   ******************************     ************************* 
(b) 
 
CSDMCS     (540)   ATKPLQRIQFIEEQAEQLPPLLKERVQLLRPKLLQMAI—-YPVKSCAAFKIELPGSWPLT  
DMCS/mal-1 (540)   ATKPLQRIQFIEEQAEQLPPLLKERVQLLRPKLLQMAILPYPVKSCAAFKIELPGSWPLT  
                   **************************************  ******************** 
 
 Figure 67: Comparison of the mal-1 with Canton-S wild type molybdenum cofactor 
sulfurase nucleotide and deduced protein sequences at the site of the mutation. 
(a) Nucleotide sequence alignment of the Canton-S and mal-1 Drosophila  a mutant strain, 
which was obtained when the PCR product was aligned using CLUSTAL X program (Larkin 
et al., 2007). The 6bp insertion is shown in red text. (b): Predicted protein sequence of the 
mal-1 mutant. In frame addition of two amino acids are resulting from the 6bp insertion 
shown in red text were aligned using CLUSTAL X program (Larkin et al., 2007). CSDMCS = 
Canton-S molybdenum cofactor sulfurase. DMCS/mal-1 = molybdenum cofactor sulfurase of 
mal-1 strain 
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 3.6.3.2. Identification of the mutations responsible for the MFE-deficiency 
observed in the mal-f1 Drosophila strain. 
When the sequence data obtained from the mal-f1 strain was compared to that of the 
wild type strain a mutation was identified in exon 4 of the MCS gene (Figure 68). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of the sequence data obtained from the mal-f1 and wild type strains 
identified a 23bp deletion c.2219_2220delCGTGGACATGAATGGCATGGCGT 
(Figure 69).  
 
 
mal-f1: 
 
Wild type: 
 
 
Figure 68: Comparison of the sequencing electrophoretograms of the MCS gene from the 
wild type and the mal-f1 D.melanogaster  strains using primer set DMCS-8.  
Top electrophoretrogram shows sequence obtained from mal-f1 strain and the red arrow 
indicates the points of deletion in mal-f1. Bottom electrophoretrogram shows sequence 
obtained from wild type strain. Red box highlights a 23 bp deletion. 
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DMCS-malf1 (+2173) GGCCATTGACGGATCAAGGTTTGAAATATGACCGTGAGTGGATGAT-------------- 
CSDMCS     (+2173) GGCCATTGACGGATCAAGGTTTGAAATATGACCGTGAGTGGATGATCGTGGACATGAATG 
                   **********************************************               
DMCS-malf1 (+2233) ---------TGACCCAGAAACGCTGCACGGAGTTGTGCCTAATTAGGCCAGTGATTAAGG 
CSDMCS     (+2233) GAATGGCGTTGACCCAGAAACGCTGCACGGAGTTGTGCCTAATTAGGCCAGTGATTAAGG 
                            *************************************************** 
DMCS-malf1 (+2293) TTGACCAATTGGAGTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCTGGA 
CSDMCS     (+2293) TTGACCAATTGGAGTGCAGTTTGGAGAAAATTCCACCATCTCGGTGCCCCTTTCTCTGGA 
                   ************************************************************ 
Figure 69: Nucleotide sequence alignment of the Canton-S and mal-f1 molybdenum cofactor 
sulfurase gene at the site of the 23bp deletion in exon 4.  
The 23bp deletion is shown in red text. CSDMCS = Canton-S molybdenum cofactor 
sulfurase. DMCS/mal-1 = molybdenum cofactor sulfurase of mal-f1 strain. 
 
Translation of the predicted mRNA from the mal-f1 strain identified that the 23 bp 
deletion resulted in a frame shift at codon position 550 and the addition of a premature 
stop codon at position 562 (Figure 70).  
CSDMCS          MTSYRPEFSASEQSQIDAEFSRLASNKSVYLDHAGTTLYAESQVTAAAEQLQRNVICNPH (60) 
DMCSmal-f1      MTSYRPEFSASEQSQIDAEFSRLASNKSVYLDHAGTTLYAESQVTAAAEQLQRNVICNPH (60) 
                ************************************************************ 
CSDMCS          TCRLTGDFVDQVRFKILEFFNTTAEDYHVIFTANATAALSLVAENFDFGSSGEFHFCQEN (120) 
DMCSmal-f1      TCRLTGDFVDQVRFKILEFFNTTAEDYHVIFTANATAALSLVAENFDFGSSGEFHFCQEN (120) 
                ************************************************************ 
CSDMCS          HTSVLGMRERVRENGIYMLRENEISGGKHKANGKVHEVSGKTGNSLLTFSAQCNFSGYKI (180) 
DMCSmal-f1      HTSVLGMRERVRENGIYMLRENEISGGKHKANGKVHEVSGKTGNSLLTFSAQCNFSGYKI (180) 
                ************************************************************ 
CSDMCS          PLEVIEQIQIDGLAKPGKELWSSLGEKKKNMHNDYYICLDAASFVATSPLDLQKYRPDYV (240) 
DMCSmal-f1      PLEVIEQIQIDGLAKPGKELWSSLGEKKKNMHNDYYICLDAASFVATSPLDLQKYRPDYV (240) 
                ************************************************************ 
CSDMCS          CLSFYKIFGYPTGVGALLVSRRGAEVFQKRRFFGGGTINYAYPHAMDYQLRETFHQRYED (300) 
DMCSmal-f1      CLSFYKIFGYPTGVGALLVSRRGAEVFQKRRFFGGGTINYAYPHAMDYQLRETFHQRYED (300) 
                ************************************************************ 
CSDMCS          GTLPFLSIVGLLEGFRTLERLVPRTDEFSTMERISRHVFGLAKYLEDQLRQLHHPNGEPL (360) 
DMCSmal-f1      GTLPFLSIVGLLEGFRTLERLVPRTDEFSTMERISRHVFGLAKYLEDQLRQLHHPNGEPL (360) 
                ************************************************************ 
CSDMCS          VKLYNKVGYQDKSRQGGIVAFNVRTESGSFVGFGEIACVAALHGILLRTGCFCNIGACQY (420) 
DMCSmal-f1      VKLYNKVGYQDKSRQGGIVAFNVRTESGSFVGFGEIACVAALHGILLRTGCFCNIGACQY (420) 
                ************************************************************ 
CSDMCS          YLGLDEDALDAIYKRAGRICGDYFDLIDGQPTGAVRVSFGYMTTIQDVDQLLQMLRSSYL (480) 
DMCSmal-f1      YLGLDEDALDAIYKRAGRICGDYFDLIDGQPTGAVRVSFGYMTTIQDVDQLLQMLRSSYL (480) 
                ************************************************************ 
CSDMCS          ATKPLQRIQFIEEQAEQLPPLLKERVQLLRPKLLQMAIYPVKSCAAFKIELPGSWPLTDQ (540) 
DMCSmal-f1      ATKPLQRIQFIEEQAEQLPPLLKERVQLLRPKLLQMAIYPVKSCAAFKIELPGSWPLTDQ (540) 
                ************************************************************ 
CSDMCS          GLKYDREWMIVDMNGMALTQKRCTELCLIRPVIKVDQLELQFGENSTISVPLSLDDQAAD (600) 
DMCSmal-f1      GLKYDREWMIDPETLHGVVPN*                                       (561) 
                **********    
CSDMCS          TAKCVSKVCRQPVEGLDCGDRVAQWLSENLGMEGLRLLRQSGQRNSSKDQQKLSLVNQAQ (660) 
CSDMCS          FLLLNKSSVRSLQFEEPLDETVDRFRANIIIDTGSAFEELTYKALSIGGIQFQVEGPCQR (720) 
CSDMCS          CDMICINQRTGERSPETLTTISRLQKGRMRFGIYITRIPQDTKELEPKEQHMTCGDVVLV (780) 
CSDMCS          E (781) 
 
 
Figure 70: Comparison of the predicted molybdenum cofactor sulfurase protein sequence of 
the mal-f1 and Canton-S wild type strain. Sequences were aligned using CLUSTAL X 
program (Larkin et al., 2007).  
Red text indicates the altered amino acid sequence at the carboxyl-terminus in the mal-f1 
mutant strain. CSDMCS = Canton-S molybdenum cofactor sulfurase. DMCS/mal-1 = 
molybdenum cofactor sulfurase of mal-f1 strain. 
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4. Discussion.   
This discussion section follows the order of the results section.  
4.1.1. Spectrophotometric and HPLC investigation of 
molybdoflavoenzymes characterisation in wild type Canton-S 
Drosophila strain.  
Only two studies have directly measured the kinetics of substrates disappearance or 
product generation on Drosophila melanogaster AO. Wurzinger and Hartenstein 
(1974) used vanillin as substrate of Drosophila  AO with O2 as an electron acceptor in 
a spectrophotometric assay (Wurzinger & Hartenstein, 1974) and  a fluorometric assay 
was used for acetaldehyde as substrate of AO (Dickinson & Gaughan, 1981). Rather 
than directly measure substrate disappearance or product generation AO activity many 
studies measure AO activity indirectly using artificial electron acceptors. Several 
studies have used acetaldehyde substrate with 2,6-dichlorophenolindophenol (DCPIP) 
as an artificial electron acceptor for aldehyde oxidase in a spectrophotometric assay 
(Browder & Williamson, 1976; Dickinson, 1971; Dickinson & Gaughan, 1981; Wahl 
et al., 1982; Warner & Finnerty, 1981) and heptaldehyde was used as a substrate with 
DCPIP as an artificial electron acceptor (Cypher et al., 1982). The majority of 
previous studies on Drosophila  AO have been using a semi-quantitative histochemical 
assay for acetaldehyde, benzaldehyde, anisaldehyde, p-chlorobenaldehyde, 
cinnamaldehyde, citral, citronellal, dimethylaminobenzaldehyde, hexaldehydehyde, p-
hydroxybenzaldehyde, m-hydroxybenzaldehyde, o-hydroxybenzaldehyde, 
salicylaldehyde, pyridoxal and vanillin substrates of Drosophila  AO with phenazine 
methosulfate as an artificial electron acceptor (Cypher et al., 1982; Dickinson & 
Gaughan, 1981). Interestingly, no AO N-heterocyclic substrates or retinaldehyde that 
are a major important class of substrates for mammalian aldehyde oxidase (Table 1) 
(Garattini et al., 2008; Kitamura et al., 2006) have been investigated as substrates for 
145 
 
Drosophila  AO. In this study N-heterocyclic compounds including drugs and the 
vitamin metabolite (N1-methylnicotinamide) and  vitamin A (retinaldehyde) were used 
in the first time for Drosophila  AO using sensitive spectrophotometric and HPLC 
methods as a new direct assay for determining the AO activity for Drosophila 
melanogaster. In the AO spectrophotometric assays one N-heterocyclic compound, 
phenanthridine was used as a substrate. Two aldehyde compounds, vanillin and 
dimethylaminocinnamaldehyde, were also used as aldehyde substrates of AO. XDH 
was also studied using its endogenous substrate, xanthine in a spectrophotometric and 
HPLC assay.  
Prior to testing with the large number of substrates the optimal conditions of the 
activities of both molybdo-flavoenzymes were studied in Drosophila . The activity of 
AO and XDH of Drosophila  was measured as at different incubation temperatures for 
30 minutes as described in section 2.8.2.1. The rate of reaction of Drosophila  AO with 
DMAC gradually rose with increase temperature from 20˚C up to 37˚C, then the 
activity decreased above this value (Figure 29). A similar result was obtained with 
Drosophila  XDH where the activity of XDH enzyme rose with increasing temperature 
up to 45˚C, and these results resemble those with most animal enzymes that become 
denatured at temperatures above 40˚C (Figure 29) (Pfeiffer, 1954). This present result 
showed that the assay temperature of 37˚C is suitable for use with the Drosophila  
MFE enzymes.  
The effect of pH on Drosophila AO and XDH was assayed under standard assay 
condition, except that the reaction pH was varied between 5.6 and 8.0 as described in 
section 2.8.1. The maximum activity of AO and XDH was achieved at a similar pH 
optimum between pH 7 and 7.5 as shown figure 30. These result agree with Egwim et 
al. 2005 studied which found that the optimum pH of cow and goat milk XOR were 
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7.5 (Egwim et al., 2005). The optimum pH for AO from Drosophila  melanogaster 
was observed in the present study is similar to that found by Stoddart et al. who found 
the optimal pH of rabbit AO was 7.5, when oxygen was used as the electron accepter 
(Stoddart & Levine, 1992). 
Km and Vmax were determined from the Eadie- Hofstee plot of V versus V/[S] as 
described in the section materials and methods using simple rapid spectrophotometric 
assays. Enzyme activity of AO was measured spectrophotometrically using three 
different substrates with O2 as electron acceptor as follows. These were chosen for the 
following reasons. The DMAC is a specific substrate for rat AO (Kurth & Kubiciel, 
1984; Maia & Mira, 2002; Moriwaki et al., 1998) and phenanthridine has been shown 
to be a good specific substrate for monitoring mammalian AO activity in many studies 
(Beedham et al., 1989; Lake et al., 2002; Pirouzpanah et al., 2006; Sorouraddin et al., 
2008; Terao et al., 2000). Vanillin has also been shown to be a good substrate with a 
high affinity for AO guinea pig liver (Panoutsopoulos & Beedham, 2004; 
Panoutsopoulos et al., 2004).  
The lowest Km value for an AO substrate was found with DMAC being 50 ± 5.4 µM 
(mean ± SD) with Canton-S cytosol. In agreement with the present result Li et al. 
(2009) found that the DMAC is an excellent substrate for rat liver AO with a low Km 
value (9.6 µM) (Li et al., 2009). The results of this study indicated that DMAC is 
better substrate of Drosophila  AO than the phenanthridine (Km = 80 ± 9.1 µM) and 
vanillin (Km = 303 ± 11.7 µM). The Km value for Drosophila  AO with vanillin was 
approximately 2.5 times greater than that found guinea pig liver AO that has a Km 
value of 120 µM (Panoutsopoulos et al., 2005). In contrast, the Drosophila  enzyme 
has a 100 fold difference in its Km value for vanillin than the human enzyme. Obach, 
(2004) found vanillin is an excellent substrate for human liver AO with a low Km (2.7 
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µM) (Obach, 2004). Cypher et al. (1981) found the Km value for heptaldehyde as 
substrate for Drosophila  AO was 2500 µM. This suggests that the aromatic aldehyde 
vanillin is a better substrate for Drosophila  AO than the aliphatic aldehyde 
heptaldehyde. Phenanthridine as a specific substrate of AO has been used in several 
papers and Km previously has been estimated were < 1 μM with rabbit and guinea pig 
liver AO enzyme and 6 μM and 14 μM with rat and human liver AO, respectively 
(Beedham, 2001; Rashidi et al., 1997; Stubley & Stell, 1980). The present result is 
indicated that phenanthridine a good substrate of Drosophila  AO, in terms of a Km of 
phenanthridine (Km = 80 ± 9.1 µM) (mean ± SD) but this value is considerably greater 
than the previously studies of mammalian AO. Comparison of the Km values between 
the different Drosophila  strains showed that there were no significant differences 
between Canton-S and ry506 strains for phenanthridine and DMAC as substrates. 
However, the Km of vanillin obtained for the ry506 strain was significant lower than 
that with Canton-S. This might be due to a polymorphism in the Drosophila  AO gene. 
Further time consuming and costly molecular genetic studies would be required to 
clarify this however.  
Kinetic analyses of XDH enzymes revealed that xanthine is the preferred substrate for 
XDH (Self & Stadtman, 2000). The Km for XDH with xanthine using NAD+ as an 
electron acceptor was 27 ± 4.1 µM (mean ± SD) with Canton-S cytosol (Table 23). 
These results supported by the finding of Edwards et al. (1977) and Doyle et al. 
(1996) results, who found that Km of the Canton-S wild type of Drosophila  was 29 
µM and 24 µM respectively in xanthine hydroxylation assay (Doyle et al., 1996; 
Edwards et al., 1977). Krenitsky et al. (1986) reported that the xanthine is an excellent 
substrate of liver human XO and bovine milk XO with a low Km (7 μM and 8 µM, 
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respectively) (Krenitsky et al., 1986). Thus the Drosophila  enzyme is has an 
approximately 4-fold weaker affinity for xanthine than its mammalian ortholog.  
4.1.2. Spectrophotometric and HPLC investigation of 
molybdoflavoenzyme characterisation in transgenic and 
molybdoflavoenzyme deficient Drosophila strains.  
Following the assay optimisation and kinetic measurements with wild type Canton-S, 
spectrophotometric assays were also made using DMAC, phenanthridine, vanillin and 
xanthine in transgenic, ry506 and maroon-like strains. XDH activity in ry506 and 
maroon-like strains was absent (Table 23 using the spectrophotometric assay) and this 
was confirmed by a sensitive HPLC assay with extended assay times (Figure 32). It 
was therefore confirmed that the ry506 and maroon-like strains were deficient in XDH 
that they were bona fide contamination-free stocks that could be used in this research 
study. Spectrophotometric and HPLC assays of vanillin incubated with fly extracts of 
transgenic and ry506 strains showed the conversion of vanillin to vanillic acid by AO 
(Figure 31). These results confirmed that the key enzyme responsible for the oxidation 
of vanillin to vanillic acid is AO as the ry506 strain is XDH deficient. Canton-S, 
transgenic and ry506 had similar activities but the ry506 was slightly higher than in 
Canton-S. This might have been due to a compensation effect due to the fact that ry506 
strain has only got AO and Canton-S has both AO and XDH. It is hypothesised that 
the higher AO activity present in ry506 mutants may be to compensate for not having 
XDH, possibly due to up regulation of AO gene transcription. This results agree with 
Panoutsopoulos et al. (2004) who indicated that the guinea pig liver AO is able to 
convert vanillin to vanillic and that vanillin is not a good substrate for milk xanthine 
oxidase (Panoutsopoulos et al., 2004). When the transgenic and ry506 strains cytosol 
were incubated with phenanthridine as substrate 6(5H)-phenanthridone was produced 
(Figure 31). This result agrees with the several papers reported that the phenanthridine 
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is a good substrate and has a very high affinity towards AO (Beedham, 2001; Rashidi, 
1996; Stubley & Stell, 1980). In order to determine that there was definitely no 
activity present in maroon-like strains for phenanthridine and vanillin a HPLC assay 
was used to confirm lack of product formation (Figure 31).  
Table 22 shows a summary of the all AO assay results in ry506 and ma-l strains. No 
DMAC, phenanthridine and vanillin oxidase activity was found in ma-l strains, but 
ry506 strain had AO activity for these substrates. This confirmed that AO enzyme is 
deficient in the ma-l strains. These results are consistent with Browder and 
Williamson (1976) who found the AO activity was completely missing in ma-l strain 
when acetaldehyde was used as a substrate and DCPIP was the electron acceptor 
(Browder & Williamson, 1976).  
4.1.3. In vitro Quantification of molybdo-flavoenzyme activities in 
wild type, transgenic and mutant Drosophila melanogaster strains by 
HPLC assays. 
A high performance liquid chromatography with UV and diode array detector was 
used for the determination of the conversion of AO and XOR substrates and products 
that did not have simple spectrophotometric assays. For oxidation reactions, substrates 
in this study have been classified into two structure types: aldehydes, which undergo 
oxidation to carboxylic acids and aromatic azaheterocyclic compounds, which 
undergo oxidation to lactams.  
All HPLC protocols for analytes were tested for method linearity, accuracy and 
precision were checked. Regression for calibration (r2) standards injected were more 
than 0.997 for all analytes tested. Accuracy for the method was more than 95% and 
precision < 3.5%, calculated by using three injections on the same day as calibration 
standards (intraday) (Tables 2 and 3 in appendix 3). For the linearity for the results, 
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the lower limit of Quantification (LOQ) and limit of detection (LOD) were determined 
for each analyte (Table 4 in appendix 3). According to (Miller & Miller, 2005) these 
methods have acceptable limits for both accuracy and precision and were therefore 
used to analyze samples from this study.  
4.1.3.1. Biotransformation of xanthine and methylxanthines by D. melanogaster 
strains 
The HPLC chromatogram in figure 35 represents incubated Canton-S cytosol (wild 
type) with xanthine in which NAD+ was present. The uric acid peak was only 
produced with NAD+ as electron acceptor (Figure 35). No uric acid was produced 
when O2 was the sole electron acceptor. These finding agree with Hughes et al. (1992) 
who observed that XDH of wild type Drosophila  strains converted xanthine to uric 
acid only with NAD+ present (Hughes et al., 1992). The XOR inhibitor oxipurinol was 
used to investigate that the uric acid came from oxidation of xanthine by XDH (Figure 
36). The chromatogram produced from the incubation of Canton-S cytosol, xanthine, 
NAD+ and oxipurinol that showed the peak of uric acid decreased dramatically to 
approximately 90% with enzyme inhibitor present. This agrees with Wahl et al. 
(1982) who reported that allopurinol is a potent inhibitor of Drosophila XOR with 
pterin as a substrate (Wahl et al., 1982). Canton-S cytosol was also able to convert 1-
methylxanthine to 1-methyluric acid when NAD+ was present as an electron acceptor 
but no product was formed without NAD+ (Figure 36). In contrast the mono-
methylxanthines of 3 and 7-methylxanthine were not converted to their uric acid 
metabolites by Drosophila  cytosol. This suggests that the position of the methyl group 
in mono-methylated xanthines has a dramatic effect on the oxidation of 
methylxanthines substrates in Drosophila . These results agree with Reinke et al. 
(1987) who found the XDH of rat can catalyse the oxidation of 1-methylxanthine to 1-
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methyluric acid, but could not metabolise 3- methylxanthine and 7- methylxanthine to 
3- methyluric acid and 7-methyluric acid respectively (Reinke et al., 1987). Krenitsky 
et al. also reported that the catalysis of mono-methylated xanthine by bovine milk 
XOR was affected by the position at which oxidation occurred in purine ring. The 
bovine milk xanthine oxidase catalyses the oxidation of 7-methylxanthine, 1-
methylxanthine and theophylline, to varying degrees with the 1-methylxanthine being 
the best substrate (Krenitsky et al., 1972). HPLC analysis of XDH activity in rosy and 
maroon-like strains revealed a lack of any detectable uric acid, 1, 3 and 7 methyluric 
acid peaks, even after extended incubation times of 120 minutes. These results are 
consistent with Wahl et al, (1982) who did not detected XDH activity in ma-l and 
ry506 strains respectively.  
4.1.3.2. Biotransformation of 6-mercaptopurine and methotrexate by D. 
melanogaster strains  
In the present study, 6-MP was incubated with cytosolic fraction of all Drosophila 
strains. According to the in vitro studies, 6-MP is not a substrate for both XOR and 
AO of Drosophila  melanogaster as no metabolites were detected with or without 
NAD+ in the incubation (Figure 37).  In contrast when rabbit liver cytosol was 
incubated with 6-MP the 6-MP was oxidized to 6-thiouric acid via 6-thioxanthine 
(Figure 38). This is in agreement with Hall and Krenitsky (1986) who showed that, in 
vitro 6-MP is a substrate for rabbit liver AO with a relatively low Km of 1.6 mM (Hall 
& Krenitsky, 1986) but is poor a substrate for bovine milk xanthine oxidase with a 
low oxidation rate (Krenitsky et al., 1972). In contrast, Rashidi et al. (2007) reported 
that in the in vitro biotransformation of 6-MP with guinea pig liver fractions, XO 
enzyme had a major contribution to the oxidation of 6-MP to 6-thioxanthine, while the 
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XO and AO enzyme both catalysed the oxidation the 6-thioxanthine to 6-thiouric acid 
via 6-thioxanthine (Rashidi et al., 2007).  
The anti-folate agent methotrexate (MTX) is widely used in the treatment of acute 
lymphocytic leukemia in children (Kitamura et al., 1999). MTX was mainly oxidized 
to 7-hydroxymethotrexate (7-OH-MTX) by AO but has widely different 
transformation rates in different species (Beedham, 1985; Kitamura et al., 1999; 
Kuroda et al., 2000; Moriyasu et al., 2006; Yu et al., 1989). Even after a 4 hrs 
incubation the MTX was not converted to its metabolite with any Drosophila  strains 
(Figure 44). Because of the results showed no activity of Drosophila  AO with MTX, 
in order to confirm that the experimental conditions were correct MTX was incubated 
with rabbit liver cytosol using the same incubation conditions as for Drosophila 
samples (Figure 44). 7-OH-MTX was formed by the action of AO from the rabbit 
liver cytosol, due to the rabbit liver AO having a very high hydroxylating activity 
towards this substrate compared with other species (Johnson et al., 1966; Jordan et al., 
1999; Kitamura et al., 1999). The lack of MTX-hydroxylation activity in Drosophila 
is not that surprising as MTX oxidase activity varies greatly between species. MTX 
oxidase activity is highest in rabbits followed by rats, hamsters and monkeys but is 
undetectable in dogs (Kitamura et al., 1999). In-vitro human liver AO catalyses the 
oxidation of MTX to 7-OH-MTX at a relatively low rate (Jordan et al., 1999; 
Kitamura et al., 1999).  
4.1.3.3. Biotransformation of allopurinol by D. melanogaster strains  
Allopurinol is a prodrug that is metabolised to oxipurinol by the action of both AO 
and XOR (Ichida et al., 1998; Pacher et al., 2006; Reiter et al., 1990; Yu et al., 2009). 
It was used as a substrate for determining if ry506 and ma-l strains were good animal 
models for hereditary xanthinuria type I and II respectively. Using O2 as an electron 
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acceptor Canton-S strain biotransformed allopurinol to oxipurinol is suggesting AO 
involvement in this catalysis (Figure 39). The addition of NAD+ further enhanced the 
conversion, indicating the involvement of XDH as is the situation in normal humans. 
To confirm the hypothesis that AO plays a role in the oxidation of allopurinol to its 
metabolite, the ry506 cytosol that is XOR deficient was incubated with allopurinol. 
Mimicking the findings with human hereditary xanthinuria type I, the chromatogram 
(Figure 40) showed that ry506 strain can metabolise allopurinol to oxipurinol without 
the XDH enzyme indicating that like human AO (Reiter et al., 1990; Yamamoto et al., 
1991) and rat AO (Moriwaki et al., 1993) the Drosophila  AO also contributes to the 
oxidation of allopurinol as in type I hereditary xanthinuria. In comparison, the results 
obtained from this in vitro study showed that the mal-1 and mal-f1 strains of 
Drosophila melanogaster that are deficient in both AO and XDH were not able to 
generate oxipurinol following incubation with allopurinol even with extended 
incubation times. This is similar to the situation reported by Yamamoto et al. (1989), 
Reiter et al. (1990), Yamamoto et al. (1991) and Simmonds, (2003) who found that 
patients with hereditary xanthinuria type II cannot metabolise allopurinol to 
oxipurinol. This confirms that the maroon-like mutants that have MCS gene mutations 
are good animal models for this human dual enzyme genetic deficiency.  
4.1.3.4. Biotransformation of pyrazinamide by D. melanogaster strains  
Pyrazinamide is a drug used to treat tuberculosis that is metabolised to 5-
hydroxypyrazinamide by the action of XOR and AO in mammals (Kitamura et al., 
2006; Mehmedagic et al., 2002; Mehmedagic et al., 1997; Moriwaki et al., 1997). 
When pyrazinamide was incubated with Canton-S and ry506 cytosol 5-
hydroxypyrazinamide was produced (Figures 40 and 41). To confirm if Drosophila  
XDH could also contribute to pyrazinamide hydroxylation, pyrazinamide was 
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incubated with Canton-S cytosol with and without NAD+ and HPLC analysis were 
carried out. After incubation with Canton-S cytosol with NAD+ the HPLC 
chromatogram showed a 18% increased amount of  5-hydroxypyrazinamide when 
compared with the incubation without NAD+ (Figure 40). This indicated that 
pyrazinamide is a substrate for both enzymes. This result was consistent with finding 
in previous in vitro study, which confirmed that both AO and XOR can oxidise 
pyrazinamide to 5-hydroxypyrazinamide in humans. In addition Yamamoto et al. 
(1989) suggested that AO may play a major role in the oxidation of pyrazinamide to 
5-hydroxypyrazinamide in the xanthinuria type I patient (Yamamoto et al., 1989). A 
similar situation to the human xanthinuria type I was found with ry506 flies. The 
production of 5-hydroxypyrazinamide peak by the ry506 strain indicates that AO can 
substitute for XOR in the conversion of pyrazinamide to 5-hydroxypyrazinamide. This 
result mimics the situation in humans in which patients with xanthinuria type I that 
have a normal activity of AO were able to convert pyrazinamide to 5-
hydroxypyrazinamide at a normal rate (Yamamoto et al., 1989). In experiments in this 
study there was no conversion of pyrazinamide to 5-hydroxypyrazinamide by maroon-
like strains. This proved the mal-1 and mal-f1 flies were deficient in both AO and 
XDH as no pyrazinamide oxidase activity was seen and resembled the situation found 
in human hereditary xanthinuria type II patients (Yamamoto et al., 1989). 
Unfortunately there is no available commercial standard of 5-hydroxypyrazinamide to 
confirm the identity of this metabolite peak and due to the low concentration of this 
metabolite no results were obtained by LC-MS.  
4.1.3.5. Biotransformation of cinchonine by D. melanogaster strains  
The cinchona alkaloids have been widely used the treatment of malaria (Hunter, 
1988). All four cinchona alkaloids, quinine, quinidine, cinchonine and cinchonine, are 
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oxidised by AO to the 2'-quinolone derivatives in mammals (Al-Tayib, 2009; 
Beedham et al., 1992; Palmer et al., 1969; Stubley et al., 1979; Zhao & Ishizaki, 
1997). With incubation of Canton-S and ry506 cytosol a metabolite of cinchonine ( -
cinchoninone) was produced (Figure 43). The mal-1 and mal-f1 strains thought to be 
deficient showed no oxidation of cinchonine even after extended times compared with 
Canton-S, transgenic and ry506 strains. These results indicate Drosophila  AO plays an 
important role in the metabolism of cinchonine. Unfortunately there is no available 
commercial standard of 2'-cinchoninone to confirm the identity of this metabolite peak 
and due to the low concentration of this metabolite no results were obtained by LC-
MS.    
4.1.3.6. Biotransformation of vitamin B6 (pyridoxal) in D. melanogaster strains  
Vitamin B6 is a water-soluble compound that contains a pyridine ring. Vitamin B6 is 
present in nature as several different forms such as pyridoxal (PL), pyridoxine (PN), 
pyridoxamine (PM) and their active form is pyridoxal 5'-phosphate (PLP) forms 
(Fitzpatrick et al., 2007). PLP is the coenzymatically active form of vitamin B6 and 
plays an important role in maintaining the biochemical homeostasis of the body 
(Meister, 1990; Snell, 1990). There are more than 100 PLP-dependent enzymes in a 
cell that perform essential roles in various metabolic pathways including amino acid 
metabolism (such as amino acid synthesis and degradation), fatty acid metabolism 
(such as the synthesis of polyunsaturated fatty acids) and carbohydrate metabolism 
(such as the breakdown of glycogen) (Mooney et al., 2009). The preferred degradation 
route from PLP to 4-pyridoxic acid involves the dephosphorylation of PLP by the 
phosphatase (Jang et al., 2003) followed separately by the actions of aldehyde oxidase 
and β-nicotinamide adenosine dinucleotide-dependent dehydrogenase (Schwartz & 
Kjeldgaard, 1951; Stanulovic et al., 1976). Drosophila  has been documented as 
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having at least two of these degradation enzymes, namely pyridoxal oxidase and PLP-
dependent (Jang et al., 2003). 
Pyridoxal oxidase was identified in D. melanogaster by Forrest et al. (1961) and was 
demonstrated by its ability to catalyse the oxidation of pyridoxal to pyridoxic acid 
(Forrest et al., 1961). Further studies by Keller and Glassman, (1964) suggested that 
pyridoxal oxidase was closely related to aldehyde oxidase (Keller & Glassman, 1964) 
as it had a similar ontogeny and joint regulation (Browder & Williamson, 1976).  
When pyridoxal was incubated with Canton-S, transgenic and ry506 Drosophila  
cytosol pyridoxic acid was produced (Figure 45). No pyridoxic acid was produced by 
the ma-l strains. The result confirms that conversion of pyridoxal to its metabolite due 
to the AO enzyme as in wild type strain in agreement with Cypher et al. (1982) who 
found that pyridoxal oxidase was present in wild type Drosophila melanogaster  using 
a  histochemical assay (Cypher et al., 1982). Similarly Warner and Finnerty, (1981) 
confirmed the activity of pyridoxal oxidase in wild type Drosophila  and it’s absent in 
ma-l strains by measuring indirectly using DCPIP as an artificial electron acceptor in a 
spectrophotometric assay. The in vitro result in this study is reflected in the study by 
Kamleh et al. (2009) that showed ma-l strains did not produce pyridoxic acid in 
contrast to wild type strains (Kamleh et al., 2009).  
4.1.3.7. Biotransformation of vitamin A (all-trans-retinaldehyde) in D. 
melanogaster strains  
Another potential substrate of AO of physiological importance is all-trans-
retinaldehyde which oxidised it to retinoic acid (Huang et al., 1999). Retinoic acid is a 
key regulator of the homoeostasis of keratinized epithelia and a recognized 
morphogen of the vertebrate organisms (Chambon, 1996) although its role in 
Drosophila  is less well understood. Retinal congeners are components of rhodopsin 
157 
 
visual system in all vertebrate and invertebrates including Drosophila (Lee et al., 
1996; Seki et al., 1998). Interestingly the retinal determination network that is 
responsible for controlling eye development is one of the most extensively studied 
gene regulatory networks in both invertebrate and invertebrate species (Datta et al., 
2011). Drosophila  mutants have been the most important organism in delineating this 
network (Datta et al., 2011). Although the genes and proteins that control eye 
development are fully understood proteins that might regulate the levels of retinal and 
retinoic acid in Drosophila  are poorly understood. To date however there has been 
retinal oxidase documented activity in Drosophila .  
In this study, it was important to establish if Drosophila  AO is capable of oxidizing 
retinaldehyde to its metabolite retinoic acid like vertebrate AO (Garattini et al., 2008; 
Garattini & Terao, 2011, 2012; Huang et al., 1999; Huang & Ichikawa, 1994; 
Kitamura et al., 2006; Terao et al., 2009). On incubation of Canton-S, transgenic and 
ry506 Drosophila cytosol with all-trans-retinaldehyde this generated retinoic acid 
(Figure 45). These finding are consistent with Huang and Ichikawa, (1994) and Tsujita 
et al. (1994) who first observed the role of AO in the oxidation of all-trans-
retinaldehyde to retinoic acid without NAD+ in rabbit by liver AO cytosol (Huang & 
Ichikawa, 1994; Tsujita et al., 1994). The maroon-like strains (mal-1 and mal-f1), 
which lack AO were not able to catalyse the oxidation all-trans-retinal confirming that 
AO in Drosophila  is responsible for this conversion.  
In mice a knockout model that is deficient in retinal oxidase activity although viable 
and fertile has perturbations and cellular secretion. In addition this model also had up 
regulation of genes involved in hypertrophic responses upon UV exposure (Terao et 
al., 2009). In view of a lack of retinal oxidase activity, reduced lifespan and reduced 
tolerance to chemical and physical stresses it in maroon-like mutants it would be 
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interesting to use transcriptomic and proteomic analysis to determine if similar 
pathological responses were present in this strain of Drosophila  as the ones found in 
mice. 
4.1.3.7. Biotransformation of N1-methylnicotinamide by D. melanogaster strains  
N1-methylnicotinamide (NMN) is often used as a marker for aldehyde oxidase 
(Beedham, 1987; Felsted & Chaykin, 1967; Stanulovic & Chaykin, 1971; Sugihara et 
al., 2006). NMN which is formed from nicotinamide by nicotinamide N-
methyltransferase which is widely distributed in animals (Yan et al., 1997). Many 
findings are consistent with the role of AO in the conversion of NMN to 2-PY and 4-
PY in the final steps of the nicotinamide degradation pathway (Beedham, 1987; 
Felsted & Chaykin, 1967; Hava Peretz et al., 2011; Stanulovic & Chaykin, 1971; 
Sugihara et al., 2006). As Drosophila  utilises NAD+ as a cofactor for multitudes of 
enzymatic reactions by dehydrogenases it is reasonable to suggest that Drosophila 
may also have pathways for nicotinamide degradation and have NMN oxidase activity 
however to date there is no report of this.  
When NMN was incubated with Canton-S, transgenic and ry506 cytosol two product 
peaks were found (Figure 46) suggesting that there was AO activity towards this 
compound. Based on what is found in mammals it is assumed that these might be N1-
methyl-2-pyridone-5-carboxamide (2-PY) and N1-methyl-4-pyridone-5-carboxamide 
(4-PY) (Figure 46). The metabolism of NMN to 2-PY and 4-PY has been reported to 
be catalysed by AO in a number of mammals including humans (Felsted & Chaykin, 
1967; Stanulovic & Chaykin, 1971; Sugihara et al., 2006). NMN showed different 
metabolic profiles in mice and humans by AO in vivo and in vitro; for example the 
major product was 2-PY in humans, whereas in mice were 2-PY and 4-PY (Kitamura 
et al., 2008). The ratio of 2-PY/4-PY from NMN differs and varies among species 
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(Garattini et al., 2008; Garattini & Terao, 2011; Kitamura et al., 2008; Kitamura et al., 
2006). Unfortunately there is no available commercial standard of 2-PY and 4-PY to 
confirm the identity of these metabolite peaks and due to the low concentration of 
these no results were obtained by LC-MS. The mal-1 and mal-f1 strains showed no 
oxidation of NMN even after extended time incubation, supporting the hypothesis that 
the two metabolite peaks were generated by AO mediated catalysis. In agreement with 
the present result Reiter et al. 1990 found that the xanthinuria type II patients lacking 
both XDH and AO were unable to oxidize NMN to its metabolites. The in vitro 
metabolism of all compounds tested as substrates for AO and XOR in all Drosophila  
strains (wild type, transgenic and mutants) is summarised in the following table 36. 
Table 36: Summary of the in vitro oxidation of molybdoflavoenzyme substrates by 
Drosophila  strains.  
Substrates 
Drosophila melanogaster strains 
Canton-S Transgenic (T1 and T2) ry
506
 
Maroon-like  
(mal-1 and mal-
f1) 
1-methylxanthine ++ ++ - - 
3-methylxanthine - - - - 
7-methylxanthine - - - - 
6-mercaptopurine - - - - 
Allopurinol +++ +++ ++ - 
All-trans-retinaldehyde ++ ++ ++ - 
Cinchonine ++ ++ ++ - 
Methotrexate - - - - 
N1-methylnicotinamide ++ ++ ++ - 
Phenanthridine ++ ++ ++ - 
Pyrazinamide +++ +++ ++ - 
Pyridoxal +++ +++ +++ - 
Vanillin +++ +++ +++ - 
Xanthine +++ +++ - - 
(+++ = high activity ++   = intermediate activity + = low activity - = no activity). 
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4.2. The chemoprotective role of molybdo-flavoenzymes against 
xenobiotic toxicity. 
At present despite MFEs being classed as phase I detoxication enzymes (Amdur et al., 
1991; Hodgson & Smart, 2001; Pryde et al., 2010) their role in chemoprotection in 
vivo has not been proven. It is an objective of this section to measure the physiological 
detoxification role of AO and XDH in Drosophila melanogaster strains (wild type, 
transgenic and mutants). The potential toxicants used to evaluate this included drug 
such as cinchonine (anti-malaria drug), pyrazinamide (tuberculosis drug), 
methotrexate (anti-cancer drug), 6-mercaptopurine (anti-cancer drug) and allopurinol 
(gout drug). Other well known AO substrates phenanthridine (environmental 
pollutant) and vanillin (foods and pharmaceuticals) were also tested. Methylxanthines 
(caffeine, theobromine, theophylline and paraxanthine) were also used to test the 
detoxificative role of XDH. Finally the endogenous vitamin metabolite N1-
methylnicotinamide was also evaluated as a toxic agent to the different Drosophila  
strains.  
4.2.1. In vivo metabolism and toxicity of methylxanthines on D. melanogaster 
strains 
After 4 days of treatment with caffeine, theobromine, theophylline and paraxanthine 
samples of the wild type and transgenic strains did not show any known caffeine 
metabolites (Figures 49 and 50). Both Canton-S and transgenic flies showed a similar 
profile. It can be seen in figure 48 that when the strains are exposed to 20 mM of 
caffeine, theophylline and theobromine there was a difference in the survival times of 
different strains. Mutant strains (ry506, mal-1 and mal-f1) had a higher sensitivity to 
the toxic methylxanthines than wild type (Canton-S) and transgenically rescued (T1 
and T2) strains. Because all of the Drosophila  strains were not affected by a dose of 
20 mM paraxanthine, a higher dose of 100 mM was given to observe effects for 
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mutant strains (Figure 48). There was no difference between the Canton-S and the 
transgenic T2 and T1 strains of Drosophila  which suggests that the transgenic ry 
strains had been rescued by the insertion of ry gene. This also demonstrated that it was 
the XDH gene that was conferring protection as mutant ry506 had a much reduced 
survival time. All toxicity results show that the mutant strains (ry506, mal-1 and mal-
f1) have a higher sensitivity to the toxic methylxanthines than wild type (Canton-S) 
and transgenically rescued (T1 and T2). The lifespan of mutant (ry506 and maroon-
like) strains were reduced to 9 days when exposed to 100 mM of paraxanthine, but 
wild type and transgenic rescued strains were unaffected by this treatment. With 
regards the biochemical basis of the results obtained, caffeine and theophylline, 
theobromine and paraxanthine ingested are partly broken down into its metabolites by 
the cytochrome P4501A2 (CYP1A2), N-acetyltransferase and XDH enzymes 
(Rasmussen & Brosen, 1996). So, without XDH, the maroon-like and ry506 strains 
cannot fully catabolise the caffeine metabolites as the missing enzyme converts the 
methyl-xanthines to the more polar methyl-uric acids in the final steps of caffeine 
degradation. The mutant strains were affected more by the absence of the XDH, but 
the wild type and transgenic strains are still affected by the 20 mM caffeine and 
theophylline and all flies were dead after 13 days. By comparing the toxicity of 
methylxanthines treated with wild type and transgenic Drosophila  strains it was found 
that caffeine (20 mM; Figure 59) has a greater toxicity than theophylline (20mM; 
Figure 59). This agrees with Zimmering et al. 1977 that found that caffeine is lethal to  
adult D. melanogaster (Zimmering et al., 1977)  and at lower concentration decreases 
longevity and fecundity in Drosophila prosaltans (Carrillo & Gibson, 2002; Itoyama 
et al., 1998). Graf & Wurgler (1986) found that caffeine media with 4% w/v
 
killed 
approximately 75% of exposed flies. Zimmering et al. (1977) found a high mortality 
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rate in the ry506 flies after three days exposure to 1.25-2.5 mg/ml caffeine. Zimmering 
et al., (1977) found that the Canton-S strains mortality rate was around 40% after 
three days, which is higher than the results obtained from the current toxicity test 
(40% after 8 days). From the ry506 strain used in the Zimmering et al. (1977) study the 
mortality rate was almost 100% after three days, which is slightly higher than this 
current toxicity test found (100% dead after 6 days). This result confirms the fact that 
caffeine is not only mutagenic but it also causes a reduction in lifespan (Kuhlmann et 
al., 1968). Nikitin et al. 2008  showed that the lifespan of Canton-S Drosophila 
melanogaster males is reduced with varying caffeine concentration (1.5-13 mM) 
(Nikitin et al., 2008). However, theobromine (20 mM) is much less active than 
caffeine or theophylline (Tarka, 1982), with regard to the above results (Figure 59). 
Similarly paraxanthine showed a weak toxicity and wild type and transgenic strains 
were only affected by a higher dose of paraxanthine (100 mM; Figure 48). Cozk 1974 
reported the action of the theobromine in the central nervous system is weak or 
virtually absent (Czok, 1974), which  agrees with the results obtained from the current 
toxicity test (20 mM theobromine  had no effect in Canton-S and transgenic strains 
during experiment). The literature is devoid of any reference to human toxicity data on 
theobromine, except one general statement that “in large doses” theobromine may 
cause nausea and anorexia (Pharmacopeia, 1984). Comparative results for the acute 
toxicity of caffeine, theophylline and theobromine given orally for mouse and rat, it is 
of interest to note a very similar acute toxicity for caffeine and theophylline in the rat 
whereas theobromine was appeared to have no toxicity (Stravic, 1988; Tarka, 1982). 
These results agree with the results obtained from the current toxicity study. 
Paraxanthine, although not found in plants or foods, is a major metabolite of caffeine 
in humans (Aranda et al., 1983). There is little information in the literature concerning 
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its toxicological potential, but the available information indicates that its toxicological 
potency in man is very low (Stravic, 1988). In spite of this, there is surprisingly little 
information in the literature about the toxicological potential of paraxanthine, 
especially in humans. A number of major reference books, including the Merck Index 
(10th Ed.) and Martindale-The Extra Pharmacopoeia  (1982), do not list paraxanthine 
(Stravic, 1988). These results agree with the paraxanthine results obtained from the 
current toxicity study in that 100 mM paraxanthine did not have an effect on the 
Canton-S and transgenic strains (shown figure 59).  In conclusion, it may be the 
specific locations of methyl groups on the purine ring are important determinants on 
the biological effects of these compounds. Because theobromine (3, 7- 
dimethylxanthine) and paraxanthine (1, 7- dimethylxanthine) were not toxic to 
Canton-S and transgenic strains, but caffeine (1, 3, 7 trimethyl-xanthine) and 
theophylline (1, 3- dimethylxanthine) were toxic, these findings may be comparable to 
the results of Ho et al. who reported that several purines such purine, adenine, 2,6 
purine, xanthine and guanine have different effects on the survival rate of Drosophila 
melanogaster related to the specific location of amino and carboxyl groups, because 
of these positions on the purine ring were important determinants of the biological 
effects of these compounds (Ho et al., 1984). In the study detailed in this thesis it was 
concluded that the methyl groups in the number 1 and 3 positions (theophylline) was 
more critical than the number 3 and 7 positions (theobromine), while the number 1 
and 7 positions (paraxanthine) was not toxic to wild type (Canton-S) strain. The three 
positions of methyl groups in purine ring of caffeine (1,3,7-trimethylxanthine) was 
critical to survival of Canton-S strain. Overall the results of the studies here show that 
the loss of AO and/or XOR activity combined (ma-l strains) had greater effect on the 
ability of Drosophila  to survive in the methylxanthine medias than the deficiency of 
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XOR alone (ry506 strain). This suggests that AO has either an involvement in the 
metabolism of methylxanthines or secondary protective effect.  
4.2.2. In vivo biotransformation and toxicity of allopurinol on D. melanogaster 
strains  
Canton-S and transgenic T1 and T2 generated oxipurinol (Figure 52) when treated 
with allopurinol. Allopurinol also caused an approximately 50% decrease in uric acid 
production and a significant increase in xanthine and hypoxanthine to approximately 
75% and 25% respectively when compared them with untreated Canton-S. This 
resembles the situation in humans and rats where oxipurinol inhibits XOR which is 
responsible for the oxidation of hypoxanthine to xanthine and of xanthine to uric acid 
(Figure 52). These results are also consistent with Al Bratty et al who found that 
feeding wild type (Oregon-R) flies on allopurinol medium for 3 days, caused the level 
of xanthine and hypoxanthine to increased and uric acid levels dropped (Al Bratty et 
al., 2011).  
In previous studies in rats and humans, it has been suggested that both AO and XOR 
may oxidise allopurinol to oxipurinol based on in vitro data with purified enzymes and 
in vivo data with hereditary xanthinuria type I and II patients (Moriwaki et al., 1993; 
Yamamoto et al., 1991). In the present study the ry506 mutant strain that lack XDH 
activity and has AO activity, (which represents the classical xanthinuria type I due to 
XOR gene deficiency) and maroon-like strains (mal-1 and mal-f1) due to lack of both 
XOR and AO activity, (which resemble classical xanthinuria type II) were treated 
with allopurinol and analysed by HPLC. It was found in this study that the ry506 strain 
that has AO is able to convert allopurinol to oxipurinol (see figure 52) whereas ma-l 
strains did not generate oxipurinol both in vitro and in vivo (Table 24). This 
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demonstrated that like mammalian AO the corresponding Drosophila  enzyme 
contributes to oxipurinol oxidation.  
The percentage survival in all strains for allopurinol and oxipurinol treated flies can be 
seen in figure 51. When exposed to 20 mM of allopurinol all the maroon-like flies 
were dead after 9 days. In contrast the ry506 strain behaved similarly to the wild type 
and transgenic strains when exposed to 20 mM of allopurinol in that they all survived 
in this concentration. Canton-S, transgenic and ry506 strains were treated with a higher 
100 mM dosage of allopurinol. This concentration was more toxic to the ry506 strain 
indicating XDH involvement in protection against allopurinol toxicity (Figure 51).  
Ma-l strains with a combined deficiency of AO and XOR had a reduced ability to 
survive allopurinol toxicity indicating the additional importance of AO in protecting 
against this toxicant. In conclusion the results clearly show that AO and XOR protect 
against allopurinol toxicity in Drosophila melanogaster . 
4.2.3. In vivo biotransformation and toxicity of 6-mercaptopurine on D. 
melanogaster strains  
6-mercaptopurine (6-MP) is toxic to rats and mice (Higuchi et al., 1978; Tapner et al., 
2004). Interestingly, 6-MP was not metabolised in vitro by Canton-S, transgenic and 
ry506 strains. On comparing the percentage survival of wild type and transgenic strains 
with ry506 and mal-1 and mal-f1 strains, there was no statistically significant difference 
between them when they were administered 20 mM 6-MP in the media (Figure 51). It 
can be concluded that AO and XOR in Drosophila  do not have a role in 6-MP 
metabolism and thus there was no involvement in any chemoprotection against this 
toxic anticancer drug.   
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4.2.4. In vivo biotransformation and toxicity of cinchonine on D. melanogaster 
strains 
The wild type and ry506 mutant of Drosophila melanogaster treated with cinchonine 
showed a metabolite peak in the chromatograms (Figure 54). In theory cinchonine 
may be oxidised to its metabolite 2'-cinchoninone by Drosophila  AO as has been 
observed with other species such as hamster, rabbit, guinea pig and man (Al-Tayib, 
2009; Beedham et al., 1992; Palmer et al., 1969). Because its metabolite 2'-
cinchoninone is not commercially available; LC-MS was used check the identity of 
the cinchonine metabolite. Unfortunately due to the low level of 2˜-cinchoninone in 
the complex biological matrix no result was obtained to confirm its identity.  There 
was no conversion of cinchonine to the putative 2'-cinchoninone peak for maroon-like 
strains. The fact that there was no metabolite in ma-l strains suggest that the 
metabolite generated by the other AO-active strains is due to AO catalysis. This result 
also suggests that Drosophila  AO has a greater contribution to the overall metabolic 
profile of cinchonine than microsomal mono-oxygenases; otherwise the metabolite 
peak would be found in maroon-like strains. In the present research the effect of 
cinchonine toxicity on wild type, transgenic and mutant strains of Drosophila  was 
observed as shown in figure 53. The results indicated that the cinchonine had a high 
potential toxicity and caused the faster death of the maroon-like strains than wild type, 
ry506 and transgenic strains. This is presumably because the AO-deficient maroon-like 
strains flies are unable to metabolise the cinchonine. 
4.2.5. In vivo biotransformation and toxicity of phenanthridine on D. 
melanogaster strains 
All Drosophila  strains were kept on media containing phenanthridine and fly extracts 
were analysed by HPLC. Both wild type (Canton-S) and ry506strains generated the 
metabolite of 6(5H)-phenanthridone (Figure 54). This result is not surprising because 
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of the several papers reported that the phenanthridine is a good substrate and has a 
very high affinity towards AO (Beedham, 2001; Rashidi, 1996; Stubley & Stell, 
1980). In contrast, the results obtained from this research showed that the mal-1 and 
mal-f1 strains of Drosophila melanogaster that are deficient in AO and XDH could 
not generate 6(5H)-phenanthridone. Due to the detoxification effect of AO being 
present Canton-S, transgenic and ry506 flies were less affected than maroon-like strains 
by phenanthridine toxicity due to the presence of AO as shown in figure 64.  
4.2.6. In vivo biotransformation and toxicity of pyrazinamide on D. melanogaster 
strains 
Pyrazinamide a drug used to treat tuberculosis is extensively metabolised in vivo. The 
main steps of pyrazinamide metabolism, which take place in mammalian liver, 
involves enzymatic deamidation, followed by formation of the main active metabolite, 
2-pyrazinoic acid (Mehmedagic et al., 2002) (Figure 61). This acid is further oxidized 
by the action of XOR to 5-hydroxypyrazinoic acid, the main excretory metabolite of 
pyrazinamide. Direct oxidation of pyrazinamide by XOR is also possible, leading to 
the formation of 5-hydroxypyrazinamide (Figure 61) (Kitamura et al., 2006; Moriwaki 
et al., 1997). More than 50% of pyrazinamide metabolism is mediated by XOR 
(Mehmedagic et al., 2002). All samples of Drosophila melanogaster strains treated 
with pyrazinamide showed similar profiles that did not show any clear peaks of 
metabolites. Two HPLC methods (isocratic and gradient) were used in the in vitro 
study to confirm that there were no metabolites generated from in vivo pyrazinamide 
metabolism by Canton-S and ry506 strains (data not shown). Interestingly, although 
pyrazinamide is not metabolised in vivo by Drosophila  it was converted to 5-
hydroxypyrazinamide on in vitro incubations with Drosophila  cytosol. This is may be 
due to the concentration dose and/or incomplete absorption in Drosophila  or that it is 
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very rapidly metabolised and excreted. However, this might not be the only reason for 
the difference in activity of AO and XOR that was observed. The discrepancy between 
the in vitro findings compared with the in vivo situation in Drosophila melanogaster 
might be due to the fact that the metabolism may have undergone a different 
metabolic pathway, which may have given other metabolites.  
5-hydroxypyrazinamide
XOR
AO / XOR
OHOH
COOHCONH2
COOH
Deamidase
Deamidase
CONH2
Pyrazinamide 2-pyrazinoic acid
5-hydroxypyrazinoic acid
 
Figure 71: The principal metabolic pathways of pyrazinamide in mammals (Kitamura et al., 
2006; Lacroix et al., 1989). 
 
This drug was also investigated to discover any toxic effects in the different 
Drosophila  strains. The results of flies fed on media containing 20 mM pyrazinamide 
are shown in figure 53. In terms of Canton-S and transgenic strains there was no effect 
by pyrazinamide, but mutant strains (ry506, mal-1 and mal-f1) were affected by 
pyrazinamide toxicity and the mortality starts from the early days of exposure, 
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probably due to the absence of XOR or AO/XOR enzymes and lack of any oxidation 
products in vitro studies.  
4.2.7. In vivo biotransformation and toxicity of N1-methylnicotinamide on D. 
melanogaster strains 
In this study, N1-methylnicotinamide (NMN) was fed to the different strains of 
Drosophila melanogaster. All samples of Drosophila melanogaster strains treated 
with NMN did not show any clear peaks of metabolites using two HPLC methods as 
described in materials and methods chapter. Interestingly, although NMN is not 
metabolised in vivo by Drosophila  it was biotransformed in vitro by Drosophila  
(section 3.2.5). This is may be due to the dose concentration and incomplete 
absorption in Drosophila  or distribution of NMN in the fly media. However, the 
concentration of NMN in the fly media cannot to be the only reason for the difference 
in activity of AO that was observed. Alternatively, the metabolism may have 
undergone a different metabolic pathway. The results observed from the NMN 
toxicity tests as seen in figure 55 shows that the maroon-like strains of Drosophila 
lacking AO is less able to survive in media containing NMN. This is presumably 
because the flies are unable to metabolise NMN as they lack AO. Although the 
toxicity of N1-methylnicotinamide has not been previously reported in any organism it 
has been reported that nicotinamide does have a very low acute toxicity to mammals 
(Florin et al., 1980).  
4.2.8. In vivo biotransformation and toxicity of vanillin on D. melanogaster 
strains 
Canton-S, transgenic and ry506 strains treated with vanillin generated its metabolite 
vanillic acid (Figure 59). These results proved that vanillin is converted into vanillic 
acid by AO because the ry506 strains only have AO and not XDH. The present study 
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therefore confirmed that vanillin is a good substrate of Drosophila  AO as it is in 
mammals (Panoutsopoulos et al., 2005). HPLC analysis of maroon-like strains 
revealed a lack of any detectable vanillic acid peak, with ma-l strains (Figure 59). This 
further confirmed AO is the major route of vanillin oxidation in vivo in Drosophila . 
For toxicity tests Drosophila  from each strain were exposed to vanillin in low and 
high concentration (20 mM and 100 mM). The results showed no toxicity with all 
strains of Drosophila  when exposed to the 20 mM of vanillin (Figures 56). However, 
the effects of vanillin observed at a five times higher concentration (100 mM) in 
strains that harbouring mutations in MCS genes (mal-1 and mal-f1) had an increased 
sensitivity when treated with the high concentration of vanillin (shown figure 58). 
This may be because the vanillin dosage was high enough to compromise this strains 
ability to detoxify this chemical. This indicated that AO in Drosophila  serves to 
protect the organism from the toxic effects of high vanillin concentration. 
4.2.9. Summary of enzyme assays, in vivo metabolism and toxicity of compounds 
in Drosophila strains. 
A summary of the toxicity, in vivo and in vitro metabolism of all compounds tested in 
wild type, transgenic and mutant of Drosophila melanogaster treated with compounds 
is shown in table 37. 
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Table 37: Summary of the toxicity, in vivo and in vitro oxidation of purines, non purines, N-
heterocyclic and aldehyde substrates by Drosophila  strains used in this study. 
AO/ XDH substrates 
Drosophila melanogaster strains 
Canton-S Transgenic (T1 and T2) ry
506
 Maroon-like  
Allopurinol 
 (AO and XDH) 
In vivo metabolite +++ +++ ++ - 
In vitro metabolite +++ +++ ++ - 
Toxicity - - - +++++ 
Caffeine 
 (XDH) 
In vivo metabolite - - - - 
Toxicity +++ +++ +++++ +++++ 
Cinchonine  
(AO) 
In vivo metabolite ++ ++ ++ - 
In vitro metabolite ++ ++ ++ - 
Toxicity +++ +++ +++ +++++ 
N1-
methylnicotinamide 
(AO) 
In vivo metabolite - - - - 
In vitro metabolite ++ ++ ++ - 
Toxicity 
- - - +++++ 
6-mercaptopurine 
(AO and XDH) 
In vivo metabolite - - - - 
In vitro metabolite - - - - 
Toxicity +++ +++ +++ +++++ 
Paraxanthine 
(XDH) 
In vivo metabolite - - - - 
Toxicity + + +++++ +++++ 
Phenanthridine 
(AO) 
In vivo metabolite ++ ++ ++ - 
In vitro metabolite ++ ++ ++ - 
Toxicity + + + +++++ 
Pyrazinamide 
(AO and XDH) 
In vivo metabolite - - - - 
In vitro metabolite +++ +++ ++ - 
Toxicity + + + +++++ 
Theobromine 
(XDH) 
In vivo metabolite - - - - 
Toxicity ++ ++ +++++ +++++ 
Theophylline  
(XDH) 
In vivo metabolite - - - - 
Toxicity +++ +++ +++++ +++++ 
Vanillin  
(AO) 
In vivo metabolite +++ +++ +++ - 
In vitro metabolite ++ ++ +++ - 
Toxicity 
- - - ++ 
 (+++++ = extremely high activity or toxicity, +++ = high activity or toxicity, ++   = intermediate 
activity or toxicity, + = low activity or toxicity, - = no activity or no toxicity).  
 
The difference observed between the mutant strains, transgenic and wild type strains 
supports the conclusion that lack of MFEs is responsible for the strains reduced 
survival in the presence of toxin. The caffeine, theobromine, theophylline and 6-
mercaptopurine had similar effects as these compounds were not biotransformed by 
Drosophila  molybdo-flavoenzymes. In contrast, the allopurinol, vanillin, N1-
methylnicotinamide, phenanthridine and pyrazinamide which are substrates for AO 
and/or XOR had no or less toxic effect on the wild type and transgenic strains due to 
these substrates being in vitro and in vivo biotransformed by AO and/or XOR in 
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Drosophila (Table 37). A summary of the relative toxicity of each compound is shown 
in table 38.  
Table 38: Summary of the toxicity of purines based, purines analog, N-heterocycles and 
aldehyde compounds to Drosophila melanogaster  strains. 
 
None: not affected  
----: not tested  
Yellow: 2-7days, blue: 8-19 days and green: None. 
 
As seen in table 38 it was observed that of the compounds tested the anti-malarial 
alkaloid cinchonine was the most toxic of the compounds tested, killing wild type and 
ry506 flies within 7 days and maroon-like strains within 5 days of administration of a 
20 mM concentration in media. This may be due to the fact that it has more efficient 
properties in increasing the intracellular cytotoxicity (Genne et al., 1994). The second 
most potent class were alkylated purine drugs, caffeine and theophylline with wild 
type strain dying within 13 days of administration. It was determined that the 
maximum life of mutant (ry506 and ma-l) flies was 8 days of administration of a 20 
mM concentration of caffeine and theophylline in media (Table 38). Theobromine was 
Compound 
50% mortality (days) 100% mortality (days) 
Canton-S ry
506
 mal-1 mal-f1 Canton-S ry
506
 mal-1 mal-f1 
Allopurinol (20mM) None None 4  4 None None 9  9  
Allopurinol (100mM) None 10 ---- ---- None 15 ---- ---- 
Caffeine (20mM) 9 3 2 2 13 8 6 6 
Cinchonine (20mM) 4  3 2 2 8 8 5 5 
6-mercaptopurine (20mM) 7  6 4  4  15  13  9  7 
N
1
-Methylnicotinamide  
(20mM) 
None None 4  4  None None 9  9  
Paraxanthine (100mM) None 4  4  4  None 9 9  9  
Phenanthridine (20m) None None 6  6  None None 12  13  
Pyrazinamide (20 mM) None 5  5  5  None 12  8 8 
Theobromine (20mM) None 3 3 3 None 8 8 8 
Theophylline (20mM) 8 4  4  4  13 10 7 8 
Vanillin (100mM) None None 8 8 None None 19 18 
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more toxic with ry506 and maroon-like strains dying within 8 days, but it had no 
lethality at 20 mM concentration with wild type strain. The third-most toxic 
compound tested was 6-mercaptopurine (anti-cancer drug), which reduces lifespan in 
wild type, ry506 and maroon-like strains to 16 days, 13 days and 7 days respectively. 
Allopurinol and paraxanthine had no lethality at low and higher doses of 20 and 100 
mM respectively (allopurinol and paraxanthine) with wild type strain. The food 
constituent, vanillin and the urban air pollutant phenanthridine had no toxicity at any 
dose tested for wild type and ry506 strains. The anti-tuberculosis drug, pyrazinamide 
had no toxicity at 20 mM tested for wild type strain. In comparison, a great toxicity 
effect was observed on the lifespan of the maroon-like strains (mal-1 and mal-f1) 
when exposed to the toxicity of purines, purines analogs, N-heterocycles and aldehyde 
compounds (Table 38), that are AO substrates indicating its essential role in 
chemoprotection in vivo.  
4.3. The effect of molybdo-flavoenzyme deficiencies on lifespan of 
Drosophila melanogaster.   
D. melanogaster is a powerful model to study lifespan and aging (Lim et al., 2006; 
Shaw et al., 2008) and its lifespan is approximately 60 days (Shaw et al., 2000). 
Antioxidants that help reduce free radical damage have been shown to have an effect 
on the longevity of Drosophila  (Le Bourg, 2001). Uric acid which has antioxidant 
characteristics has been observed to increase the longevity of flies (Le Bourg, 2001). 
As XOR plays an important role in the generation of uric acid, a known antioxidant, it 
has been hypothesised that it may play an important role against ageing and therefore 
increases the lifespan of individuals (Ames et al., 1981; Cutler, 1984; Hediger, 2002). 
XOR-deficient ry506 flies are a good model for testing this hypothesis. It was also 
decided to investigate the effects mutations in the MCS gene have on lifespan that 
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have a dual deficiency of AO and XOR.  In the study presented in this thesis, to 
confirm the level of uric acid in all Drosophila  strains, the extracts of all strains were 
analysed by HPLC. HPLC profiles for all Drosophila  strains are shown in figure 58. 
Comparison of the endogenous purine levels of mutant Drosophila  strains (ry506 and 
maroon-like ) (Table 27) with the normal Drosophila  strain (Canton-S) indicated that 
the xanthine to hypoxanthine ratio was approximately 4 times the level of normal fly 
which is similar to the situation in human patients with severe hereditary xanthinuria 
(Simmonds, 2003; Simmonds et al., 1995) (Table 27). The xanthine level of this 
mutant was 7 fold higher than in the normal strain, but no difference in the 
hypoxanthine level was seen. Mutant strains (ry506 and maroon-like) had no detectable 
uric acid demonstrating that these strains mimic human hereditary xanthinuria (Table 
27). The total absence of uric acid in the three mutant strains also demonstrated that 
the XOR enzyme was totally inactive. These results were consistent with Hilliker et 
al. and Kamleh et al. who found that ry506 mutants are unable to make uric acid 
(Hilliker et al., 1992; Kamleh et al., 2008). The effect of the lack of XOR and AO has 
on the longevity of Drosophila  wild type, transgenic, ry506 and ma-l strains are shown 
in figure 60. The ry506 strain had a mean lifespan that was approximately 60% that of 
the Canton-S strain. Maroon-like flies (mal-1and mal-f1) had a considerably decreased 
lifespan compared with Canton-S and ry506 strains respectively, with their lifespan 
being only approximately 30% and 60% of these strains respectively. The ry506 strains 
that have had the ry gene re-inserted by transgenesis (T1) had a lifespan which is 
similar to that of the Canton-S strain lifespan. The difference observed between the 
wild type and mutant strains (Table 28) confirms the observation of Shepherd et al. 
(1989) who found that a  mutant ry506 strain lacking XOR activity had a reduced 
lifespan compared to the wild type strain (Shepherd et al., 1989). As seen in the table 
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32, it was observed that the maximum lifespan of the wild type strain was 65 days, 
this is consistent with Ayar et al., (2009) who found that the maximum lifespan of 
wild type strain was 70 days (Ayar et al., 2009). The results observed during longevity 
studies carried out under normal conditions reflect the observation that uric acid has 
antioxidant properties that protect against free radicals and therefore extend an 
organism’s longevity. This finding also agrees with studies, which found that the 
urate-null strains of Drosophila  are sensitive to oxidative stress (Hamatake et al., 
2009; Hilliker et al., 1992). The results in this thesis agree with the study of Kim et al. 
(2001) who found the ry506 mutants had a reduced lifespan that was 40% of that found 
in the wild type strain. Along with a reduction in lifespan the ry506 flies also had a 
reduced immune response to bacterial infection when compared to a wild type strain 
(Kim et al., 2001). 
 The results obtained demonstrated that the lack of AO activity along with XOR 
activity has greater effect on the ability to survive than the loss of only XOR activity. 
This was surprising, because AO does not generate or remove any known endogenous 
chemicals that are at present known to affect lifespan. From the in vitro experiments 
detailed in section 3.2 the AO-deficient maroon-like strains could not metabolise 
several endogenous vitamins, namely vitamin A, B3 and B6 so perhaps this inability 
may affect lifespan due to accumulation of precursors or lack of generation of the 
metabolites. Obviously further experiments would be required to prove this hypothesis 
(see toxicity section 2.4).   
176 
 
4.4. The effect of heat and cold shock on wild type and MFE- 
deficient Drosophila strains. 
To determine whether or not the lack of these enzymes have any effect on the flies 
defences against extreme temperatures flies were exposed to cold and heat shock 
treatments. 
4.4.1. Effect of 25, 37 and 39 °C heat shock on Drosophila melanogaster strains. 
The relationship between longevity and ageing of insects and stress factors have been 
known for some time (Vermeulen & Loeschcke, 2007). An insect’s survival depends 
on its ability to survive different types of environmental stress which include exposure 
to high and low temperatures. Cells continuously exposed to either exogenous or 
endogenous stress such as heat or radiation have developed variety protective 
mechanisms such as the synthesis of stress proteins, antioxidant defence or DNA 
repair enzymes (Bochner et al., 1984; Niedzwiecki et al., 1992). The similarity of 
response to elevated temperatures and various oxidative stresses in bacteria 
(Christman et al., 1985), plants (Czarnecka et al., 1984) and Drosophila  (Ashburner & 
Bonner, 1979) suggest the possibility that increased temperature and oxidative stress 
may be related. Exposure to heat is accompanied by an elevation in oxygen 
consumption. Thus, exposure to high temperature most likely results in an increased 
production of free radicals, which generate the need for an elevated level of 
scavenging antioxidant enzymes to remove these toxic species (Niedzwiecki et al., 
1992).  Though an effective antioxidant-scavenging system in necessary during 
normal metabolic conditions to protect cellular components against oxidative damage, 
the need for this protection increases during periods of stress, such as exposure to heat 
(Niedzwiecki et al., 1992; Yano et al., 1987).  In this study, the effects of heat shock 
on longevity were studied in wild type Drosophila  and mutants lacking the antioxidant 
uric acid. 
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Figure 61 shows the mean percentage survival for all strains at 37°C for various 
durations (1, 2, 4 and 6 hours). All strains had no effect when exposed to heat shock at 
37°C for 2 hours. All the Canton-S flies survived at 4 hours but had a relatively high 
mortality rate at 6 hours (approximately 50%) at 37°C, whereas the rosy strain had a 
significantly higher mortality rate after four hours (approximately 30%) and after six 
hours was approximately 60%. The heat shock at 37°C also had a significant effect on 
the mortality of maroon-like strains; the survival rate of mal-1 and mal-f1 strains was 
approximately 40% at 4 hours and all the flies were dead at six hours. The highest 
temperature of 39˚C at four and six hours found none of maroon-like strains survived. 
The heat shock at 39˚C results show that the ry506 strain had a significantly reduced 
percentage survival after four and six hours compared to the wild type Canton-S strain 
(shown figure 61). At 39˚C the rosy mutant strain at two hours appears to have a low 
percentage survival (approximately 60%) and mal-1 and mal-f1 strains at the same 
duration appear to have a highly significant death levels with mortality being 
approximately 90% when, compared with Canton-S strain (approximately 20%). The 
heat shock results show that the rosy and maroon-like strains have a significantly 
reduced percentage survival after four and six hours when compared to the wild type 
Canton-S. With the maroon-like strains, all flies were dead after 6 hrs when exposed 
to heat shock both at 37˚C and after 4 and 6 hrs at 39˚C. This leads to the conclusion 
that the lack of AO activity along with XOR activity has greater effect on the ability to 
survive during extreme environmental changes than the lack of only XOR activity. 
The heat shock itself would cause environmental stress, raising the amount of free 
radicals, thus without XDH no uric acid would be protecting from these free radicals 
as antioxidant. The molecular basis of additive effect on mortality due to the lack of 
AO is unknown.  
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4.4.2. Effect of 0 and -3 °C cold shock on Drosophila melanogaster strains. 
Insects living along altitudinal and latitudinal gradients survive better in lower than in 
higher temperatures (Anderson et al., 2005). Subzero temperatures can be deadly for 
various insect species including D. melanogaster.  D. melanogaster populations from 
cold climates are more cold tolerant (Guerra et al., 2000). In many studies, some stress 
factors (i.e.: heat or cold shock) when applied at a low rate and in a short time show an 
hormetic effect in Drosophila , but when intensity and time of application were 
increased, it was observed that there were harmful effects (Ayar et al., 2009; Le 
Bourg, 2007). In earlier studies, direct application of cold shock brings about sudden 
structural changes on protein and cell membranes in Drosophila  (Kelty & Lee, 1999). 
Induction of stress protein cryoprotectants may also play a role in the cold shock 
response in some insects, while the importance of these factors is less clear in the case 
of D. melanogaster (Chen & Denlinger, 1992; Kelty & Lee, 2001; Nielsen et al., 
2005; Qin et al., 2005). Death after a cold shock is not due to the cold shock, but is 
linked to the loss of membrane function due to depolarization of the cell membrane, 
since the ultimate freezing point of D. melanogaster is -20°C (Overgaard et al., 2005). 
Cold shock and freezing also induce apoptosis (programmed cell death) (Yi et al., 
2007). In addition cold shock causes insects to lose motor activity in a reversible state 
known as chill coma. Although the mechanisms of the chill coma onset are poorly 
understood, Goller and Esch (1990) suggest that it results from a loss of function of 
the ion channels necessary for maintaining the membrane potential, leading to voltage 
equilibration and a loss of muscle cell excitability (Goller & Esch, 1990). D. 
melanogaster exposed to cold shock express Hsp70, not from the cold shock, but as a 
result of heating up during recovery from the effects of the cold shock (Overgaard et 
al., 2005; Sejerkilde et al., 2003).  
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The results obtained when wild type and mutant strains were exposed to cold shock 
temperatures (0 and -3°C) for different periods (1, 2, 4, and 6 hrs) are summarised in 
figure 62. There was no significant effect between strains when were exposed to cold 
shock at 0°C for 1 hr. However, between 2 and 6 hrs at 0°C cold shock there was 
steady decrease in percentage survival to approximately 60% for Canton-S strain, 
while for the period between 1 and 6 hrs the ry506, mal-1 and mal-f1 strains had a 
significantly high mortality rate with approximately 85% of rosy and 100% of 
maroon-like strains dying (Figure 62). The results of -3°C cold shock temperature 
experiment are presented in figure 66. No significant differences were observed 
between CS and rosy strains at -3°C degree for 1 hr. The survival percentage of ry506 
and maroon-like strains showed a highly significantly mortality rate for these strains 
from 1 to 4 hrs periods, while all flies are dead after 4hrs. -3°C cold shock 
temperature had a significant and large effect on the mean percentage survival of 
Canton-S strain at 4 hrs and all flies were dead after 6 hrs (Figure 62). These findings 
are consistent with Duncker et al. 1995 results. Duncker serendipitously demonstrated 
the protection role of XDH in cold stress. Duncker et al. (1995) incubated non-
transgenic adult D. melanogaster  P[ry,YP 1, 2: wAFP2; YP 1-3 ]3 without antifreeze 
proteins gene (AFPs) gene as control, transgenic flies (Ifm(3)3 ry+) with AFPs gene 
and mutant flies (Ifm(3)3 ry8) (uric-null or non-Xdh gene) with AFPs gene as a marker 
gene to identify it is important for the improved cold tolerance in ice (0°C) and low 
temperature water bath (-7°C) for long period (24-34 hours) (Duncker et al., 1995). 
They found that all transgenic strains demonstrated higher survival rates than (Ifm(3)3 
ry8) (uric-null) mutant. It was hypothesised that the cold shock protection might be 
due to the Xdh genes role. This would seem to support the idea that the mutant strains 
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which do not contain the XDH uric acid producing enzyme have a reduced antioxidant 
capability that might protect them against cold stress.  
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4.5. Identification of mutations in the MCS Gene in ma-l mutants. 
The cloning and sequencing of the entire MCS gene of Drosophila  strains identified 
several nucleotide differences between the databank sequences and the strains studied. 
This section aims to discuss the consequence of these nucleotide variations. 
Nucleotide sequence variations between Canton-S (wild type) DNA and database 
AC01178 and AF162681 were found. Several silent variations were found in intron 1 
(IVSI-93C>T, IVSI-135A>T and IVSI-151A>G), exon 3 (c.260T>A, c.808C>A and 
c.1196G>A) and exon 4 (c.1884A>C, c.2483A>C, c.2143C>A, c.2289G>T, 
c.2567C>T and c.2890C>T) (see figure 65).  
4.5.1. Cloning and sequencing of the mal-1 mutant strains.  
The MCS gene was also sequenced in the maroon-like strains. When the sequence 
results from these mutants were aligned to the wild type strain (Canton-S) the 
following differences were found in PCR product DMCS-8. Alignment of the 3463 bp 
contig from the mal-1 mutants with the wild type gene are shown in figures 66 and 67; 
this revealed mutations in exon 4 of MSC gene. In order to determine the effect of 
these mutations on the deduced amino acid sequence, cDNA sequences were derived 
from the mutant gene sequences by computerised removal of intron sequence from the 
mutant strains. This indicated that the mutations would result in a 6 bp insertion at 
positions c.1569_1573ins from the ATG codon in the predicted mRNA transcripts 
from the mal-1 mutants. Translation of the predicted mRNA from the mal-1 mutant 
indicated the 6 bp insertion was in-frame and resulted in 2 amino acids 
(p.Ile577_Tyr578insLeuPro) being inserted into the predicted protein (Figure 67). In 
order to determine whether the mutation affects vital domains in the MCS protein the 
evolutionary conservation of MCS protein was determined. This was done by 
deducing the protein sequence from the mal-1 mutant strain of Drosophila  and 
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comparing it to the sulphurase sequence of kingdoms of eukaryotic and metazoan, for 
example taxa (plant and green algae, fungi and bacteria) and taxon or phylum 
(sponges, protostomes, deuterostomes and chordates) obtained from the NCBI 
database. The mutations identified in the mal-1 strains were then superimposed on the 
wild type (Canton-S) sequence to show if the mutations are found in a conserved 
region (Figure 72). Figure 72 identifies that the insertion of the amino acids leucine 
(L) and proline (P) disrupts between the conserved amino acid sequence (Y/F), P, 
(V/I) and (KSC). The insertion of two amino acids might affect the folding of the 
protein which may mean that vital active sites are no longer accessible. This along 
with the disruption of a region of amino acids conserved almost completely 
throughout evolution leads to the conclusion that the 6bp insertion observed in the 
mal-1 mutant strain is responsible for the phenotype observed. This insertion in mal-1 
was found in MOSC N-terminal beta barrel domain whose exact mechanism function 
in MCS gene function is still unclear (Bittner et al., 2001; Ping-Min et al., 2009).  
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ma-l strain              QMAILPYPVKSCAA 
Canton-S strain          QMAI  YPVKSCAA 
Anophelas gamlae         QLCL  YPVKSCGP 
Bombus terrestris        QLYI  YPIKSCGA 
Camponotus floridonus    ALFI  YPIKSCGA 
Bombyxmori               EICI  FPIKSCGA 
Tribolium castaneum      QIIL  YPIKSCGG 
Acyrthosiphon pisum      RLFV  FPIKSCGA 
Human                    NLYL  YPIKSCAA 
Dog                      NLYL  YPIKSCAA 
Monodelphis domestica    NIYI  YPIKSCAA 
Bovine                   NLFL  YPIKSCAA 
gallus                   NIYL  YPIKSCSA 
Meleagris                NIYL  YPIKSCSA 
Danio rerio              NLFI  FPVKSCAS 
Oreochromis              NIYI  YPIKSCGA 
Medicago truncatula      NLYL  YPIKSCAA 
Oryctolagus              NIYL  YPIKSCAA 
Ornithorhynchus          NIYI  YPIKSCAA 
Taeniopygia gallopavo    KIYL  YPIKSCSA 
Amphimedon-queenslan     RILL  YPVKSCAG 
Sporisorium reilianum    NITV  YPIKSCAG 
Arabidopsis              SITV  YPIKSCAG 
Trichophyton             KLCI  YPIKSCGA 
Brachypodium             SIII  YPVKSCQG 
Glycine                  QMAI  YPVKSCAA 
Oryza sativa             SIII  YPVKSCQG 
Ostreococcus taui        ELVT  YPVKSCAG 
A.nidulans               SLSV  YPIKSCGA 
Batrachochytrium         AIHV  YPIKSCGA 
 
 
Figure 72: Alignment of MCS protein sequences from species throughout evolution.  
The deduced amino acid sequence of MCS gene product was aligned with its homologs using 
CLUSTAL X programme (Larkin et al., 2007). Amino acids shaded in grey indicate 
similarity. Yellow = regions conserved throughout all species. Arabidopsis thaliana  (plant) 
(AY034895), human (BAA91354), cattle (Bos taurus, BAA98133), Canton-S (D. 
melanogaster), ma-l (D. melanogaster), hxB of A. nidulans, (AAF22564), Japanese rice 
(Oryza sativa japonica) (plant) (Q655R6), Bombyx mori- (insecta) (InQ8IU29) (domestic 
silkworm), Gallus gallus (chicken) (XP_419048), Oreochromis niloticus (Nile tilapia) 
(XP_003441281), Tribolium castaneum (beetle) (XP_967646), Camponotus floridanus 
(insecta) (EFN72786), Danio rerio (zebrafish) (XP_701766), Canis lupus familiaris (dog) 
(XP_547604 gene), Amphimedon queenslandica  (sponge) (XP_003388765), Sporisorium 
reilianum SRZ2 (plant) (CBQ73967), Batrachochytrium dendrobatidis JAM81 (fungi) 
(EGF79866gene), Glycine (plant) (AW318329), Meleagris gallopavo (turkey) 
(XP_003204917), Ostreococcus tauri (green alga) (XP_003083410 ), Anopheles gambiae 
(insecta) (XP_310528 ), Brachypodium distachyon (plant) (XP_003563394), Bombusterrestris 
(insecta) (XP_003397325), Monodelphis domestica  (vertebrata) (XP_001367755), 
Trichophyton CBS 118892  (XP_003232784), Ornithorhynchus anatinus (platypus) 
(XP_001506730), Medicago truncatula  (plant) (AES73058) and Acyrthosiphon pisum 
(insecta) (NP_001191876). Amino acids highlighted in red text are those inserted in ma-l- 
strain. 
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4.5.2. Cloning and sequencing of the mal-f1 mutant strains.  
The same procedure above was also carried out for the maroon-like mutant mal- f1. 
Alignment of the 3463 bp contigs from the mal-f1 mutant with the wild type gene 
shown in figure 68, revealed a mutation in exon 4. Comparison of the sequence data 
obtained from the mal-f1 and wild type strains identified a 23 bp deletion at nucleotide 
positions c.2219_2220delCGTGGACATGAATGGCATGGCGT (Figure 68).  
 Translation of the coding region of the mal-f1 strain resulted in a frame shift and the 
addition of a premature stop codon at codon position 562, 23 bp downstream of the 
deletion (Figure 69). In contrast to the wild type strain that has 782 amino acids the 
truncated protein formed in the mal-f1 strain is ~28% shorter than wild type protein, 
from which are removed 221 of the 782 amino acids residues . The mutation also 
introduces ETLHGVVPN at the C-terminus (Figures 70 and 73). The premature stop 
codon introduced by the mal-f1 mutation leads to the removal of a number of amino 
acid residues that are highly conserved throughout evolution, and the loss the C-
terminus of the protein (Figure 73) that contains a domain for the conversion of bound 
desulpho-molybdenum cofactor into sulphurated molybdenum cofactor, which is 
required to activate XDH and AO enzymes (Bittner et al., 2001; Schwarz et al., 2009; 
Wollers et al., 2008). So it is evident that this truncated protein has lost the MOSC N-
terminal beta barrel and a C-terminal domain in MCS protein which may act as a 
scaffold protein prior to the activation of XDH and AO (Wollers et al., 2008). This 
leads to the conclusion that the 23bp deletion observed in the mal-f1 strain is 
responsible for the phenotype observed (Figure 73). Interestingly the MCS gene 
mutation in tomato flacca  occurs at the C-terminus of the MoCo sulfurase protein 
(Sagi et al., 2002) that disrupted MoCo sulfurase function and results in the lack of 
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AO and XDH activities and Aba content in plant tissues and leading to a wilty 
phenotype (flacca) (Seo et al., 2004). 
 
 
Figure 73: Amino acid sequence alignment of deduced ma-l MCS proteins and homologs in 
other species.  
The deduced amino acid sequence of MCS gene product was aligned with its homologs using 
CLUSTAL X programme (Larkin et al., 2007). Dotted lines indicate gaps that were 
introduced to maximize the alignment. Numbers on the left indicate the position of the first 
residue in each string. The putative PLP binding site domain is framed by red box and the 
conserved lysine residue in the PLP domain is indicted in red text. The conserved cysteine 
residue is indicated with a red asterisk. The MOSC N-terminal beta barrel domain is framed 
by black box. The carboxy-terminus indicted by blue box; 2Fe-2S, iron-sulfur binding region 
(2Fe/2S) is framed by green box.  The carboxy-terminus indicated by blue box. Red text 
indicates amino acid sequence following deletion in D. melanogaster mal-f1 strain. Amino 
acids shaded in grey indicate similarity and amino acids highlighted in red are those inserted 
in D. melanogaster mal-1 strain. Yellow = regions conserved though out all species. Green = 
regions conserved between four and five of the species. Blue = regions conserved between 
three of species. Pink = regions conserved between two of species. GeneBank accession 
numbers are in parentheses, Ar = Arabidopsis thaliana  (Aba3, AY034895), tomato (FLACCA) 
(AY074788), human (BAA91354), cattle (MCSU of Bos taurus, BAA98133), Canton-S, MCS 
(D. melanogaster), mal-1 MCS (D. melanogaster), mal-f1 MCS (D. melanogaster) and 
Aspergillus (hxB of A. nidulans, AAF22564). 
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Ar.          (1) --------------MEAFLKEFGDYYGYPDGPKNIQEIRDTEFKRLDKG-VVYLDHAGSTLYSELQMEYIFKDFTSNVFGNPHSQSDISSATSDLIADARHQVLEYFNASPEDYSCLFTSGATAALKLVGETFPWTQDSN------FLYTMENHNSVLGIRE 
Tomato       (1) --------MNIESEKEQFLKEFGSYYGYANSPKNIDEIRATEFKRLND--TVYLDHAGATLYSESQMEAVFKDLNSTLYGNPHSQSTCSLATEDIVGKARQQVLSFFNASPREYSCIFTSGATAALKLVGETFPWSSNSS------FMYSMENHNSVLGIRE 
Human        (1) MAGAAAESGRELWTFAGSRDPSAPRLAYGYGPGSLRELRAREFSRLAGT--VYLDHAGATLFSQSQLESFTSDLMENTYGNPHSQNISSKLTHDTVEQVRYRILAHFHTTAEDYTVIFTAGSTAALKLVAEAFPWVSQGPESSGSRFCYLTDSHTSVVGMRN 
Cattle       (1) ---------------MQSRQP--------------RALLP----RSPGT--VYLDHAGTTLFPQSQITSFMKDLMENVYGNPHSQNISSKLTHDTVEQVRFRILAHFHTSPEDYTVIFTSGSTAALKLVAEAFPWVSPGPEGSGSCFCYLTDSHTSVVGMRK 
Canton-S     (1) ---------------MTSYRPEFS--------ASEQSQIDAEFSRLASNKSVYLDHAGTTLYAESQVTAAAEQLQRNVICNPH----TCRLTGDFVDQVRFKILEFFNTTAEDYHVIFTANATAALSLVAENFDFGSSGE------FHFCQENHTSVLGMRE 
mal-f1       (1) ---------------MTSYRPEFS--------ASEQSQIDAEFSRLASNKSVYLDHAGTTLYAESQVTAAAEQLQRNVICNPH----TCRLTGDFVDQVRFKILEFFNTTAEDYHVIFTANATAALSLVAENFDFGSSGE------FHFCQENHTSVLGMRE 
mal-1        (1) ---------------MTSYRPEFS--------ASEQSQIDAEFSRLASNKSVYLDHAGTTLYAESQVTAAAEQLQRNVICNPH----TCRLTGDFVDQVRFKILEFFNTTAEDYHVIFTANATAALSLVAENFDFGSSGE------FHFCQENHTSVLGMRE 
A.nidulans   (1) ----------------MNLSKGTAAAYCSGYSEDVDVIREREYPLLKDT--TYLDHAGTTLYANSLIHSFGRDLTGNLYGNPHSMSASSQLSAQRAGRYSLRALRFFNADPDEFDLVFVANATAGIKLVADALQNSPQGF-----WYGYYVDAHTSLVGVRE 
                                                                           ******:**                     ***                      *  *           *     **   **                          * *   * *  
Ar.         (162) YALAQGASACAVDIEEAANQPGQLTNSGPSIKVKHRAVQMRNTSKLQKEESRGNAYNLFAFPSECNFSGLRFNLDLVKLMKENTETVLQ---GSPFSKSK-----RWMVLIDAAKGCATLPPDLS--EYPADFVVLSFYKLFGYPTGLGALLVRNDAAKLL 
Tomato      (167) YALSKGAAAFAVDIEDTH--VGESESPQSNLKLTQHHIQRRNEGGVLKEGMTGNTYNLFAFPSECNFSGRKFDPNLIKIIKEGSERILE---SSQYSRG------CWLVLIDAAKGCATNPPNLS--MFKADFVVFSFYKLFGYPTGLGALIVRKDAAKLM 
Human       (179) VTMAINVISIPVRPEDLW-------------------SAEERGASAS-NPDCQL-PHLFCYPAQSNFSGVRYPLSWIEEVKS-GRLRP----VSTPGK--------WFVLLDAASYVSTSPLDLS--AHQADFVPISFYKIFGFPTGLGALLVHNRAAPLL 
Cattle      (146) ITAAMNVSSIPVRPEDMW-------------------SAERQDAAAAGDPAGQP-PHLFCYPAQSNFSGTRYPLSWIGEVKS-GRRRP----ASRPGK--------WFVLLDAAAFVGTSPLDLS--VHQADFVPISFYKIFGFPTGLGALLVNNRLAALL 
Canton-S    (150) RVRENGIYML--RENEIS-------------------GGKHKANGKVHEVSGKTGNSLLTFSAQCNFSGYKIPLEVIEQIQIDGLAKPGKELWSSLGEKKKNMHNDYYICLDAASFVATSPLDLQ--KYRPDYVCLSFYKIFGYPTGVGALLVSRRGAEVF 
mal-f1      (150) RVRENGIYML--RENEIS-------------------GGKHKANGKVHEVSGKTGNSLLTFSAQCNFSGYKIPLEVIEQIQIDGLAKPGKELWSSLGEKKKNMHNDYYICLDAASFVATSPLDLQ--KYRPDYVCLSFYKIFGYPTGVGALLVSRRGAEVF 
mal-1       (150) RVRENGIYML--RENEIS-------------------GGKHKANGKVHEVSGKTGNSLLTFSAQCNFSGYKIPLEVIEQIQIDGLAKPGKELWSSLGEKKKNMHNDYYICLDAASFVATSPLDLQ--KYRPDYVCLSFYKIFGYPTGVGALLVSRRGAEVF 
A.nidulans  (159) LAKMGSRCFVNEDEVDSW--------------------------ISGLGSRREESLGLFAYPAQSNMNGRRVPMRWCEQIRAQKENADN----------------MIYTLLDAASFVSTSPLDLSKIAAAPDFTVLSFYKIFGFPD-LGALIVRKSSGDVF 
                                                                                 *        *  *                                              ***    *  *  *       *     **** ** *    *** *              
                                                                                                                                                                                   * * 
Ar.         (288) KKT-YFSGGTVAASIADIDFVKRRE--RVEEFFEDGSASFLSIAAIRHGFKLLKSLTP--------SAIWMHTTSLSIYVKKKLQALRHGNGAAVCVLYGSENLELSSHKS-GPTVTFNLKRPDGSWFGYLEVEKLASLSGIQLRTGCFCNPGACAKYLEL 
Tomato      (307) KKT-YFSGGTVTAAIADVDFFKRRE--GVEEFFEDGTISFLSITAIQHGFKIINMLTT--------SSIFRHTTSIAAYVRNKLLALKHENGEFVCTLYG-----LLSSEM-GPTVSFNMKRPDGTWYGYREVEKLATLAGIQLRTGCFCNPGACAKYLGL 
Human       (290) RKT-YFGGGTASAYLAGEDFYIPRQ--SVAQRFEDGTISFLDVIALKHGFDTLERLTG------GMENIKQHTFTLAQYTYMALSSLQYPNGAPVVRIYSDSEFSSPEVQ--GPIINFNVLDDKGNIIGYSQVDKMASLYNIHLRTGCFCNTGACQRHLGI 
Cattle      (258) RKT-YFGGGTAAAYLAGDDFYVPRE--SVAERFEDGTISFLDVIALKHGFDALERLTG------GMESIRQHTFTLAQYTYTALSSLRYPNGAPVVQIYSDSDFSSPEVQ--GPVISFNVLDDHGNVVGYSQVDKMASLHNIHVRTGCFCNTGACQRHLGI 
Canton-S    (264) QKRRFFGGGTINYAYPHAMDYQLRE--TFHQRYEDGTLPFLSIVGLLEGFRTLERLVPRTDEFSTMERISRHVFGLAKYLEDQLRQLHHPNGEPLVKLYNKVGYQDKSRQ--GGIVAFNVRTESGSFVGFGEIACVAALHGILLRTGCFCNIGACQYYLGL 
mal-f1      (264) QKRRFFGGGTINYAYPHAMDYQLRE--TFHQRYEDGTLPFLSIVGLLEGFRTLERLVPRTDEFSTMERISRHVFGLAKYLEDQLRQLHHPNGEPLVKLYNKVGYQDKSRQ--GGIVAFNVRTESGSFVGFGEIACVAALHGILLRTGCFCNIGACQYYLGL 
mal-1       (264) QKRRFFGGGTINYAYPHAMDYQLRE--TFHQRYEDGTLPFLSIVGLLEGFRTLERLVPRTDEFSTMERISRHVFGLAKYLEDQLRQLHHPNGEPLVKLYNKVGYQDKSRQ--GGIVAFNVRTESGSFVGFGEIACVAALHGILLRTGCFCNIGACQYYLGL 
A.nidulans  (260) KHRKFFGGGTVDMVLTDGNPWHAKKQSSIHQSLEDGTLPFHSIIALDSAFETHGRLFR------SMENVASHTRFLAKRLRDRMNALKHYNGSKVCQLYMSPNSSYDDASSQGPILAFNLRNSRGMWIGKSEVERLASIKNIQIRSGTLCNPGGTALSLGW 
                       * ****                      ***   *         *     *               *              *   **      *             *    **     *   *       *    *  * *  ** *     *       
Ar.         (390) SHSELRSNVE-AGHICWDDNDVINGKPTGAVRVSFGYMSTFEDAKKFIDFIISSFASPPK-----------KTGNGTVVSGRFPQLPSEDLESKESFPS--------------------------------------------------HYLKSITVYPIK 
Tomato      (339) SHLDLLSNIE-AGHVCWDDRDILHGKPTGAVRVSFGYMSTFEDAMKFVNFVESNFVIS--------------SFNRCALQPRSISLPIEGIA--EAAAR--------------------------------------------------HFLTSITVYPIK 
Human       (388) SNEMVRKHFQ-AGHVCGDNMDLIDGQPTGSVRISFGYMSTLDDVQAFLRFIIDTRLHSSGDWPVPQAHADTGETGAPSADSQAD-VIPAVMGRRSLSPQEDALTGSRVWNNS-STVNAVPVAPPVCDVARTQPTPSEKAAGVLEGALGPHVVTNLYLYPIK 
Cattle      (356) SDEMVKKHLQ-AGHVCGDDVDLIDGQPTGSVRISFGYMSTLEDAQAFLRFIIATRLHSSHGQPLPLATP--GEAGAPPEDSEAQNAMPAARARGSSSPQEDTSPHSGVWNNSPTAVDAEGLCPPLLEATGTQQTTSEKAADVPDGDLRSHVITNLFLYPIK 
Canton-S    (375) DEDALDAIYKRAGRICGDYFDLIDGQPTGAVRVSFGYMTTIQDVDQLLQMLRSSYLATKP------------LQRIQFIEEQAEQLPPLLKER------------------------VQLLRPKLLQMA---------------------------IYPVK 
mal-f1      (375) DEDALDAIYKRAGRICGDYFDLIDGQPTGAVRVSFGYMTTIQDVDQLLQMLRSSYLATKP------------LQRIQFIEEQAEQLPPLLKER------------------------VQLLRPKLLQMA---------------------------IYPVK 
mal-1       (377) DEDALDAIYKRAGRICGDYFDLIDGQPTGAVRVSFGYMTTIQDVDQLLQMLRSSYLATKP------------LQRIQFIEEQAEQLPPLLKER------------------------VQLLRPKLLQMAILP-------------------------YPVK 
A.nidulans  (360) TGADMLRHFS-AGMRCGDDHDIMDERPTGILRISLGAMSSLTDVDTFIAFLEEFYVDKPP-----------EGLPVPLTGNVSLHQPSFYVES-------------------------------------------------------------LSVYPIK 
                             **  * *        **   * *   *    *                                                                                                                  ** *               
Ar.         (547) SCAGFSVIR---WPLCRTGLLHDREWMVQGL-TGEILTQKKVPEMSLIKTFIDLEEGLLSVESSRCEDKLHIRIKSDS-------------YNPRNDEFDSHANILENRNEETRINRWFTNAIGRQCKLLRYSSSTSKDCLN------------------- 
Tomato      (507) SCAGFSVDQ---WPLTSTGLLHDREWILKST-TGEILTQKKVPEMCYISTLIDLNLGKLFVESPRCKEKLQIELKSSS-------------LVTERDEMDIQNHRYEVTSYNNEVDIWFSRAIDRPCTLLRNSDSQSHSCIN------------------- 
Human       (565) SCAAFEVTR---WPVGNQGLLYDRSWMVVNH-NGVCLSQKQEPRLCLIQPFIDLRQRIMVIKA-KGMEPIEVPLEENS-------------ERTQIRQSRVCADRVSTYDCGEKISSWLSTFFGRPCNLIKQSSNSQRNAK-------------------- 
Cattle      (503) SCAAFEVIR---WPLGSQGLLYDRSWMVVNH-NGICLSQKQEPRLCLIQPFIDLQRRIMVIKA-QGMEPIEVPLEENS-------------EQVQICQSKVCADRVNTYDCGEKISNWLSKFFGRPYHLIKQSSDFQRNAK-------------------- 
Canton-S    (515) SCAAFKIELPGSWPLTDQGLKYDREWMIVDM-NGMALTQKRCTELCLIRPVIKVDQLELQFGE-NSTISVPLSLDDQA-------------ADTAKCVSKVCRQPVEGLDCGDRVAQWLSENGMEGLRLLRQSG--QRNSS-------------------- 
mal-f1      (428) SCAAFKIELPGSWPLTDQGLKYDREWMITDQGLKYDREWMIDPETLHGVVPN*------------------------------------------------------------------------------------------------------------ 
mal-1       (517) SCAAFKIELPGSWPLTDQGLKYDREWMIVDM-NGMALTQKRCTELCLIRPVIKVDQLELQFGE-NSTISVPLSLDDQA-------------ADTAKCVSKVCRQPVEGLDCGDRVAQWLSENGMEGLRLLRQSG--QRNSS-------------------- 
A.nidulans  (544) SCGAFRIPDGQRWEVRREGLAWDREWCLVHQGTGITLNQKRYPRMALIRPTLDLERCLLRITCGEANSRDGKTLEISLNRIGTNSLTTSLCQNASKPSTVCGDKVVLQAYTSPAVSRFFTDFLGVPCTLARFPPQSSTRFHSRATAAINRDQNYSQKQSPS 
                  **  *       *     **  ****       *  * **       *                                                                                * 
Ar.         (651) ----RNKSPGLCRDLESNINFANEAQFLLISEESVADLNRRLEAKDEDYKR-----AHEKLNPHRFRPNLVISG-----GEPYGEDKWKTVKIG----DNHFTSLGGCNRCQMINISNEAGLVKKSNEPLTTLASYRRVKGKILFGTLLRYEIDEKRQ—-C 
Tomato      (594) ----KNGSPGMCRDVGARLNFVNEAQFLLISEESIKDLNSRLKSNGRRRNGG----QAVQVGVMRFRPNLVASS-----GEPYAEDGWSNINIG----GKYFMSLGGCNRCQMININPEAGEVQRFTEPLATLAGYRRAKGKIMFGILLRYENNTKTESDT 
Human       (604) ----KKHGKDQLPGTMATLSLVNEAQYLLINTSSILELHRQLNTSDENGKEEL---FSLKDLSLRFRANIIING-----KRAFEEEKWDEISIG----SLRFQVLGPCHRCQMICIDQQTGQRNQ--HVFQKLSESR—-ETKVNFGMYLMHASLDLSSPCF 
Cattle      (662) ----KKHGKDQSAHTTATLSLVNEAQYLLINRSSILELQQQLSTSCENGKEEL---FPMNNLISRFRANIITNG-----TRAFEEEKWDEISIG----SLRFQVLGPCHRCQMICIDQQTGQRNQ--DVFQKLSERR—-ERKVKFGVYLMHTSLDLSSPCY 
Canton-S    (671) ----KDQQK---------LSLVNQAQFLLLNKSSVRSLQFEE---------------PLDETVDRFRANIIIDT-----GSAFEELTYKALSIG----GIQFQVEGPCQRCDMICINQRTGERSP--ETLTTISRLQ--KGRMRFGIYITRIPQDT----- 
mal-f1       (0)  ----------------------------------------------------------------------------------------------------------------------------------------------------------------- 
mal-1       (673) ----KDQQK---------LSLVNQAQFLLLNKSSVRSLQFEE---------------PLDETVDRFRANIIIDT-----GSAFEELTYKALSIG----GIQFQVEGPCQRCDMICINQRTGERSP--ETLTTISRLQ--KGRMRFGIYITRIPQDT----- 
A.nidulans  (662) MPGSFPQAPSSPDPYPTPILLSNESPLLLISRSSVNRLNESIKSASQPCSNPGSAASKKAVAADVFRANVVVAENISTAERPYIEDTWASLSIGSGPEQLRFDVLGSCERCQMVCVDQYTGQRGD--EPYATLAKTRKIDRKILFGRHISPVGRPKDAENG 
                                        *    **    *   *                           ** *                 *     **       *   * * ** *       *                       **                                 
Ar.         (781) WIGVGEEVNPDIE------------------- 
Tomato      (774) WIRVGEEIIPNGDRH----------------- 
Human       (853) LSVGSQVLPVLKENVEGHDLPASEKHQDVTS— 
Cattle      (821) LSVGSQVLPLLKENMEHHDIPATE-------- 
Canton-S    (782) -----KELEPKEQHMTCGDVVLVE-------- 
mal-f1       (0)  -------------------------------- 
mal-1       (784) -----KELEPKEQHMTCGDVVLVE-------- 
A.nidulans  (816) CLGTIMVGDAVTPSYDNES------------- 
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4.6. Conclusions. 
Prior to this study despite AO and XOR being classed as detoxification enzymes there 
is no published unequivocal proof of this. 
In this study two mutant strains of Drosophila melanogaster were used as animal 
models to investigate this. Rosy (ry) strains have a deficiency in XOR, whilst maroon-
like (ma-l) have a lack of functional AO/ XOR due to a MCS deficiency. Biochemical 
evaluation of these two strains by sensitive HPLC assays both in vitro and in vivo 
confirmed that the ry and ma-l strains were animal models for human hereditary 
xanthinuria type I and II respectively. 
PCR cloning and DNA sequencing of the MCS gene in the maroon-like strains 
revealed that the mal-1 and mal-f1 strains had a 6 bp insertion and a 23 bp deletion in 
exon 4 respectively that are predicted to lead to changes of the deduced MCS protein 
sequence when compared to wild type sequence, thus explaining the deficiency in 
MFEs in these strains. Once again this reflects the situation found in humans where 
the dual deficiency is caused by mutations in the MCS gene.  
Initial studies using spectrophotometric and HPLC assays indicated that MFEs in 
Drosophila  were able to catalyse the biotransformation of numerous substrates of the 
well-characterised mammalian AO. These included the xenobiotics (such as 
dimethylcinnamaldehyde, phenanthridine and vanillin) and drugs (such as allopurinol 
cinchonine and pyrazinamide). Endogenous vitamin substrates included retinal, 
pyridoxal and N1-methylnicotinamide were also biotransformed by Drosophila  AO. 
Investigation of the MFEs in ry506 strain revealed a deficiency of enzyme activity to 
XOR substrates such as xanthine and the caffeine metabolite 1-methylxanthine. Mal-1 
and mal-f1 strains were found to be unable to biotransform all AO substrates tested 
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table 37. Investigation of the enzyme activity in ry strain revealed a compromised 
ability to biotransform several XOR substrates that reflected the situation in human 
hereditary xanthinuria type I with allopurinol, N1-methylnicotinamide, pyrazinamide 
and xanthine. These results confirmed that Drosophila  mutants to be good 
experimental models for testing the role of MFEs as detoxification enzymes.  
In order to test the role of the enzymes in chemoprotection MFE substrates were 
administered in Drosophila  media and survivorship monitored. This demonstrated that 
several methylated xanthines including caffeine, theophylline and theobromine were 
toxic to XOR-deficient strains. In addition a range of AO substrates including N-
heterocycles and aldehydes were toxic to ma-l AO-null strains (Table 37).  This study 
therefore provides unequivocal proof that both AO and XOR are involved in 
detoxification.   
Investigations to determine the effect of MFE deficiencies on lifespan revealed that ry 
and ma-l strains had significantly reduced lifespans when compared with the wild type 
strain, with the mean lifespan being reduced approximately 60% and 30% in the ry 
and ma-l strains respectively. The effect of MFE deficiencies on environmental heat 
and cold stress were also determined. This indicated that ry and ma-l strains had 
significantly reduced ability to survive at -3, 0, 37 and 39oC with the AO-null ma-l 
strain being most compromised in these conditions.  The effect of the toxic chemicals, 
lifespan and temperature stress were rescued in ry506 animals that had the normal ry 
(XOR) gene reinserted by transgenesis.   
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4.7. Recommendations for future work. 
Although it was proven that a deficiency of AO in maroon-like Drosophila  strains 
resulted in the absence of cinchonine, pyrazinamide and N1-methylnicotinamide 
biotransformation, the products of the reaction in AO-active strains were not 
definitively identified due to a lack of commercial availability of the metabolites.  Had 
time permitted, experiments could have been optimised in order to unequivocally 
prove the products of these AO-mediated reactions were the same as those produced 
by their mammalian counterparts using LC-MS. 
This study could be expanded to analyse a wider range of xenobiotics including drugs 
that are MFE substrates (Table 1 in introduction). Other chemicals that warrant 
attention in Drosophila  as an experimental model are substrates that are 
biotransformed by the MFEs acting as reductases such as nitrated polycyclic 
hydrocarbons, zonisamide and doxorubicin (see tables 2 and 3 in the introduction for a 
list of other compounds). It would also be of interest to evaluate a range of other 
physical stresses for example ionising radiations such as gamma rays. 
Although the reason for the reduced lifespan in ry flies is probably due to the lack of 
the antioxidant uric acid in this strain, the additional reduced lifespan in maroon-like 
strains is more difficult to comprehend. In addition, although it was conclusively 
proven that methylated xanthines such as caffeine and theophylline were significantly 
more toxic to MFE-deficient strains, the expected finding of an accumulation of toxic 
products was not apparent using HPLC.  
There are several sophisticated advanced techniques that might be used to determine 
why the lack of AO in Drosophila leads to a decreased lifespan and low survivability 
at temperature extremes. These advanced techniques include metabolomics, 
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transcriptomics, proteomics that might reveal differences in metabolites, gene 
expression or protein expression between ry and mal strains and thus the molecular 
basis for this surprising observation. These techniques could also be utilised to 
determine the unresolved molecular basis of methyl xanthine toxicity in the mutant 
strains. 
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6.0. Appendices 
 
6.1. Appendix 1 
 
Table showing the genetic code. 
 
First base 
Second 
base 
T 
 
C 
 
A 
 
G 
    
T 
TTT 
Phe 
CTT 
Leu 
ATT 
Ile 
GTT 
Val 
TTC CTC ATC GTC 
TTA 
Leu 
CTA ATA GTA 
TTG CTG ATG Met GTG 
    
C 
TCT 
Ser 
CCT 
Pro 
ACT 
Thr 
GCT 
Ala 
TCC CCC ACC GCC 
TCA CCA ACA GCA 
TCG CCG ACG GCG 
    
A 
TAT 
Tyr 
CAT 
His 
AAT 
Asn 
GAT 
Asp 
TAC CAC AAC GAC 
TAA 
STOP 
CAA 
Gln 
AAA 
Lys 
GAA 
Glu 
TAG CAG AAG GAG 
    
G 
TGT 
Cys 
CGT 
Arg 
AGT 
Ser 
GGT 
Gly 
TGC CGC AGC GGC 
TGA STOP CGA AGA 
Arg 
GGA 
TGG Trp CGG AGG GGG 
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6.2. Appendix 2. 
Single letter and triple letter codes for the amino acids. 
Amino acid Single letter code  Triple letter code 
Alanine                                             A                                   Ala 
Arginine   R                        Arg 
Asparagine   N                        Asn 
Aspartic acid   D                        Asp 
Cysteine   C                                   Cys 
Glutamic acid   E                        Glu 
Glutamine   Q                                  Gln 
Glycine   G                                  Gly 
Histidine   H                                  His 
Isoleucine   I                        Ile 
Leucine   L                                  Leu 
Lysine     K                           Lys 
Methionine   M                                 Met 
Phenylalanine   F                       Phe 
Proline   P                       Pro 
Serine   S                       Ser 
Threonine   T                                 Thr 
Tryptophan   W                      Trp 
Tyrosine   Y                                Tyr 
Valine   V                                Val 
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6.3. Appendix 3. 
 
%RSD for retention time (n=3) 
Analyte 0.01mM 0.02mM 0.03mM 0.05mM 0.1mM 
1, 3-dimethylxanthine 1.87 2.31 2.23 2.14 1.79 
1, 7-dimethylxanthine 1.19 1.49 2.58 2.11 1.61 
1,3,7-trimethylxanthine 0.57 0.09 0.14 0.19 0.16 
1,7-dimethyluric acid 1.61 2.08 1.57 2.01 1.66 
1-methyluric acid 0.72 0.98 1.02 1.23 0.88 
1-methylxanthine 1.61 1.25 1.86 1.02 0.61 
3- methylxanthine 2.76 1.68 1.15 0.71 0.54 
3,7- methylxanthine 1.87 3.05 1.63 1.19 2.08 
6-mercaptopurine 2.51 0.68 0.39 1.11 0.17 
6-thioxanthine 1.51 2.22 0.35 0.16 2.32 
7-methylxanthine 3.31 1.32 0.55 1.16 0.89 
Allopurinol 0.61 1.23 2.26 0.22 1.28 
Cinchonine 1.66 1.68 0.15 2.11 0.74 
Methotrexate 0.97 1.01 1.12 1.19 0.27 
N1-methylnicotinamide 1.12 2.13 0.52 0.27 1.66 
Oxipurinol 0.87 2.05 1.83 0.59 1.18 
Phenanthridine 2.25 3.17 1.13 0.22 0.78 
6(5H)-phenanthridone 2.41 2.14 2.17 1.21 0.26 
Pyrazinamide 1.12 1.51 0.57 1.42 1.29 
Pyridoxal 1.41 0.18 0.24 0.89 1.86 
Pyridoxic acid 2.14 0.77 0.26 1.13 0.66 
Uric acid 1.22 1.53 0.52 1.37 2.26 
Vanillic acid 0.77 1.61 0.89 0.35 0.59 
Vanillin 1.02 2.23 0.42 0.25 1.16 
Xanthine 1.21 0.98 0.19 0.11 1.79 
 
Table 2: % RSD of retention time of three replicate runs of analytes used in this study in the 
same day of calibration standard for intra- day precision. The % RSD for retention time 
between injections is in the range of 0.09-3.31. 
 
 
 
 
 
 
 
 
 
 
224 
 
Mean ± SD of accuracy (%) (n=3) 
 Nominal concentration 
Analyte 0.01 mM 0.02 mM 0.03 mM 0.05 mM 0.1 mM 
1-methylxanthine 98.5 ± 2.5 100.3 ± 0.9 99.8 ± 2.3 98.1 ± 0.7 99.9 ± 0.2 
1,3,7-trimethylxanthine 98.2 ± 2.2 99.8 ± 1.7 100.4 ± 0.2 99.9 ± 0.2 98.8 ± 1.2 
1, 3-dimethylxanthine 100.5 ± 0.3 98.7 ± 0.5 98.1 ± 1.2 99.9 ± 0.4 99.8 ± 0.7 
1, 7-dimethylxanthine 99.7 ± 1.1 95.2 ± 2.2 99.8 ± 0.7 97.7 ± 1.6 99.9 ± 0.5 
1-methyluric acid 95.1 ± 1.1 97.3 ± 0.4 96.2 ± 0.9 99.9 ± 0.2 96.7 ± 0.7 
3- methylxanthine 99.9 ± 1.3 99.7 ± 0.7 99.8 ± 1.8 98.6 ± 1.5 97.9 ± 1.1 
1,7-dimethyluric acid 95.5 ± 1.4 97.7 ± 1.3 99.8 ± 1.2 99.9 ± 0.1 99.5 ± 1.4 
3,7-dimethylxanthine 98.7 ± 2.1 98.9 ± 1.1 99.5 ± 1.5 99.6 ± 0.3 99.8 ± 1.1 
6-mercaptopurine 98.2 ± 0.3 97.2 ± 1.6 95.5 ± 1.7 98.8 ± 1.1 99.2 ± 1.7 
6-thioxanthine 100.2 ± 0.2 98.4 ± 2.3 98.5 ± 1.1 99.8 ± 1.9 98.2 ± 1.3 
7-methylxanthine 98.3 ± 0.9 99.8 ± 2.1 99.7 ± 1.2 99.6 ± 1.3 98.1 ± 1.3 
Allopurinol 98.2 ± 1.2 99.2 ± 1.1 97.1 ± 0.7 98.5 ± 1.3 98.5 ± 1.7 
Cinchonine 97.5 ± 1.5 98.3 ± 0.8 97.8 ± 1.4 105.6 ± 0.2 96.9 ± 1.2 
Methotrexate 99.3 ± 1.3 97.1 ± 1.7 98.9 ± 0.5 96.1 ± 2.4 98.9 ± 1.8 
N1-methylnicotinamide 95.1 ± 0.7 98.5 ± 0.4 99.9 ± 0.4 100.3 ± 0.7 96.8 ± 1.4 
Oxipurinol 99.2 ± 2.1 99.1 ± 1.1 100.4 ± 2.2 96.6 ± 1.9 98.8 ± 2.1 
Phenanthridine 100.6 ± 1.9 99.8 ± 1.4 99.2 ± 0.3 99.1 ± 1.3 100.8 ± 1.1 
6(5H)-phenanthridone 99.5 ± 0.7 97.5 ± 0.2 99.5 ± 1.7 99.5 ± 1.1 99.5 ± 0.8 
Pyrazinamide 100.5 ± 0.4 97.3 ± 1.3 99.9 ± 1.1 99.3 ± 1.2 98.3 ± 2.2 
Pyridoxal 98.2 ± 0.7 97.9 ± 1.6 95.9 ± 2.3 99.9 ± 0.6 100.2 ± 1.7 
Pyridoxic acid 98.4 ± 1.5 95.4 ± 0.7 99.1 ± 2.4 98.2 ± 1.8 99.2 ± 1.3 
Uric acid 95.6 ± 1.7 99.7 ± 1.1 99.7 ± 1.2 98.3. ± 1.9 97.2 ± 0.7 
Vanillic acid 97.1 ± 1.7 98.5 ± 1.8 100.5 ± 0.4 97.5 ± 1.3 99.1 ± 0.9 
Vanillin 97.1 ± 1.2 99.1 ± 1.1 98.8 ± 1.1 95.2 ± 1.7 98.5 ± 0.7 
Xanthine 97.4 ± 1.2 99.6 ± 1.3 100.2 ± 0.1 99.8 ± 0.7 99.6 ± 2.1 
 
Table 3: % Accuracy calculated for intra-day analysis of compounds used in HPLC analysis 
in this study. 
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Mean area of three injections in the same day of calibration standards (n=3) 
Analyte 
0.01 
(mM) 
 
0.02 
(mM) 
 
0.03 
(mM) 
 
0.05 
(mM) 
 
0.1 
(mM) 
 
Slope 
 
Intercept 
 
RSQ LOD (nmol) LOQ (nmol) 
1,3,7-trimethylxanthine 329073 588050 900438 1565542 3196561 16008 - 23976 0.994 0.004 0.023 
1, 3-dimethylxanthine 296357 485573 803416 1386088 2584663 12984 17166 0.997 0.005 0.024 
1,7-dimethyluric acid 350269 736064 1075433 1735800 3347587 16676 40207 0.992 0.002 0.014 
1, 7-dimethylxanthine 200588 382509 578603 953698 1951522 9733 - 3526 0.998 0.0001 0.0005 
1-methyluric acid 307169 539389 835522 1431411 2952992 14769 - 22718 0.998 0.001 0.005 
1-methylxanthine 134653 265966 408825 648214 1250231 6228 15347 0.994 0.004 0.021 
3,7-dimethylxanthine 326558 542411 881882 1519827 3156397 15821 - 36283 0.998 0.005 0.011 
3- methylxanthine 220630 380331 617750 1048771 2157284 10813 - 19424 0.995 0.007 0.034 
6-mercaptopurin 39438 79514 139407 288320 591803 6091107 -23441 0.994 0.004 0.02 
6-thioxanthine 51175 92429 134115 259511 485648 4904335 -1172 0.997 0.002 0.01 
7-methylxanthine 212000 343158 573379 994966 2037038 10230 - 22702 0.997 0.002 0.01 
Allopurinol 14726 29588 49432 96833 188236 1926912 -4388 1.00 0.003 0.015 
Cinchonine 99785 151658 197633 390061 889728 8843599 -21381 0.990 0.0002 0.001 
N1-methylnicotinamide 44454 91846 169578 308302 661872 6764775 -24091 0.996 0.001 0.005 
Methotrexate 128570 171092 276739 493204 998593 9945386 -3388 0.997 0.0006 0.003 
Oxipurinol 23394 47904 76786 129660 233588 2714 2357371 1.00 0.001 0.005 
Phenanthridine 571679 992255 1180187 2130945 4222854 41430984 66235 0.997 0.002 0.009 
6(5H)-phenanthridone 132015 260381 397202 689057 1322123 13294923 1474 0.999 0.002 0.01 
Pyridoxic acid 31017 50616 87722 138318 230686 2304745 9060 0.987 0.002 0.01 
Pyridoxal 28160 45701 77618 112825 202247 1944019 7967 0.992 0.002 0.095 
Pyrazinamide 70181 148691 217140 331506 640131 6337483 12796 0.998 0.004 0.02 
Uric acid 482658 1095004 1494725 2563976 4955041 24777 30879 0.999 0.003 0.015 
Vanillic acid 38737 99515 181284 281098 553041 5617796 -4343 0.997 0.0001 0.0005 
Vanillin 54118 146188 211879 378212 734053 7447551 -6589 0.999 0.002 0.01 
Xanthine 123857 253547 406308 642818 1253249 6273 7542 0.995 0.004 0.02 
 
Table 4: Regression calculation based on mean area of three replicates in the same day of MFE substrate and product calibration standards against the actual 
concentration.
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Figure 1: Standard curve for Bicinchoninic acid method obtained from known concentration 
of bovine serum albumin. The standard curve can then be used to calculate the protein 
concentrations of unknown sample. 
 
Figure 2: 1-methylxanthine standard curve.  
 
Figure 3:  Xanthine (X) standard curve.  
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Figure 5: Allopurinol standard curve.  
 
Figure 4: Phenanthridine standard curve.  
 
Figure 4: Vanillin standard curve.  
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Figure 6: Pyridoxal standard curve.  
 
Figure 7: Retinal standard curve.  
  
Figure 8: 1- methyluric acid standard curve.  
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Figure 9: Uric acid (U) standard curve.  
 
Figure 10: Xanthine (X) standard curve.  
 
Figure 11: Oxipurinol standard curve.  
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Figure 12: Phenanthridinone standard curve.  
 
Figure 13: Vanillic acid standard curve.  
 
Figure 14: Pyridoxic acid standard curve.  
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Figure 15: Retinoic acid standard curve.  
 
Figure 16: Pyrazinamide standard curve.  
 
Figure 17: Cinchonine standard curve.  
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6.4. Appendix 4. 
  
Temperature(°C) 
  
 
25 37 39 Total  χ2 value 
Observed(O) 100 49.4 36.5 
 
Expected(E) 100 100 100 
 
O-E 0 -50.6 -63.5 
 
(O-E)2 0 2560.3 4032 
 
(O-E)2/E 0 25.60 40.32 65.92* 
Table 1: Statistical difference in survival of wild type (Canton-S) strain after exposure to 
different heat shock temperatures at 6 hours. (*P  < 0.05 by chi2 test is 3.84) indicates when a value 
is significantly different from the control value.  
  
Temperature (°C) 
  
 
25 0 -3 Total  χ2 
value 
Observed(O) 100 58 13 
 
Expected(E) 100 79 55.5 
 
O-E 0 -21 -41.5 
 
(O-E)2 0 441 1722.25 
 
(O-E)2/E 0 4.41 12.22 21.63* 
Table 2: Statistical difference in survival of wild type (Canton-S) strain after exposure to 
different cold shock temperatures at 4 hours. (*P  < 0.05 by chi2 test is 3.84) indicates when a value 
is significantly different from the control value.  
Xenobiotics and χ2  value 
Strain 
Canton-S ry506 
T1 T2 ry506 mal-1 mal-f1 mal-1 mal-f1 
6-Mercaptopurine (20 mM)  χ2  
= 
0.04 0.02 4.14* 4.94* 4.68* 4.94* 4.68* 
Allopurinol (100 mM)  χ2  = 0.0001 0.0001 13.42* - - - - 
Allopurinol (20 mM)  χ2  = 0.02 0.01 0.58 27.22* 27.17* 27.22* 27.17* 
Caffeine (20 mM)  χ2  = 0.02 0.01 18.42* 26.66* 12.84* 26.66* 12.84* 
Cinchonine      χ2  = 0.07 0.08 0.02 8.28* 9.85* 7.21* 8.01* 
Oxipurinol (20 mM)  χ2  = 0.0001 0.0001 25.81* 37.35* 32.35* 37.35* 32.35* 
Paraxanthine (100 mM)  χ2  = 0.004 0.02 18.65* 17.94* 20.97* 17.94* 20.97* 
Phenanthridine   χ2  = 0.002 0.0002 0.001 49.29* 50.28* 48.72* 47.12* 
Pyrazinamide     χ2  = 0.0001 0.0006 27.236* 36.83* 37.69* 5.83* 5.51* 
Theobromine (20 mM)  χ2  = 0.001 0.002 24.24* 24.38* 24.55* 24.38* 24.55* 
Theophylline (20 mM)  χ2  = 0.01 0.01 9.92* 13.69* 12.67* 13.69* 12.67* 
N1-Methylnicotinamide  χ2  = 0.003 0.004 0.006 45.75* 46.13* 45.17* 44.82* 
Vanillin   χ2  = 0.00 0.00 0.00 57.02* 59.24* 59.75* 60.08* 
Table 3: Statistical difference in survival between wild type, transgenic and mutant strains 
after exposure to xenobiotics. (*P  < 0.05 by chi2 test is 3.84) indicates when a value is significantly 
different from the control value. - : not tested 
 
